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Neglected parasitic diseases (NPD) include some of the worst human infections and 
are caused by pathogens including T. brucei (human African trypanosomiasis or 
sleeping sickness), T. cruzi (American trypanosomiasis or Chagas disease), 
Leishmania spp (leishmaniasis), which cause large disease burdens, as well as high 
mortality and morbidity rates in afflicted countries. In the absence of effective 
vaccines against any trypanosomatid diseases, chemotherapy is the main mechanism 
to combat them. Many anti-protozoal drugs are inherently cytotoxic but derive their 
selectivity from preferential uptake by the pathogen rather than by the host. 
Conversely, loss of the specific drug transporters is a main cause of drug resistance. 
Identification of parasite-specific targets and uptake mechanisms is critical for the 
development of new therapeutic agents. In this project, the aim of the research is 
to understand the roles of kinetoplastid aquaporins (AQPs) in trypanosomatid 
parasites with respect to drug resistance and transport. 
The observed cross-resistance between melarsoprol and pentamidine (MPXR) of the 
parasite threatens the status of the latter as a viable drug. There is clear consensus 
that a membrane transporter protein, T. brucei aquaglyceroporin-2 (TbAQP2), is 
implicated in the uptake of both drugs and therefore appears a likely basis for MPXR 
emergence. What has remained, unclear is weather the TbAQP2 protein is acting as 
transmembrane transporter, while situated in the T. brucei flagellar pocket, with 
pentamidine being a permeant, or if the protein simply acts as a receptor for 
pentamidine to then be internalised together via receptor-mediated endocytosis or 
the natural turnover of TbAQP2.  
Investigations on TbAQP2 were conducted to determine how the structure of TbAQP2 
allows it to transport pentamidine. In T. brucei, AQP2 and AQP3 are closely related, 
but AQP2 has unusual selectivity filter amino acids residues in and around the pore 
(NSA/NPS/IVLL), compared to the latter (NPA/NPA/WGYR) in AQP3, and it also lacks 
the “aromatic/arginine (a/R)” motif. Using site-directed mutagenesis approaches, 
the TbAQP2 and TbAQP3 selectivity filter residues were therefore swapped with the 
goal of determining the effects of each amino acid on the uptake of drugs by 
Trypanosoma brucei. The results showed that the selectivity filter differences 
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between TbAQP2 and TbAQP3 are largely responsible for their differences in 
pentamidine sensitivity and transport rates. Moreover, the TbAQP2 pore width was 
constricted using amino acids of different sizes, in order to test whether size 
restrictions at the cytoplasmic end of TbAQP2, i.e. below the selectivity filter, 
would impact on pentamidine transport. Through a combination of drug sensitivity 
determinations and uptake assays, the results of the introduction of different-sized 
amino acids at selected positions showed that it is likely that the effect depended 
on the residue size at the cytoplasmic end of the TbAQP2 pore. In addition, the 
potential correlation between the T. brucei endocytosis rate and the rate of 
pentamidine uptake was investigated in order to distinguish between pentamidine 
uptake by transporters and via endocytosis. The combined evidence of the observed 
results strongly suggests that pentamidine is not taken up by endocytosis, and does 
not induce endocytosis of TbAQP2. To conclude, the obtained results highlight a 
clear, direct role for the TbAQP2 membrane transporter in pentamidine uptake, with 
the drug most likely traversing the protein’s channel to enter the cell.  
The Leishmania major AQP1 was also investigated for the uptake of heavy metals 
antimony and arsenic. For this aim, LmAQP1 was cloned and expressed into the 
TbAQP1-3 null and LmAQP1 null cell lines, which were then tested for changes in 
sensitivity to antimony and arsenic. The results show that LmAQP1 is able to sensitise 
cells to heavy metals. These findings could help to confirm and advance the 
understanding of a role of Leishmania AQP1 in the sensitivity and resistance to first-
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Definitions/Abbreviations 
°C   degree celsius 
AAT   African Animal trypanosomiasis 
ABC                        ATP-binding cassette  
BBB   blood-brain barrier  
bp   Base pairs 
BSF   Bloodstream form 
CCCP   Carbonyl cyanide m-chlorophenyl hydrazone 
CNS                        central nervous system 
dH2O            distilled water 
DRC   Democratic Republic of Congo 
E. coli   Escherichia coli 
EC50   50% effective concentration 
FBS            Foetal bovine serum 
g   Gravity force  
gDNA   Genomic DNA 
h   Hour 
HAPT1  High Affinity Pentamidine Transporter  
HAT   Human African Trypanosomiasis 
HMI-9   Hirumi’s medium 9 
IC50   50% inhibitory concentration 
ISG75   Surface Molecule Invariant Surface Glycoprotein 75 
Kb   Kilobase 
Km   Michaelis-Menten constant 
KO   Double Knockout 
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L   Litre 
LAPT1   Low Affinity Pentamidine Transporter  
LB   Luria broth 
LDL                        Low-Density Lipoprotein 
LmAQP1                  Leishmania major aquaporin-1 gene 
LS   Long slender 
M   Molar concentration 
MDR1   Multi-drug resistant transporter 1 
MFST   Major Facilitator Superfamily Transporter 
mg   Milligram      
min            Minute 
ml            Millilitre 
mM            Millimolar 
MMP                       Membrane potential 
MPXR                      Melarsoprol and pentamidine cross resistance 
mRNA            Messenger-ribonucleic acid 
MRPA                      Multidrug resistance protein A 
NECT            Nifurtimox-Eflornithine Combination Therapy 
ng   Nanogram 
nM   Nanomolar 
NPDs   Neglected Parasitic Diseases 
NTDs   Neglected Tropical Diseases 
ORF   Open reading frame 
P2                          Amino purine transporter 
PAT                        Potassium Antimony Tartrate 
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PBS   Phosphate-buffered saline 
PCF   Procyclic form 
PCF                        Procyclic form 
PCR   Polymerase chain reaction 
PMF                        proton-motive force 
pmol   Picomol 
PSG                        Promastigote secretory gel 
QRT-PCR                 Quantitative Reverse Transcription PCR 
RNA                        Ribonucleic acid 
RNAi   RNA interference 
rpm                        Revolutions per minute 
s                             Second 
SBIII                        Trivalent antimonials 
SbV   Pentavalent antimonials 
SDS                        Sodium Dodecyl Sulphate 
SEM                        Standard error of mean 
SNP                        Single Nucleotide Polymorphism 
SS                          Short Stumpy 
T. b. b                   Trypanosoma brucei brucei 
Tb427                     Trypanosoma brucei strain 427 
TbAQP1                  Trypanosoma brucei aquaporin-1gene 
TbAQP2                  Trypanosoma brucei aquaporin-2 gene 
TbAQP3                  Trypanosoma brucei aquaporin-3 gene 
TbAT1                     Trypanosoma brucei adenosine transporter 
Tet                        Tetracycline 
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TM                        Trans-membrane 
UTRs                     Untranslated regions 
UV                        Ultraviolet light 
Vmax                    Maximal velocity 
VSG                      variant surface glycoprotein Vmax 
WHO                     World Health Organization 
WT                        Wild type 
ΔG0                      Gibbs free energy 
µg                         Microgram     
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Chapter 1 General introduction 
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1.1. Kinetoplastid parasites and disease 
By definition, Kinetoplastids are a group of flagellated, unicellular, and motile 
protozoans whose specific characteristic is the presence of a kinetoplast. The 
kinetoplast is located in a single large mitochondrion, and is a term originally coined 
by Alexeieff in 1917 (Maslov et al., 2001). The Kinetoplastida belong to the larger 
group of phylum Euglenozoa, along with Diplomonads and Euglenids. Based on their 
morphological criteria, there is a division of Kinetoplastida into two major groups 
namely the biflagellate Bodonina and the uniflagellate Trypanosomatina (Dolezel et 
al., 2000). 
Trypanosoma species cause Chagas disease and sleeping sickness while Leishmania 
species cause leishmaniasis are among the most common human diseases (Stuart et 
al., 2008). Substantial morbidity is the major outcome associated with these 
diseases, especially in the world’s subtropical areas and amongst the poorest 
populations. These diseases, together with other bacterial, viral, and parasitic 
infections, are regarded to be NTDs (neglected tropical diseases) based on the 
consideration that there is inadequate donor funding tailored towards their control 
and are too often left untreated (Fidalgo & Gille., 2011).  
 
1.2. African Trypanosomiasis  
Human African Trypanosomiasis (HAT) and Animal African Trypanosomiasis (AAT), 
known more commonly as sleeping sickness and nagana, respectively, are vector-
borne diseases which pose serious health problems to people and animals throughout 
sub-Saharan Africa (SSA) causing physical suffering, food security issues and large 
economic losses (Bacchi, 2009; Holt et al., 2016). HAT is the result of infection by 
subspecies of the protozoan parasite Trypanosoma brucei, but AAT can also be 
caused by other species such as T. vivax, T. congolense, T. suis, and T. evansi 
(Birhanu, 2015; Giordani et al., 2016). The parasite is spread by an insect vector, 
which in this case is the tsetse fly of the genus Glossina spp. (Kennedy, 2013). 
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1.2.1. Life cycle of Trypanosoma brucei 
The complex life cycle of T. brucei (Figure 1.1) begins when the infected tsetse fly 
injects metacyclic trypomastigotes into a mammalian host skin and pass into the 
bloodstream during the fly blood meal. Within the bloodstream, T. brucei remains 
extracellular and enters a haemolymphatic stage, differentiating into a bloodstream 
long slender (LS) form that proliferates in both blood and lymph (Langousis & Hill, 
2014). To evade detection in the bloodstream, the protozoan parasite uses antigenic 
variation through its dense variant surface glycoprotein (VSG) coat (Pinger et al, 
2017). The coat has a stochastic switching expression pattern from a genomic 
repertoire of over 1000 VSG sequences, making a mounted host immune response 
difficult to achieve (Hutchinson et al, 2007). Early on in infection in mice, T. brucei 
has been shown to accumulate and replicate within adipose tissue, and evidence has 
revealed that parasites from within the adipose tissue are capable of infecting other 
naïve mice (Trindade et al., 2016). As the infection progresses, parasites in the blood 
breaches vessel walls, enabling access to extravascular tissue including the central 
nervous system (CNS) (Langousis & Hill, 2014). As the level of parasitaemia rises in 
the body, a quorum-sensing signal triggers non-reversible differentiation of LS forms, 
through a transition form, into non-dividing short stumpy (SS) forms of the parasite 
that are pre-adapted for survival inside a tsetse fly (Langousis & Hill, 2014; Seed & 
Wenck, 2003). It is thought the transition to non- dividing form is also a deliberate 
method of prolonging host survival until tsetse fly uptake by controlling parasitaemia 
in any given host (Seed & Wenck, 2003). Upon the next blood meal of a tsetse fly, 
SS and LS trypanosomes are taken up into the midgut of the tsetse fly. The role of 
the dermis and subcutis layers of the skin as a reservoir of vector-borne infection 
has often been overlooked. However, research from animal models has shown that 
sufficiently abundant populations of live, extravascular T. brucei residing in this 
organ play an important role in maximal parasite transmission (Capewell et al., 
2016). 
The new surrounding environment, with different pH, temperature and nutrient 
availability (Silvester et al, 2017) triggers changes in parasite gene expression and 
morphology leading to differentiation from the SS form to procyclic forms that 
proliferate in the tsetse fly midgut (Rico et al, 2013) whilst LS forms die out in the 
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midgut (Ooi & Bastin, 2013). Procyclic trypomastigote then migrate the length of 
the tsetse fly, first passing the proventriculus from where the procyclic 
trypomastigote asymmetrically divides, producing longer and shorter daughter cells. 
The latter is the epimastigote form of the trypanosome, which traverses to the 
salivary gland. On the other hand, the longer form appears to die shortly after being 
produced (Sharma et al., 2008). Upon arrival at the salivary gland, the epimastigote 
proliferates through two simultaneous cycles. The first involves symmetric division 
into daughter cells which bind to the gland epithelium and allows for the gland to 
be compromised for current and future infections. Meanwhile, the second form 
involves asymmetric division, giving rise to the infective metacyclic form of the 
parasite that is able to infect the host upon the next blood meal (Rotureau et al., 
2012).  
 
Figure 1.1: Life cycle of Trypanosoma brucei, the causative parasite of African trypanosomiasis.  
The figure highlights the important steps involved in the life cycle of the parasite in both tsetse fly and 








1.2.2. Morphology of Trypanosoma brucei 
The African trypanosome has two main morphologies: the trypomastigote and the 
epimastigote (Figure 1.2) which follow the same basic cellular architecture: a single 
copy set of organelles including a flagellum and flagellar pocket, a kinetoplast, a 
mitochondrion and a nucleus. Throughout the life cycle, the flagellar pocket is a 
crucial part of the cell as it remains the exclusive site for all endo- and exocytosis. 
Many of the cell organelle structures, including the kinetoplast, mitochondrion and 
nucleus, in all T. brucei cell forms appear to be skewed towards the posterior and 
central parts of the cell. (Matthews, 2005). 
At the posterior of the cell body the kinetoplast and the nucleus are hallmark 
features of the trypomastigote form (Figure 1.2A). The flagellum allows LS 
trypomastigote to be motile in the mammalian blood and spread to other areas of 
the body, including the CNS (Matthews, 2005). However, as the parasite 
differentiates into a non-dividing SS form in the mammalian bloodstream, the 
flagellum length decreases, which is possibly a sign of pre-adaptation to the tsetse 
fly, giving preference to environmental sensory functions over motility, akin to the 
Leishmania amastigote whilst in macrophages (Gluenz et al., 2010). As procyclic 
forms establish in the vector midgut, and differentiate into longer mesocyclic forms, 
the flagellum once again becomes a useful feature for propelling and migrating cells 
across the midgut (Ooi & Bastin, 2013; Langousis & Hill, 2014). Reaching the 
proventriculus, the mesocyclic form undergoes significant cell nucleus repositioning 
in the process to become epimastigotes (Schuster et al., 2017).  
The epimastigote morphology resembles cells with kinetoplasts that are anterior to 
the nucleus, effectively switching positions as it undergoes changes in cell length, 
width, as well as flagellar length (Ooi & Bastin, 2013). The asymmetric division by 
the proventricular epimastigote form, leading to both short and long forms, provides 
striking differences in all of these features (Figure 1.2B). However, this does not 
appear to be a hindrance, as it has thought the poorly motile short epimastigotes 
with short flagella are compensated by facilitated delivery to the SG by elongated 
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epimastigotes forms that are instead highly motile with long flagella (Van den 
Abbeele et al., 1999).  
 
Figure 1.2: Trypomastigote and epimastigote morphologies of Trypanosoma brucei.  
The figure shows the forms of the parasite that have the trypomastigote morphology, including the long 
slender bloodstream form, the short stumpy bloodstream form, the procyclic form and the mesocyclic 
form (mesocyclic is not shown in the legend) (a). The epimastigote forms that include the proventricular 
long epimastigote form and the short epimastigote form created as a result of asymmetric divison (b). 
Key cell organelles and structures, as well as relative subcellular locations within each form, are shown 
(adapted from Sunter & Gull, 2016, not drawn to scale). 
 
 
1.2.3. Epidemiology of African trypanosomiasis  
An encouraging decline has been observed in the numbers of new individuals 
contracting HAT over the last two decades, and in 2018, WHO reported only 977 
cases of HAT (Franco et al., 2020). However, HAT mostly occurs in more rural areas 
of Africa where efforts towards disease detection and surveillance are poorer 
(Franco et al, 2014b) and interventions must be continued to combat the disease as 
just under 50 million people are estimated to remain at risk (Franco et al., 2020). 
The two subspecies of T. brucei that cause HAT, Trypanosoma brucei gambiense and 
Trypanosoma brucei rhodesiense, still remain active in spreading HAT in Africa but 
only occur in highly selective foci where the parasite, host, reservoir, and vector co-
exist (Franco et al., 2014a). 
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T. b. gambiense causes a chronic form of the disease in both western and central 
Africa, with the worst affected countries including the Democratic Republic of Congo 
(DRC) and Guinea (Figure 1.3A; WHO, 2020d). Animal reservoirs play a minimal role 
in the transmission of T. b. gambiense HAT. Instead, hotspots of transmission via 
anthroponosis tend to be areas where there is humid forest, woodland, savannas and 
mangroves, or where these areas have been exploited by humans for agriculture 
such as coffee and cocoa plantations, as these are favourable habitations for tsetse 
fly vectors like Glossina palpalis gambiensis and Glossina palpalis palpalis. Here, 
proximate human-fly contact is at its greatest (Franco et al., 2014a). HAT control 
programmes like targeted screening of human populations for the infection have 
made a significant impact towards declining numbers of HAT cases in these regions 
of Africa. However, there are many rural areas that are hard to reach, leading to 
misrepresentation of numbers affected by the disease. This can be a result of regions 
in Africa with difficult terrain or with security threats that are more difficult to 
cover through programmes, resulting in less than 10% of the population being 
screened in endemic regions (Barrett et al., 2003; Franco et al., 2014a; Franco et 
al., 2014b; Steinmann et al., 2015). 
On the other hand, HAT caused by the subspecies T. b. rhodesiense has an acute 
form of progression, and exclusively affects eastern and southern African countries 
like Malawi and Zambia (Figure 1.3B; WHO, 2020d). Notably, an overlap of T. b. 
gambiense infection in Uganda exists, making human co-infection possible (Figure 
2.3) (Kennedy, 2013). T. b. rhodesiense disease is predominantly transmitted as a 
zoonosis and wildlife ranging from giraffes to impalas, as well as livestock such as 
cattle, play an important role as reservoirs that spread the parasite via vectors like 
Glossina morsitans that are found in East Africa. As a zoonosis, spread of the disease 
has proven more difficult to control, particularly as contact with domestic animals 
increases with human dependency on activities such as livestock husbandry (Franco 






















Figure 1.3: Map of Africa showing distribution of human African trypanosomiasis in 2018.  
(A) Countries in Africa coloured based on the number of reported cases of HAT caused by subspecies 
T. b. gambiense. Areas with most reported cases include the Democratic Republic of the Congo, 
Angola, the Central African Republic and Guinea (B) countries in the world coloured based on the 
number of reported cases of HAT caused by subspecies T. b. rhodesiense. Areas with most reported 
cases include Malawi, Zambia and Uganda (adapted from WHO, 2020d). 
 
 
1.2.4. Clinical manifestations 
The course of overall clinical manifestation of HAT that a patient may experience is 
dependent on the form of disease; exhibited by either T. b. gambiense or T. b. 
rhodesiense forms. Initial clinical manifestations in rhodesiense HAT involve a lesion 
(e.g. an ulcer) appearing at the site of the tsetse fly bite. As bloodstream forms of 
the parasite proliferate in the bloodstream, patients can experience headaches and 
enlarged lymph nodes, and on the skin, reddish rashes may begin to appear with 
both forms of the disease (Rodgers, 2009; MacLean et al., 2010). As previously 
mentioned, stages of the T. brucei life cycle in the host include a breach to the 
blood vessels into extravascular tissue including in organs such as the heart and liver, 
(B) (A) 
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and the effects of parasite invasion and proliferation manifest, including 
cardiovascular inflammation and fibrosis (Blum et al., 2007) as well as hepatomegaly 
(Kennedy & Rodgers, 2019). Even if the parasite has yet to cross the blood-brain 
barrier (BBB), neurological symptoms can appear in the earlier stages of the disease 
as well, though the underlying mechanisms for this warrant further research 
(Kennedy & Rodgers, 2019). 
The later development of the disease, otherwise termed the encephalitic stage, 
concerns the disruption of a wide range of neural activities, caused as T. brucei 
progresses into the CNS after crossing the BBB. This can ultimately lead to 
meningoencephalitis (inflammation of the brain), as well as disruption to sensory 
processes (particularly visual features), as well as involuntary muscle twitching and 
seizures caused by irregular and disrupted nerve signalling (Bentivoglio et al., 1994). 
There are also characteristic sleeping disorders that give the disease the label 
‘sleeping sickness’, which refers to daytime hypersomnia and night-time insomnia 
experienced by patients feeling continuously fatigued. Unless treated, or a rarer 
asymptomatic form of T. b. gambiense disease has occurred, patients with HAT 
almost always experience death from recurring symptoms (Kennedy & Rodgers, 
2019).  
Though these clinical presentations are common for both forms of HAT, important 
differences exist depending on the causative species of the disease. As previously 
mentioned, the T. b. rhodesiense form of HAT has an acute progression compared 
to the chronic T. b. gambiense form, and thus HAT duration in patients living in East 
and South Africa ranges typically from a few weeks to months whereas those in T. 
b. gambiense endemic areas have slow onset trypanosomiasis ranging from months 
to years. In the case of T. b. rhodesiense infection, shorter disease duration goes 
hand-in-hand with quicker progression to second-stage symptoms (Rodgers, 2009), 
though studies show geographical differences in clinical presentation here, such as 
less frequent presentations of T. b. rhodesiense second stage neuropathy in patients 
from Uganda compared to patients in Tanzania (Kuepfer et al., 2011). 
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1.2.5. Treatments available 
A wide range of trypanocidal chemotherapy has been explored as early as the 19th 
century (Steverding, 2010). However, treatment options in the 21st century consist 
of only few approved drugs: suramin, pentamidine, eflornithine and nifurtimox-
eflornithine combination therapy (NECT), melarsoprol, and fexinidazole. Clinical 
choice of treatment is dependent on the stage of HAT disease progression, and 
whether the disease takes the rhodesiense or gambiense form (Legros et al., 2002). 
However, despite the fatality of HAT, none of these options provide the ideal 
solution for HAT treatment, with either no means of oral administration, underlying 
toxic effects, low efficacy, a lack of knowledge on specific intracellular drug targets, 
as well as resistance to some of these existing drugs, particularly melarsoprol 
(Kennedy, 2013; de Koning, 2020).Treatment options reaching the end of the 
development pipeline are few and far between; until recent approval of fexinidazole 
in 2018 (Deeks, 2019) the last approved drug dates back to the 1970s. This reflects 
the real challenge faced with research and development for getting newer, more 
effective trialled therapies on the ground (Steverding, 2010). 
1.2.5.1. Suramin 
Suramin has been used as a first-line treatment for the haemolymphatic early stages 
of HAT caused by T. b. rhodesiense since the 1920s. It is administered intravenously, 
with five injections given to the patient every 3 to 7 days, usually over a 4 weeks 
treatment course (Barrett et al., 2007). The large size and negative charge of 
suramin prevents passive cell transport into the parasite (de Koning, 2020). Instead, 
the negative charge allows suramin to bind to the bloodstream trypanosomes 
glycolytic enzymes by means of electrostatic interactions, and in circulation almost 
all of the drug is bound to serum proteins (Barrett et al., 2007; Nok, 2003; Morgan 
et al., 2011). Multiple bodies of evidence have previously pointed towards the 
compound entering by a receptor-mediated endocytosis mechanism (Alsford et al., 
2012; Pal et al., 2002), and it is more recently apparent that the major mediator in 
this process is the surface molecule invariant surface glycoprotein 75 (ISG75), as 
well as major facilitator superfamily transporter (MFST). In turn, there is a high 
selectivity and rapid accumulation of suramin in the cell (Zoltner et al., 2015). It is 
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thought that once inside the trypanosome cell, suramin can inhibit positively 
charged glycolytic enzymes, as well as interfere with cytokinesis of parasite cells. 
Suramin can also interfere with multiple metabolic pathways, including low-density 
lipoprotein (LDL) uptake and disruption of lysosomes (Nok, 2003; Thomas et al., 
2018). A most recent study has shown that in addition to complex changes to 
metabolic pathways, a major collapse in cellular ATP levels found in suramin treated 
cells likely causes cell death (Zoltner et al., 2020). 
Perhaps unique amongst HAT treatment options, suramin has shown very rare 
treatment failure when used for early stage rhodesiense HAT, and there are almost 
no reports of drug resistance from the field (Barrett et al., 2007). However, 
administration of suramin comes with the risk of a wealth of adverse effects in some 
patients. Neurotoxic effects have been observed even at lower concentrations of 
drug administration (Barrett et al., 2007), as well as side effects including renal 




Pentamidine is an aromatic diamidine used as an alternative for early-stage HAT 
treatment. Though it is more commonly used against gambiense infection, it can 
also be used as a second-line treatment for rhodesiense disease (Kennedy, 2013) as 
well as against antimonial-resistant Leishmania (Chakravarty & Sundar, 2010). 
Pentamidine is administered intramuscularly to affected HAT patients, typically with 
seven to ten injections at doses of 4 mg kg-1 given on a daily basis (Barrett et al., 
2007; de Koning, 2020). 
The drug enters parasite cells through multiple transport channels. Partial transport 
is achieved by the aminopurine transporter P2, often referred to as Trypanosoma 
brucei AT1 (TbAT1), which has been evidenced by reduced pentamidine sensitivity 
after knockout of the encoding gene (TbAT1) (Matovu et al., 2003), as well as partial 
inhibition of pentamidine transport by adenine, a known substrate of TbAT1 (Carter 
et al., 1995). The bulk of pentamidine transport is facilitated by the presence of 
two other channels, a High Affinity Pentamidine Transporter (HAPT1) and a Low 
Affinity Pentamidine Transporter (LAPT1), discovered in 2001. This has been further 
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supported by competitive inhibition work using radiolabelled [3H]-pentamidine with 
increasing concentrations of unlabelled pentamidine substrate, causing significant 
biphasic uptake inhibition in tbat1-null mutants (de Koning, 2001; Matovu et al., 
2003). The former channel, HAPT1, has since been identified as Trypanosoma brucei 
aquaglyceroporin 2 (TbAQP2) located at the flagellar pockets of T. brucei cells 
(Munday et al., 2014). 
Though the exact mode of action of the drug is yet to be fully elucidated, recent 
research suggests pentamidine involvement in loss of kinetoplast DNA in 
trypanosome cells, as well as disruption mitochondrial membrane transport 
gradients (Thomas et al., 2018).  
The high potency for pentamidine in killing T. brucei cells has been demonstrated, 
with low nanomolar 50% effective growth-inhibitory concentration (EC50) levels, 
matched only by the toxic melaminophenyl arsenical, melarsoprol (Baker et al., 
2013). It has been established for some time now that intracellular concentrations 
of more than 1 mM pentamidine can be measured before parasite cell death (de 
Koning & Jarvis, 2001). However, like suramin, use of pentamidine can come with 
side-effects including abnormal glucose metabolism, as well as renal and GI 
disruption (Kennedy & Rodgers, 2019).  
1.2.5.3. Eflornithine and NECT Therapies 
Though both suramin and pentamidine have proven effective in the treatment of 
those affected by early-stage HAT, diagnosis of the disease is often too late, 
corresponding with when the parasite progresses into the later meningoencephalitic 
stages (Wastling & Welburn, 2011). Both suramin and pentamidine are ineffective at 
treating later stages of the disease, which is thought to be the result of difficulty in 
the drugs crossing the BBB to reach T. brucei cells. Even where possible, suramin 
and pentamidine either do not accumulate in sufficient quantities in the CNS or 
become trapped in capillary endothelia respectively, leading to little to no patient 
response against the developing infection (Sanderson et al., 2007; Sanderson et al., 
2009). 
Eflornithine is the one of the more recent registered and approved monotherapies 
for HAT, which being discovered back in the mid-1980s (De Koning, 2020). At the 
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start of the 2000s, eflornithine was most often used for the gambiense form of the 
disease, to treat later stages with a usual course comprising a dosage of 150 mg kg-
1 of body weight (for adults) or 100 mg kg-1 body weight (for children) slow 
intravenous infusions for 6 hours for 2 weeks (Burri & Bun, 2003).  
Eflornithine works by inhibiting ornithine decarboxylase, which plays a vital role in 
T. brucei polyamine synthesis and in turn, cell multiplication and differentiation 
(Priotto et al., 2007). Though initially developed for the treatment of cancers, the 
drug is thought to be particularly effective against gambiense infection as parasite 
versions of the enzyme are more stable and cannot gather polyamines from their 
external environment (De Koning, 2020). However, the short half-life of eflornithine 
makes administration difficult. Additionally, monotherapy treatment of eflornithine 
is often poorly tolerated, and causes toxicity in patients, for example in the bone 
marrow (Brun et al., 2010). 
With a push for efforts to find efficacious and safer alternatives, T. b. gambiense 
infections are now preferably treated in patients using a nifurtimox-eflornithine 
combination therapy (NECT). This involves giving 400 mg kg-1 eflornithine 
intravenously on a 7 day course, combined with nifurtimox, an oral drug usually used 
in the treatment of American trypanosomiasis (Chagas’ disease), at a dose of 15 mg 
kg-1 for 10 days (Priotto et al., 2009). Nifurtimox has the added benefit as a powerful 
oxidative agent against eflornithine-treated trypanosomes with a weakened 
oxidative stress defence because of the reduced synthesis of trypanothione 
(Babokhov et al., 2013). 
NECT has shown a range of key benefits that has led to it replacing eflornithine 
monotherapy, as evidenced from initial trials in both Uganda (Checchi et al., 2007) 
and the DRC (Priotto et al., 2009): 4-fold fewer infusions required (and therefore 
shorter hospitalisation and costs), reduced bone marrow toxicity is experienced from 
lower eflornithine doses, and combinations can delay emergence of future 
trypanosome drug resistance (Priotto et al., 2007; Priotto et al., 2009). NECT 
appears to be as efficacious in gambiense treatment as eflornithine monotherapy, 
however both eflornithine and NECT are ineffective against the rhodesiense form of 
infection due to a higher ornithine decarboxylase turnover than in the gambiense 
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form (Burri & Brun, 2003; Babokhov et al., 2013; Kennedy, 2013), leaving a more 
dangerous HAT treatment as the only treatment option. 
1.2.5.4. Melarsoprol 
Melarsoprol is an organic melaminophenyl arsenical drug, introduced as a second-
stage HAT treatment in the late 1940s due to its ability to penetrate the BBB. To 
this day, it remains first-line treatment for second-stage T. b. rhodesiense infection 
(Babokhov et al., 2013; De Koning, 2020), and although also effective for gambiense 
forms of the disease in Central and West African countries, the development of NECT 
therapy in 2009 provides a much safer and equally effective method of patients 
being treated in recent times, as explained above. The typical regime for affected 
patients currently involves the administration of melarsoprol intravenously to 
patients at 2.2 mg kg-1 every 24 hours for 10 days (Brun et al., 2010). 
After penetrating the patient BBB and reaching trypanosomes, melarsoprol enters 
the trypanosome cell via more than one transport channel. By studying resistant 
strains of T. brucei, Carter and Fairlamb (1993) established one of these as the 
adenosine TbAT1/P2 transporter, and clinical isolates and laboratory strain studies 
of the African trypanosome have demonstrated the additional importance of the 
TbAQP2 transporter, exhibiting HAPT1 activity, in melarsoprol uptake and 
trypanosome susceptibility to the drug (Bridges et al., 2007; Baker et al., 2012; Graf 
et al., 2013). Hence, both TbAT1/P2 and TbAQP2 play pivotal roles in both 
melarsoprol and pentamidine influx. 
Once in the T. brucei cell, the specific mode of melarsoprol remains unclear. 
Cunningham et al. (1994) showed that a melarsoprol derivative formed from 
subsequent intracellular reactions can disrupt activity of the antioxidant enzyme 
trypanothione reductase, most likely leading to toxicity to the parasite (Fairlamb & 
Horn, 2018). However, specific pathways are yet to be established, as well as other 
mechanisms such as underlying causes behind cell lysis of trypanosome cells that are 
observed in treated patients (Fairlamb & Horn, 2018).  
The current regime of melarsoprol treatment has proven particularly effective 
against rhodesiense forms of the disease, with cure rates as high as 96% one year 
after treatment in a study looking at T. b. rhodesiense foci in Tanzania and Uganda 
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(Kuepfer et al., 2012). Melarsoprol also has a high potency like pentamidine (i.e. 
low EC50). However, there are a number of drawbacks to melarsoprol use. Most 
striking is that 5-10% of patients exhibit post-treatment reactive encephalopathy 
(PTRE), which is fatal for around half of them. PTRE in itself is thought to be caused 
by major cytokine recruitment to neural regions in response to rapid lysis of T. 
brucei cells from melarsoprol treatment (Kennedy & Rodgers, 2019; De Koning 2020). 
However, melarsoprol can also lead to other adverse effects, such as cardiotoxicity, 
peripheral neuropathy and mild to severe skin rashes in the patient (Kennedy & 
Rodgers, 2019). 
1.2.5.5. Fexinidazole 
A new treatment option for first-stage and second-stage T. b. gambiense infection 
recently received approval from the European Medicines Agency (Deeks, 2019). It is 
the first treatment to receive approval for use since the 1970s, having entered phase 
1 clinical trials around a decade ago (Torreele et al., 2010). Fexinidazole appears to 
overcome two main obstacles of other current alternative treatments. Firstly, it is 
the first all-orally administered drug for gambiense HAT, making the treatment more 
widely available to remote and rural areas where gambiense HAT is prevalent 
(Deeks, 2019).  Secondly, adverse effects from the drug are described as minimal 
(WHO, 2019). 
Fexinidazole and its primary sulfoxide and sulfone metabolites are nitroimidazoles, 
which represent a group of compounds that bind DNA and inhibit nucleic acid and 
protein synthesis (Mital, 2009; Torreele et al., 2010). Effective treatment involves 
one dose administered orally each day over ten days (Lindner et al., 2020).  
Though a 21st century success in relation to treatments against HAT, further work 
with fexinidazole is needed refine the treatment and overcome some linked 
drawbacks, including higher treatment failure rates observed in patients with more 
severe CNS involvement in late second-stage gambiense HAT (European Medicines 





On the back of fexinidazole, focus has intensified on bringing more oral therapies 
for HAT through the development pipeline. The Drugs for Neglected Disease 
initiative has developed a promising benzoxaborole named acoziborole (Dickie et 
al., 2020). Through initial murine model studies, the orally administered drug has 
shown potential to cure second stage (Nare et al., 2010) HAT in a single dosing, and 
the success of initial clinical trials with acoziborole has now pushed the progression 
of trials to phase II/III since 2016. Efficacy and safety of the candidate drug is 
currently being assessed for HAT patients across a number of SSA countries, and 
trials are due for completion by the end of 2020 (Drugs for Neglected Diseases 
Initiative, 2020). 
1.2.6. Drug resistance 
Since Ehrlich’s early observations in the early 1900s, the underlying mechanisms 
behind African trypanosome drug resistance has been area of great research interest 
(Baker et al., 2013). By the very definition of a parasite, African trypanosomes are 
typical examples of host nutrient and ion scavengers, using transporters to take up 
substrates important for cell survival and viability from the host. Examples of such 
transporter substrates that get taken up by T. brucei transporters include adenine, 
adenosine and glucose (Schmidt et al., 2018), but also important trypanocidal 
agents, including: melaminophenyl arsenicals like melarsoprol, diamidines like 
pentamidine, eflornithine that cannot enter the cell by other means, such as passive 
diffusion (Baker et al., 2013; Schmidt et al., 2018). The study of transporters is 
therefore critical to elucidate how resistance and sensitivity to current trypanosome 
treatments has, or could, emerge (Munday et al., 2015). 
1.2.6.1. Resistance to melarsoprol and pentamidine 
The fact of melarsoprol-resistant HAT has been apparent for approximately half a 
century (Fairlamb & Horn, 2018), which only reflects the decades of over-
dependence on the arsenical for treating second-stage form of the disease (Munday 
et al., 2015). Melarsoprol treatment failure rates were around 5% in the 1990s. 
However, at the turn of the 21st century, refractoriness has accelerated, ranging 
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from 20%-30% in South Sudan, Angola and Northern Uganda and even up to 50% in 
the DRC (Fairlamb & Horn, 2018). On the other hand, field treatment failures for 
the drug pentamidine are rare. In most exceptions to this, cases are instead the 
result of misdiagnoses of the second-stage disease, to which pentamidine is not 
effective. Despite this, pentamidine-resistant strains can, and have been, generated 
in vitro (Bridges et al., 2007; Delespaux & De Koning, 2007). 
One of the clearest and most well-identified patterns from T. brucei drug resistance 
work is that of melarsoprol and pentamidine cross resistance (MPXR). The 
phenomenon has since been associated with the reduced uptake of both drugs from 
MPXR-resistant trypanosome cells, either through genetic changes to, or loss of, key 
transporter proteins (Baker et al., 2013).  
The first transporter protein implicated in this manner was the TbAT1/P2 
transporter that has unusual specificity for adenine and adenosine (Carter & 
Fairlamb, 1993; de Koning & Jarvis, 2001). TbAT1/P2 has a role to play in both 
melarsoprol (Carter & Fairlamb, 1993) and pentamidine (Carter et al., 1995; De 
Koning, 2001) uptake. For example: knockout of the encoding gene, TbAT1, has been 
shown to decrease both melarsoprol and pentamidine sensitivity in T. brucei cells in 
vitro (Matovu et al., 2003; Bridges et al., 2007); heterologous expression of TbAT1 
in Saccharomyces cerevisiae confers melarsoprol sensitivity, amongst other 
melaminophenyl arsenicals (Mäser et al., 1999) and T. b. gambiense clinical isolates 
have been identified that possess mutant versions of TbAT1,  exhibiting reduced 
pentamidine sensitivity (Graf et al., 2013). However, the levels of resistance 
reported from these studies, for example resistance factors of 2.3 (melarsoprol) and 
2.4-fold (pentamidine) (Matovu et al., 2003), do not match the high resistance levels 
achieved with MPXR strains in vitro, indicating other transporters are involved in 
creating the high resistance profile of MPXR (Baker et al., 2013).  
Since then, two other transporters have been linked with the transport of both 
melarsoprol and pentamidine; namely TbAQP2 (previously known as HAPT1) and 
LAPT1 (De Koning, 2001). The former shows a high affinity (Km: ~36 nM) and low 
capacity for pentamidine transport, whilst the latter displays a low affinity (Km: ~56 
µM) and high capacity for pentamidine transport (De Koning, 2020). An in vitro study 
found a highly adapted pentamidine and melarsoprol tbat1-null strain, B48, had lost 
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HAPT1 activity (implying additional loss or disruption to the TbAQP2 transporter as 
well as TbAT1) and had, as a result, become 130-fold resistant to pentamidine, 
whilst LAPT1 activity was retained unchanged. In this study, melaminophenyl 
arsenicals similar to melarsoprol showed similar patterns of resistance (Bridges et 
al., 2007). This shows a marked difference of the impact on resistance with the 
combined functional removal of TbAT1 and TbAQP2 transporters. Support for the 
critical role that TbAQP2 plays in melarsoprol and pentamidine uptake has been 
demonstrated in other bodies of work, for example in a double-gene-knockout study 
of AQP2 and neighbouring gene AQP3 (aqp2-3 null). Here, increases of 15-fold 
resistance to pentamidine and 2-fold resistance to melarsoprol were observed when 
compared with wild-type AQP2 expressed in a AQP1-3 null background cells as a 
reference (Alsford et al., 2012). Additionally, RNAi library screening has shown re-
introduction and expression of TbAQP2 to aqp2-aqp3 null cells controlled both 
pentamidine and melaminophenyl arsenical sensitivity (Baker et al., 2012). From the 
same study, the specific role of TbAQP3 was not as apparent as TbAQP2 which 
seemed to be the deciding factor between normal sensitivity and MPXR (Baker et 
al., 2012). 
1.2.6.2. Resistance to suramin 
Despite being one of the oldest anti-HAT treatments still in use, the evidence for 
suramin treatment failure in the field remains scarce. Along with pentamidine as a 
fellow first-stage treatment, suramin failure is reported in patients with 
misdiagnosed second-stage HAT, as the drug cannot reach the parasite after it 
crosses the BBB (De Koning, 2020). Inducible resistance of factors 20-140 have been 
shown in vivo after selection with the drug, but the phenotypic effect is short-lived 
and normal suramin sensitivity levels are restored once the parasite re-enters the 
tsetse fly stages (Scott et al., 1996). However, use of transcriptomics and reverse 
genetics has recently revealed that T. brucei cell lines selected with high suramin 
doses can develop resistance from a switch in expression of their outer membrane 
VSG coat to a particular glycoprotein called VSGSur. The resistance developed is over 
90-fold, and takes a matter of days to achieve in bloodstream forms in vitro 
(Wiedemar et al., 2018). 
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1.2.6.3. Eflornithine resistance 
Similar to pentamidine and suramin, reports of field eflornithine treatment failures 
are rare, but underlying mechanisms to understand future risks of resistance have 
been explored (Vincent et al., 2010). Eflornithine-resistant procyclic trypomasigotes 
were first observed to have a reduced uptake and accumulation of eflornithine 
compared to wild-type cells, implicating a potential transporter as part of an 
underlying mechanism (Bellofatto et al., 1987; Philips & Wang, 1987). Indeed, 
deletion of the gene encoding the amino acid transporter TbAAT6 was identified in 
2010 with two separate resistant T. brucei lines, which concurred with findings from 
RNA interference analysis (Alsford and Horn, 2008) that removal of TbAAT6 from 
wild-type lines, and re-expression from resistant lines ultimately determined 
eflornithine sensitivity (Vincent et al., 2010). 
 
1.3. Leishmaniasis 
Leishmaniasis is a neglected tropical disease caused by at least 21 species of an 
obligate intracellular parasite of the genus Leishmania. The parasite relies upon a 
sand fly vector as a form of transmission between human and mammal hosts, and to 
complete an essential stage of its life cycle development (Rodrigues et al., 2014). 
Leishmania species are classified into two subgenera based on their location in the 
vector's intestine: Leishmania (found in both the Old and New Worlds) and Viannia 
(restricted to the New World) (Stevens et al., 2001). In tropical and subtropical areas 
across the globe, Leishmania spp. infect humans and mammals with two major forms 
of disease: cutaneous (CL) and visceral leishmaniasis (VL), as well as rarer forms 
such as mucocutaneous leishmaniasis (MCL) (Barrett & Croft, 2012). Though 
leishmaniasis was discovered in the early 20th century by William Leishman and 
Charles Donovan, the parasite’s reliance on a vertebrate host to complete its life 
cycle has shaped the evolution and spread of the disease ever since early human 
activity (Steverding, 2017). 
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1.3.1. Life cycle of Leishmania 
Completion of the complex digenetic Leishmania life cycle (Figure 1.4) requires both 
a female sand fly and mammalian host (Handman, 1999).  The life cycle of the 
Leishmania parasite begins with the regurgitation of infectious metacyclic 
promastigotes into a mammal’s skin by an infected female sand fly. There is little 
understanding of how the regurgitation of gut content occurs during blood-feeding, 
however it is indicated that it happens as a result of the blockage produced by the 
promastigote secretory gel (PSG) (Rogers, 2012). Consequently, parasite inoculation 
involves the transmission of several components, including vector saliva, released 
parasite proteophosphoglycans, exosomes, and the insect gut microbiota. Together 
these facilitate the establishment and survival of the parasite by modulating the host 
immune response at the bite site (Gomes & Oliveira, 2012; Rogers, 2012; Atayde et 
al., 2015; Dey et al., 2018).        
It has been shown that once in the wound metacyclic promastigotes are either directly 
phagocytised by skin macrophages (primary target cells) or engulphed by neutrophils 
("trojan" cells). The activation signals originate from components of the alternative 
complement pathway of the host (C3bi and C3b), which promote parasite uptake by 
macrophages via CR3 and CR1 receptors (Peters & Sacks, 2006). When the 
Leishmania parasites are ingested by neutrophils, the parasite activates the 
programmed cell death of the polymorphonuclear cells which are then ingested by 
macrophage cells (Ritter et al., 2009; Dey et al., 2018). Irrespective of the infection 
route, once inside macrophages the metacyclic promastigotes enter the 
phagolysosome, which is a hostile environment for the parasite. Next, the metacyclic 
parasite transforms to the amastigote stage and multiplies by binary division to infect 
other macrophage cells.        
When the Leishmania amastigote is returned by the sand fly within its blood meal, it 
transforms into procyclic promastigotes (first replicative stage). Following this, 
promastigotes replicate in the gut of the sand fly until they transform into non-dividing 
motile nectomonads; these then escape the peritrophic matrix via the posterior 
opening and attach to midgut microvilli in the anterior midgut. Nectomonads then 
develop into leptomonads (second replicative stage) in the sand fly’s anterior midgut 
 42 
and then differentiate into metacyclic promastigotes, they can then produce 
Promastigote Secretory Gel (PSG) which alters the feeding behaviour of the fly 
(Rogers et al., 2002). Infected sand flies usually have difficulty with feeding because 
of the action of PSG stimulating regurgitation after the blood meal is mixed in their gut, 
this ensures transmission of the metacyclic-promastigote. Multiple blood feeds are 
known to be fundamental in Leishmania transmission by inducing sand fly 
infectiousness, this is achieved by enhancing Leishmania amplification. It is of interest 
that the ingestion of a second uninfected blood meal triggers "reverse differentiation" 
of the metacyclic promastigotes into retroleptomonad promastigotes, these then 
rapidly multiply and progressively differentiate back to metacyclic promastigotes 
(Serafim et al., 2018).         
 
Figure 1.4: The Leishmania life cycle.  
Metacyclic promastigotes enter the mammalian host skin when a sand fly bites a mammalian host 
during a blood meal. The parasites become internalised by means of phagocytosis by several host 
cells, including tissue-resident macrophages. Within, they are then delivered to a phagolysosome where 
they transform into intracellular amastigotes that proliferate leading to lysis of the cell, either reinvading 
other phagocytes or being taken up in the next sand fly bite. The first stage as showed in the diagram 
involves the sand fly feeding on a vertebrate mammal, and introduction of different vector’s components 
from vector to facilitate the migration of metacyclic promastigotes. Afterwards the vector’s components 
multiply within the mammal’s host cells inform of amastigotes as showed in process 1. The life cycle 
continues as another sand fly feeds on the infected blood to continue the development to procyclic 
promastigotes stage as showed in process 2 in the diagram. As labelled in the diagram, process 3 
involves the development of the parasite life cycle to long motile nectomonads. Process 4 on the other 
hand illustrates escape of the necomonads and their attachment to the midgut microvilli, which are later 
transformed to Leptomondas. Process 5 in the diagram involves the transformation of the Leptomonads 


























as illustrated in the diagram play an imperative role in the production of Promastigote Secretory Gel 
(PSG) which fills the thoracic midgut of the sand fly. Once inside the sand fly, amastigotes transform 
into procyclic promastigotes that proliferate in the midgut, and then move to the anterior of the sand fly 
where they become the infective and highly motile metacyclic promastigotes ready to infect another 
host (Dostalova and Volf, 2012; Serafim et al, 2018; Kaye & Scott, 2011).  
 
1.3.2. Morphology 
Over the span of its life cycle, the single-celled Leishmania parasite possesses two 
main cell morphologies as it traverses between vectors and hosts – a promastigote 
and amastigote morphology. The architecture of the cell is mostly conserved 
throughout both, for example, single copies of organelles; a flagellar pocket; a 
kinetoplast (containing mitochondrial DNA) anterior to the nucleus; and the 
attachment of the kinetoplast to the flagellar basal body (Ogbadoyi et al., 2003; 
Ambit et al., 2011; Sunter & Gull, 2017). However, notable differences lie in the 
cell’s shape, flagellum length and distance between the nucleus and kinetoplast. 
Whilst the promastigote is elongated, has an extended flagellum protruding from 
the basal body at its anterior end, and a segregated nucleus and kinetoplast, the 
amastigote is ovoid, has a rudimentary flagellum and its nucleus proximal to the 
kinetoplast (Gluenz et al., 2010; Sunter & Gull, 2017) (Figure 1.5). 
Precise morphologies in promastigote and amastigote forms translate directly into 
important functions for the parasite during different stages of the life cycle. During 
the time spent within the sand fly, the Leishmania procyclic promastigote uses its 
elongated cell shape with a long, motile flagellum to propel itself across different 
parts of the sand fly’s digestive tract, and to attach to the midgut epithelium (Bates, 
2008). Meanwhile, the much-reduced size of the amastigote relative to the 
promastigote reduces overall exposure to hostile conditions within the 
phagolysosome of host phagocytes (Sunter & Gull, 2017). The amastigote’s short 
flagellum highlights the lack of a need for high motility through the host; however, 
there is evidence to suggest that this feature holds a sensory function within the 






Figure 1.5: Schematic comparing the morphology of Leishmania promastigote and amastigote 
forms.  
Showing from the posterior end of the parasite cell to the anterior end. Key cell organelles and 
structures, as well as relative subcellular locations within each form, are shown (Sunter & Gull, 2017).  
 
1.3.3. Epidemiology of leishmaniasis  
Leishmaniasis remains a global threat to many people around the world; from over 
89 countries known to have had the disease, 12 to 15 million people become infected 
by the leishmaniases at any given time (Georgiadou et al., 2015; Torres-Guerrero et 
al., 2017). Meanwhile, 700,000 to 1 million new cases are collectively reported every 
year (WHO, 2020a) and over 350 million remain at risk of contracting one form or 
another (Torres-Guerrero et al., 2017).  In areas where the leishmaniases are 
endemic, as high as 9% of the entire healthy population can test positive for the 
disease (Bari, 2006). 
Over 10 years ago, it was reported that 90% of new cases of VL were located to 
Brazil, Sudan, South Sudan, as well as India and neighbouring countries (Blackwell 
et al., 2009).  These regions remain hotspots of burden of VL today, but this now 
also includes Ethiopia, which has experienced a substantial increase in cases over 
the past decade (Tadese et al., 2019) (Figure 1.6A). The two major species of the 
parasite that cause VL are Leishmania (Leishmania) donovani and Leishmania 
(Leishmania) infantum. In almost all cases, L. donovani infection remains exclusive 
to Africa, Asia and Europe. In India it is alternatively labelled ‘Kala-Azar’ or ‘Black 
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Fever’, because of a blackening of skin that is associated with this disease there, 
and spreads as an anthroponosis. On the other hand,  L. infantum infection extends 
to both the Old World and Latin America and spreads as a zoonosis (Ready, 2014), 
resulting from the well-studied domestic dog as the natural reservoir, but also 
including other important reservoirs such as cats and opossums (Ready, 2014; Roque 
& Jensen, 2014). There are now been reports of human immunodeficiency virus (HIV) 
that co-infects leishmaniasis patients in over 35 countries. Increased risk of 
developing VL in areas that are HIV endemic comes as no surprise, given that HIV 
severely compromises the immune system. Indeed, patients who are co-infected 
often have high parasite load, a sign that the compromised immune system has 
become overwhelmed (Sundar et al., 2019). 
Clinical CL is more common and more widely distributed than VL (Georgiadou et al., 
2015), impacting almost all Latin American countries including Brazil, Peru, 
Colombia and Costa Rica, as well as Algeria, North Sudan and Ethiopia in Africa, and 
Iran and Syria in the Middle East (WHO, 2020b) (Figure 1.6B). Although there has 
been a decline in reported CL cases in Saudi Arabia, the country still stands as the 
fourth most endemic for the disease in western Asia (Alvar et al., 2012; Abuzaid et 
al., 2017). Over 20 species of Leishmania can cause CL, and the predominant 
aetiological agents in the Old World are the species Leishmania major and 
Leishmania tropica, whilst in the Americas, this applies to the complexes Leishmania 
mexicana and Leishmania braziliensis (Torres-Guerrero et al., 2017). Whilst it is 
understood that L. tropica related disease spreads as an anthroponosis, and L. major 
disease as a zoonosis, there is no defined natural reservoir at present for the latter, 
though the domestic dog has been the most extensively studied and associated 
(Roque & Jensen, 2014; Bamorovat et al., 2018). Another cutaneous form, MCL, is 
found in Bolivia, Brazil, Peru and Ethiopia which collectively accounts for over 90% 
of known cases (WHO, 2020a) and is caused by species such as L. braziliensis and 
Leishmania amazonensis with show more regional distribution patterns (Torres-







Figure 1.6: Maps showing endemicity status of leishmaniasis in 2018.  
(A) Countries in the world coloured based on the number of new cases of visceral leishmaniasis (VL). 
Areas with highest endemicity include Brazil, Sudan, South Sudan, Ethiopia and southern Asia (B) 
countries in the world coloured based on the number of new cases of cutaneous and mucocutaneous 
leishmaniasis (CL). Areas with highest endemicity include: Central and South America, North Africa 





The spread and persistence of the leishmaniases is exacerbated by a range of 
political and socioeconomic factors. Conflict outbreaks in Afghanistan (Ahmad, 
2002) and Syria (Al-Salem et al., 2016), poor housing and irregular garbage 
collections in Latin American countries (which in turn promote sand fly resting 
grounds and breeding) as well as delays in access to healthcare in India (Okwor & 
Uzonna, 2016) have all been shown to contribute towards increased incidence of the 
leishmaniases. 
1.3.4. Clinical manifestations 
The leishmaniases can range from asymptomatic to clearly visible clinical 
presentations (Figure 1.7). Manifestations are normally distinguished between the 
two most common forms CL and VL, as well as the rarer MCL form.  
 
 
Figure 1.7: Different clinical presentations of the leishmaniases.  
(Left panel) Child affected by visceral leishmaniasis, with a striking protruding abdomen, (middle panel) 
a man afflicted with mucocutaneous leishmaniasis, with almost total destruction to the mucous 
membranes of his nose and mouth (right panel) human skin with an ulcer lesion, characteristic of 
cutaneous leishmaniasis (Stanford University, 2008). 
 
1.3.4.1. Cutaneous Leishmaniases 
CL, caused by species such as L. major and L. tropica, leads to lesions on exposed 
areas of the skin, and are typically ulcers (WHO, 2020a) as shown in Figure 1.7 (right 
panel). The type of lesion can vary depending on the causative species of Leishmania 
and host immune response to infection (Torres-Guerrero et al., 2017). For example, 
L. tropica infection leads to a manifestation of large, scaly oriental sores on many 
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areas of the skin, which are commonly identified in Middle Eastern, North African 
and Central Asian countries (Cairns, 1968). In comparison, Chiclero’s ulcer, which 
appears exclusive to the ear region, is the result of infection by L. mexicana that 
are endemic to areas like Mexico (Andrade-Narváez et al., 2001) and Ecuador 
(Calvopiña et al., 2013). In any case, self-healing of the lesion eventually leaves 
depressed scarring (WHO, 2020c). The approximate incubation period of CL varies 
based on parasite species from weeks to months (Weiss et al, 2009) with L. major 
usually taking less than 4 months to present symptoms, and L. tropica infection 
usually manifesting after between 2 to 8 months (WHO, 2020c). A large proportion 
of those asymptomatic for CL in endemic regions are able to control the infection, 
though the underlying mechanisms behind this are yet to be fully elucidated 
(Bahrami et al., 2018). 
Particularly in the Americas, MCL can also occur where the nasal and oral cavities 
become partially or fully eroded as pictured in Figure 1.7 (middle panel). This form 
of the disease, which disfigures the host, either takes place after resolution of 
previous CL lesions, or a co-existing presentation on the skin. MCL appears to be 
primarily the consequence of L. braziliensis infection (Handler et al., 2015).   
1.3.4.2. Visceral Leishmaniasis 
In the case of VL, the disease itself gains its name because of the causative parasite’s 
ability to progress away from the skin and infect, survive, and proliferate in several 
of the host’s visceral organs, most of all the liver and spleen. VL is therefore fatal 
if left untreated. Pathogenesis ensues from parasite proliferation within the viscera, 
ultimately causing hepatosplenomegaly (enlargement of the spleen and liver) which 
gives rise to the presentation of a distended abdomen as shown in Figure 1.7 (left 
panel) (McCall et al., 2013). Other features include pancytopenia (destruction of 
blood cells) thought to be the result of causative Leishmania species triggering over-
activation of the host macrophage and T-cell response (Gagnaire et al., 2000), as 
well as polyclonal hyper-gammaglobulinemia (a marked increase in production of 
immunoglobulins in the bloodstream) (Makaritsis et al., 2009). VL has an incubation 
period of around 3 to 8 months (Weiss et al., 2009).  
 49 
In some cases, both during and after a course of VL infection, a complication called 
post-kala-azar dermal leishmaniasis (PKDL) can develop. This is particularly the case 
in L. donovani endemic regions like Sudan and India, and affects 5%-60% of patients 
whereby papular, micropapular or nodular lesions appear as a rash, spreading from 
the mouth area to other areas of the body if the patient’s case of PKDL is more 
severe. The lesions are created as a result of an inflammatory reaction to the 
parasite, but interestingly lack plasma cells unlike lesions with CL (Zijlstra et al., 
2003). Incidence of asymptomatic VL has been vastly underestimated in the past, 
mainly due to remaining poorly understood. Carriers can be diagnosed by means of 
PCR or leishmaniasis skin testing, which estimated that a large number of people in 
VL endemic areas are asymptomatic. One such example is Sudan where 
asymptomatic L. donovani and L. infantum VL infections form around 30% of all cases 
(Singh et al., 2014).  
1.3.5. Treatments available  
Due to the variety of clinical manifestations and the number of causative Leishmania 
parasite species causing the disease, there is no one general first choice of 
treatment for leishmaniasis. Instead, treatment options must be considered in line 
with the challenges that disease forms pose in each affected area (Moore & 
Lockwood, 2010). The options to treat both major forms of the disease, CL and VL, 
are limited by several factors, for example: local availability of the drug, efficacy 
rates impacted by levels of resistance at the regional level, and side effects that 
can range from mild to adverse depending on the patient (Miranda-Verastegui et al., 
2009; Moore & Lockwood, 2010). Leishmaniasis being mostly a disease of developing 
countries, cost of the medication can also be an important factor. 
1.3.5.1. Pentavalent antimonials (Sbv) 
For over 60 years, antimonial drugs (Sbv), such as sodium stibogluconate (SSG) and 
meglumine antimoniate (MA), have been used as first line of treatments for all forms 
of leishmaniasis (Haldar et al., 2011). The standard treatment prescribed for 
affected VL patients is either a daily intravenous (SSG) or intramuscular injection 
(MA) of 20 mg kg-1 body weight for up to 30 days, whilst for CL patients antimonials 
 50 
are administered intralesionally (1-5ml of Sbv every 3 to 7 days) and systemically (20 
mg kg-1 for 20 days) (Sundar & Chakravarty, 2015).  
There have been three models proposing the mechanism of action for Sbv activity, 
including a stage-specific thiol-mediated process of reducing Sbv to the more lethal 
trivalent antimony SbIII in amastigotes once engulfed within macrophages. In turn, 
SbIII would target, bind and inhibit trypanothione reductase and zinc-finger proteins 
to kill the cell from within by compromising the cell to oxidative damage and metal 
toxicity. The second model proposes that Sbv may directly inhibit macromolecular 
synthesis by disturbing intracellular metabolic pathways, though this model has not 
evidenced a specific target in the process of disruption. The third model suggests 
that Sbv may activate innate and adaptive immune responses by the host by 
influencing host effector and signalling pathways that can lead to eventual parasite 
cell death. One such example is generation of host reactive oxygen species and 
nitrogen oxide within infected macrophage cells by means of the PI3K-PKC-Ras/Raf 
and P13K/Akt pathways respectively (Haldar et al., 2011).   
To this day, Sbv compounds are the treatment of choice in many areas of the world 
affected by CL and VL, particularly developing countries in Africa and South 
America, as well as central and some southern Asian countries including Bangladesh, 
Nepal and most of India (Haldar et al., 2011; WHO, 2020b). Despite this, the efficacy 
of the chosen SSG drug for patients in India has gradually declined over the last few 
decades, with the greatest apparent loss in the eastern state of India, Bihar, where 
cure rates between 1994-1997 were as low as 35% (Sundar et al., 2000; Rijal et al, 
2003). 
Success of Sbv treatment to CL conditions is not as clear cut, as sensitivity levels to 
Sbv sensitivity vary greatly, correlating with mixed CL patient response to treatment 
(Haldar et al., 2011). However, a 28 day course of Sbv remains highly recommended 
against L. braziliensis infection in America, achieving 75% cure rates for those with 
mild to moderate MCL, and to prevent disfiguration from mucosal lesions from an 
earlier onset of CL (Torres-Guerrero et al., 2017).  
Though Sbv remains one of the more popular choices of leishmaniasis treatment 
across affected nations, with exceptions to Bihar, the drug is by no means ideal due 
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to adverse effects like high toxicity (such as nephrotoxicity and cardiotoxicity), poor 
tolerability presented by some patients and high recurrence rates in patients who 
relapse (Elmahallawy & Agil, 2015). 
 
1.3.5.2. Amphotericin B 
The polyene antifungal drug Amphotericin B (AmB) has been a major treatment for 
cases of VL, and was the only ‘rescue treatment’ for patients who didn’t respond 
successfully to Sbv or relapsed, at the beginning of the 2000s (Alves et al., 2018). It 
was previously used in its conventional form, sodium deoxycholate, but due to its 
high toxicity, alternative formulations were desired. Fortunately, a lipid-associated 
formulation has been developed since then, known as liposomal amphotericin (L-
AmB), and successfully contains the drug until it reaches target parasite cells, 
making it a preferred option in order to significantly reduce exposure, and thus toxic 
effects, particularly to the kidneys (Aguirre & Hamid, 2015). L-AmB therapy has been 
the recommended choice of VL treatment by the National Program of Nepal, after 
increasing rates of local VL treatment failure with Sbv as well as areas of India like 
Bihar where Sbv  drug resistance is already firmly established (Torres-Guerrero et 
al., 2017) whilst conventional AmB appears to be reserved mostly for teaching and 
district hospitals (Alves et al., 2019), and L-AmB remains unaffordable for the many 
affected (Barrett & Croft, 2012). Whilst conventional AmB is administered 
intravenously at 0.75-1 mg kg-1 either daily or on alternating days for 15-20 days, 
patients co-infected with HIV on L-AmB therapy courses can afford extended courses 
of periodic infusions up to total doses of 40 mg kg-1, which provide less chances of 
patient relapse without significantly increasing the risk of adverse effects (Sundar & 
Chakravarty, 2010). 
Similar to their action on fungal cell membranes, AmB is understood to bind to 
ergosterol in Leishmania cell membranes and increase permeability of the cell to 
metabolites, by forming pores (Saha et al., 1986). L-AmB has been shown to be 
rapidly taken up by parasite-loaded phagocytes that are located in vital organs, 
effectively killing the parasite ‘from within’ and preventing further development of 
disease to the viscera (Adler-Moore & Proffitt, 2003).  
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With this mode of action, L-AmB has proven to be highly effective at treating VL, 
with over 95% efficacy shown from a study in India using the treatment, regardless 
of slight variations in dose regimens (Thakur et al., 1996). Though data on L-AmB 
treatment is less available for other forms of leishmaniasis, it does appear to also 
be highly effective in systemic forms of particular forms of CL and treatment of MCL 
in the New World (Alvar et al., 2006; Cunha et al., 2015). Despite this effectiveness, 
the drug is not usually administered except where challenges are faced with Sbv 
administration, given the high costs to buy sufficient quantities to effectively treat 
the disease. In addition, clinical studies indicate that VL patient response rates to 
L-AmB are lower in East Africa and South America than India (Barrett and Croft, 
2012).   
1.3.5.3. Paromomycin 
Paromomycin is an aminoglycoside antibiotic identified in the 1960s as a potential 
treatment for leishmaniasis. However, it only became clinically available in the mid-
2000s after patient response rates were found to be over 90% for topical treatment 
of Old World CL (Asilian & Davami, 2006) and comparable with efficacy rates of AmB 
in VL treatment, passing phase III trials (Sundar et al., 2007).  
During phase III trials, a treatment course consisting of 15 mg kg-1 paromomycin for 
21 days with intramuscular administration delivered 95% efficacy, and is now the 
licensed dose for VL patients in India, and standard for VL treatment in the 
surrounding regions (Sundar et al., 2007). However, similar efficacy could not be 
replicated with paromomycin in East Africa and the World Health Organisation 
(WHO) now recommends combination therapies with Sbv, allowing for shorter VL 
treatment courses to Sbv monotherapy with similar levels of efficacy (Uliana et al., 
2018). 
The mechanism of paromomycin against Leishmania cells is similar to those 
described against bacteria such as Staphylococcus strains (Ibrahim et al., 2019); it 
plays a major inhibitory role on protein synthesis at the ribosome by binding to the 
30S ribosomal subunit and disrupting polypeptide chain initiation and elongation 
from subsequent mRNA misreading (Sundar & Chakravarty, 2008). This mechanism 
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has also been supported by proteomic studies based on paromomycin-resistant L. 
donovani (Jhingran et al., 2009). 
So far, paromomycin is one of the cheapest anti-leishmanial treatments, costing as 
little as $10 per course (Barrett & Croft, 2012) and without major, non-reversible 
side effects (Sundar & Chakravarty, 2008). However, it has little efficacy for 
systemic treatment of CL or MCL, with the exception of New World CL in Brazil 
(Sundar & Chakravarty, 2015). Therefore, it seems likely that current recommended 
combination regimens with Sbv for VL treatments will be the only way it is used for 
the future. 
1.3.5.4. Miltefosine 
The alkyl phospholipid, miltefosine, became the first orally available VL treatment 
in 2002 when registered in India, two decades after being identified for possessing 
anti-leishmaniasis properties in the 1980s with L. donovani (Barrett & Croft, 2012; 
Uliana et al., 2018). A 94% VL cure rate was found from one phase III trial with a 28 
day treatment course (Sundar et al., 2002). Since, it has also shown promise as an 
orally administered CL treatment in some regions. However, there is large 
geographical variation in response rates, for example a phase II-III clinical trial in 
Brazil reported a 71.4% cure rate for L. guyanensis New World CL compared to a 
53.6% cure rate with Sbv treatment (Chrusciak-Talhari et al., 2011), whilst a phase 
III trial in Colombia reported a 69.8% cure rate for L. braziliensis and L. panamensis 
New World CL compared to 85.1% cure rate with Sbv  treatment (Vélez et al., 2010). 
The treatment was also shown to be non-inferior to Sbv treatment for L. major Old 
World CL from Iran.  
Current recommendations point to the same 28 day treatment course with a dosage 
dependent on the individual patient’s body weight: daily doses of 2.5 mg kg-1 for 2-
11 year olds, 50 mg for patients over 12 years of age but less than 25 kg, 100 mg for 
patients between 25 kg and 50 kg and 150 mg for patients over 50 kg (Dorlo et al., 
2012). 
As a drug that is also used to target human cancers, miltefosine has multiple targets 
and effects on Leishmania cells that influence cell multiplication. The drug targets 
an enzyme called phosphocholine cytidylyltransferase, preventing intracellular 
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phosphatidylcholine biosynthesis pathways. The presence of phosphatyidylcholine is 
critical for cell survival, with the miltefosine intervention instead resulting in the 
triggering of apoptosis (Braga, 2019). Apoptotic programmed cell death also seems 
to be triggered by miltefosine causing overexpression of methionine aminopeptidase 
2 (MAP2) in Leishmania cells treated in vitro (Kumar et al., 2017). Another target 
appears to be the replication machinery of the Leishmania cell, with RNA synthesis 
being downregulated by over 96%, triggering a ‘domino effect’ on protein and DNA 
synthesis in the cell (Braga, 2019). 
The discovery of miltefosine has been praised as a success on the path to a wider 
range of accessible options for treating leishmaniasis. However, it hasn’t completely 
met expectations on the ground, with inefficient drug supply chains and limited 
access to the drug from availability of the drug and high price tags, making it 
inaccessible for patients most in need but living in poverty (Sunyoto et al., 2018). 
Miltefosine also involves a much longer course of treatment in comparison to other 
treatment options, and has been shown to exhibit teratogenicity (defects to, or 
death of, an embryo or foetus). Additionally, phase IV trials have also revealed toxic 
side effects in the gastro-intestinal (GI) tract, kidneys and liver (Singh et al., 2016).  
1.3.5.5. Pentamidine  
Pentamidine is a diamidine drug synthesised in the late 1930s, and became a 
treatment of Sbv-refractory VL in India in the early 1940s for patients who did not 
respond to treatment. After the 1980s, the frequency of pentamidine use for VL 
treatment declined due to poor efficacy rates, combined with patient relapses and 
high frequency of adverse reactions including cardiotoxicity, diabetes mellitus onset 
and disruption to metabolic processes (Sundar & Chakravarty, 2015; Uliana et al., 
2018). 
Pentamidine, however, still has a role in treating particular CL forms, particularly 
in South America with New World CL (Barrett & Croft, 2012). Studies from South 
America have reported 90% (Suriname) and 95% (Colombia) cure rates against L. 
guyanensis and L. panamensis infections respectively (Soto et al., 1994; Lai et al., 
2002). Pentamidine has also shown to be effective for treating MCL lesions in Brazil, 
reporting 90-94% cure rates for affected patients with treatment courses of 2 - 4 mg 
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kg-1 given on alternate days usually over a week to two weeks (Sundar & Chakravarty, 
2015).  
Electron microscopy of pentamidine-treated Leishmania cells, in addition to L. 
mexicana diamidine-resistant strain studies suggest pentamidine works by 
accumulating in the mitochondria of Leishmania and thereby causing disintegration 
of the mitochondrion and its membrane potential (MMP) (Basselin et al., 2002). 
Disintegration of the kinetoplast is also observed through electron microscopy, 
which a study suggests may be due to the accumulation of pentamidine leading to 
disruption of kinetoplast DNA replication (Yang et al., 2016). 
1.3.6. Leishmania drug resistance 
Pathogen resistance to drug treatments is normally the result of changes to uptake, 
efflux, the way a drug is metabolised, or interactions between drugs and their target 
(Baker et al., 2013). The use of current anti-leishmaniasis drugs is constantly under 
threat from an underlying emergence of Leishmania drug resistance, particularly in 
the Indian sub-continent where VL treatment refractory rates have been the most 
apparent. Whilst in many affected countries, Sbv remain the preferred drugs for the 
range of clinical forms, use of Sbv as well as other second-line treatments are met 
with increasing treatment failure, compromising future dependence on the existing 
line of treatments (Ponte-Sucre et al., 2017).  
1.3.6.1. Resistance to pentavalent antimonials (Sbv) 
Antimonial-resistant Leishmania has been studied over the sixty-year course of Sbv 
treatment of VL. Reports of resistance first came in Bihar in India, where treatment 
failure rates were ~30% in the 1980s. Although WHO recommendations to increase 
both dosage and duration of the Sbv treatment course to 20 mg kg-1 for 20 days had 
a modest short-term impact on helping to revive cure rates, a progressive decline 
was monitored in the region (Croft et al., 2006), with Sundar et al. (2000) reporting 
treatment failure rates as high as ~65% in North Bihar in one study. In neighbouring 
regions and countries, there is variation in the patient response; whilst some areas 
are largely unaffected, such as 2% failure rates reported in Uttar Pradesh, patient 
refractoriness in the Nepalese Terai regions were near 24% (Rijal et al., 2003). 
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Treatment failure is strongly associated with the emergence of L. donovani 
resistance in Bihar in vitro, where a three-fold lower sensitivity has been shown in 
L. donovani amastigote stage isolates in non-responsive patients compared with 
patients who responded to treatment (Lira et al., 1999). 
Historically, the emergence of Sbv resistance in sub-continental India has been a 
result of widespread misuse of the drug. It had become easily accessible to many in 
the population without qualified medical diagnosis for guidance on Sbv use. 
Additionally, regimens that had an increasing dose progression or with intervals were 
previously recommended and thought to boost chances of treatment success. 
Pronounced Sbv treatment failure in newly treated patients appears to be almost 
exclusive to sub-continental India and surrounding regions, with the anthroponotic 
nature of VL transmission in this area accelerating the spread of drug resistance 
once acquired by the parasite (Haldar et al., 2011). 
Various cellular processes have been pinpointed as possible underlying causes for Sbv 
resistance, including: reduced conversion of Sbv into its trivalent more active and 
toxic form SbIII; increased levels of thiols such as trypanothione that have been 
shown to protect Leishmania cells from oxygen radical attack caused by antimonials, 
and overexpression of ATP-binding cassette (ABC) and of multidrug resistance 
protein A (MRPA) transporters that boost efflux and sequestration of Sbv metabolites 
respectively and lower drug accumulation inside the cell (Mandal et al., 2007; Singh 
et al., 2014; Ponte-Sucre et al., 2017). Another Leishmania transporter, 
aquaglyceroporin 1 (AQP1), has been implicated in the facilitated uptake of SbIII in 
Leishmania species. In vitro, greater Leishmania cell sensitivity and resistance to 
SbIII can be altered with over-expression or deletion of the encoding gene, AQP1, 
respectively (Gourbal et al., 2004; Richard et al., 2004), and in VL and PKDL L. 
donovani field isolates, down-regulation of AQP1 RNA levels have been found to 
correlate with reduced accumulation of SbIII and drug resistance in the area (Mandal 
et al, 2010). 
1.3.6.2. Resistance to amphotericin B 
Reports of Leishmania treatment failure and resistance to the antifungal drug AmB 
have been relatively rare, posing a low threat over the last 60 years of use as an 
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anti-leishmaniasis agent (Ponte-Sucre et al., 2017). Despite this, there are some 
sparse cases of treatment failure that have been identified. For example, L. 
donovani isolates from a patient who relapsed in a non-endemic region of India were 
reported to exhibit in vivo drug tolerance (Srivastava et al., 2011) and an 
immunosuppressed patient in Switzerland was identified with L-AmB primary 
treatment failure. Cases from non-endemic regions may be the result of increasing 
migration and travel globally (Eichenberger et al., 2017) though future AmB 
resistance in endemic areas is equally probable. One factor that may exacerbate 
this is single-shot minimal dosage L-AmB regimens supported by WHO, widely used 
across India which have the effect of facilitatating selection of less AmB sensitive 
forms of the parasite (Ponte-Sucre et al., 2017). 
Several mechanisms have been linked with AmB resistance from laboratory studies. 
One study showed that L. donovani isolates selected for 8-fold AmB resistance 
circumvented AmB binding cell membranes from loss of ergosterol. Instead, the 
sterol was replaced with the precursor cholesta-5,7,24-trien-3β-ol, thereby 
decreasing AmB action on membrane permeability (Purkait et al., 2012). Secondly, 
the efflux transporter multi-drug resistant transporter 1 (MDR1), was shown to have 
been 3-fold overexpressed in resistant promastigotes, with treatment of a MDR1 
inhibitor beforehand partially reversing the AmB resistance phenotype (Purkait et 
al., 2012). Separate studies have also identified that mutations to the gene sterol 
14α-demethylase can result in ergosterol loss and changes to sterol metabolism 
(Mwenechanya et al., 2017). Resistant parasites also appear to upregulate a range 
of defence mechanisms against AmB oxidative stress (Sundar et al., 2019). 
1.3.6.3. Resistance to miltefosine 
Miltefosine has been a promising drug alternative to replace traditional Sbv in the 
Indian sub-continent for nearly two decades, with high initial cure rates of around 
94% (Ponte-Sucre et al., 2017). However, in as little as a decade, increasing patient 
relapses in India, Nepal and Bangladesh reflect a cure rate decline down to 85% in 
these areas (Rahman et al., 2011; Sundar et al., 2012; Rijal et al., 2013). Low 
efficacy rates have been more recently identified for VL treatment in Kenya and 
Sudan with standard miltefosine monotherapy regimens (Wasunna et al., 2016). Risk 
of resistance to the drug is compounded by the long elimination half-life of 
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miltefosine in the body (~120 h), causing long-lingering low concentrations of the 
drug that promote parasite resistance selection whilst being largely ineffective for 
parasite cell death. This problem is exacerbated where patients don’t comply with 
the full medication regimen (Ponte-Sucre et al., 2017; Sundar et al., 2019).   
Miltefosine resistance can be induced in vitro, with the first evidence emerging from 
a paper in 2003. Here, defects to internal protein-dependent phospholipid 
translocation of the drug were suggested as a possible causative resistance 
mechanism (Pérez-Victoria et al., 2003). The proteins implicated as part of the 
translocation machinery have now been identified as the L. donovani miltefosine 
transporter (LdMT) and the L. donovani subunit for LdMT (LdRos3), which appear to 
both be required for Leishmania miltefosine uptake and sensitivity (Pérez-Victoria 
et al., 2006). Both in vitro and in vivo assays have demonstrated that mutations or 
deletions to encoding genes that compromise the function of LdMT and LdRoS3 lead 
to high-fold increases in miltefosine resistance levels by L. donovani cells (Ponte-
Sucre et al., 2017). It is also now clear that LdMT function, whilst essential, does 
not fully account for wild-type or drug-induced levels of sensitivity or resistance 
respectively. To this end, additional mechanisms, such as overexpression of ABC 
transporters MDR1, ABCG4 and ABCG6 increase efflux of miltefosine, reducing 
accumulation of the drug in the parasite to achieve sufficient potency (Pérez-
Victoria et al., 2006; Sundar et al., 2019).  
Though recent studies using ‘omics’ technology have revealed that Leishmania 
miltefosine resistance is in fact multifaceted and beyond the scope of just LdMT and 
ABC efflux transporters, the roles that other components play are yet to be 
elucidated (Ponte-Sucre et al., 2017). 
1.3.6.4. Resistance to pentamidine 
Historically, pentamidine had been used to successfully combat VL in the North Bihar 
region, with cure rates of 99%. In the short space of time of only two decades, 
however, treatment failures up to ~30% were reported. This led pentamidine to be 
abandoned in the surrounding region as a second-line treatment in favour of more 
effective currently used treatments such as miltefosine (Chakravarty & Sundar, 
2010). As a first-line treatment it is now almost exclusively used for specific forms 
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of CL and MCL in the New World, and for this it has retained a relatively high efficacy 
(Barrett & Croft, 2012). Its current limited use in South America for Leishmania 
species that spread by zoonotic transmission has fortunately reduced the possible 
risk and burden of acquired drug resistance on treatment failures with new world 
leishmaniasis (Croft et al., 2006). However, the situation in India suggested from 
early on that selection against pentamidine could be easily achieved by the parasite, 
especially by anthroponotic transmission and widespread use (Uliana et al., 2017).  
Early work showed that pentamidine resistance can be quickly obtained in multiple 
parasite species in vitro, including: L. major (Ellenberger & Beverley 1986) L. 
mexicana (Basselin et al., 2002) and L. amazonensis (Coelho et al., 2008).  A study 
using L. mexicana showed that the resistance phenotype corresponds with a 
substantially lower intracellular pentamidine accumulation than wild-type lines, 
particularly within the mitochondria as shown by fluorescent labelling (Basselin et 
al., 2002). This may be partly due to alterations made to AT-rich regions of 
kinetoplast DNA in resistant lines that are understood to be necessary for 
pentamidine binding (Basselin et al., 1998). As a result of a higher proportion of 
pentamidine in the cytosol as opposed to organelles, more of the drug is available 
for efflux (Basselin et al., 2002; Bray et al., 2003). Reduced accumulation was 
suggested to be at least partly the result of reduced uptake by a transport-carrier 
mechanism (Basselin et al., 1996; 2002) which is supported by observed 18-fold and 
75-fold reduced uptake rates of pentamidine in L. donovani and L. amazonensis 
promastigote clones respectively (Croft et al., 2006). However, the exact 
mechanism for resistance remains unclear, although one proposed involves reduced 
uptake through a Leishmania high-affinity plasma membrane transporter, driven by 
reduced MMP rather than a change to the transporter itself. This has been supported 
by findings that the membrane transport carrier remains unaltered despite 
resistance, and that the use of MMP inhibitors is able to reduce wild-type cell 
pentamidine uptake (Basselin et al., 2002; Bray et al., 2003). Moreover, the 
expression of a pentamidine transporter, TbAQP1, in L. mexicana promastigotes, 
increased rates of uptake as well as pentamidine sensitivity (Munday et al., 2014).  
Efflux of pentamidine in resistant lines of L. major and L. infantum promastigotes 
and amastigotes are likely mediated by the ABC transporter pentamidine resistance 
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protein 1, PRP1, that was identified through functional cloning. Overexpression by 
transfection of PRP1 conferred resistance to pentamidine in both promastigotes and 
amastigotes (Coelho et al., 2003; Coelho et al., 2007). Though a specific mechanism 
for efflux is not established, it has suggested that PRP1 may transport pentamidine 
into vesicles that then exit the cell via exocytosis from the flagellar pocket (Coelho 
et al., 2007). However, the role of PRP1 in pentamidine resistance does not appear 
to be shared in all Leishmania species, for example in L. amazonensis (Coelho et al., 
2008). 
1.4. Trypanosomatid aquaporins: as new drug targets  
The presence of aquaporins (AQP), which are integral membrane protein 
transporters, is critical in playing the role tailored towards facilitating the regulated 
and rapid movement of non-polar solutes such as water in and out the cells (Borgnia 
et al., 1999; Gourbal et al., 2004). AQPs belong to the Major Intrinsic Protein (MIPs), 
a super-family of integral membrane proteins present throughout the kingdoms of 
viruses, bacteria, plantae, animalia, archaea, fungi, and protista (Thomas et al., 
2010). With aquaporin monomers comprising six transmembrane helical segments 
and two short helical segments covering cytoplasmic and extracellular vestibules 
bound by a narrow aqueous pore, they have a similar basic structure (Verkman, 
2013).  It is possible to functionally classify these small channels of integral 
membrane protein into two primary sub-groups namely the aquaglyceroporins 
(which are responsible for the transportation of different small, uncharged solutes 
as well as water) and orthodox aquaporins (which chiefly serve as water specific 
channels). Uncharged solutes transported by aquaglyceroporins include 
methylglyoxal, dihydroxyacetone, urea, polyols, glycerol, and metalloids such as 
antimony (SbIII) and trivalent arsenic (AsIII) (Bhattacharjee et al., 2009).  
It has been determined that the success of kinetoplastid parasites such as 
Trypanosoma brucei and Leishmania major is dependent on their respective abilities 
to meet the diverse challenges presented by different environments both in insects 
and mammals. Following the nature of trypanosomatid parasites to be frequently 
traveling between the mammalian and insect hosts, they are often exposed to the 
risk of facing severe osmotic challenges (Rohloff & Docampo, 2008). Therefore, 
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there is an interface that exists between the kinetoplastid cells and its respective 
environment, which is in part constituted of numerous membrane transporter 
proteins and glycoproteins, and this serves in overcoming diverse unavoidable 
biological barriers. Several aquaporins have been identified in trypanosomatid 
parasites (Chen et al., 2005; Beitz et al., 2006; Montalvetti et al., 2004; Figarella et 
al., 2007). In comparison, it has been generally determined that parasite AQPs have 
a higher level of transporting water than mammalian and E. coli aquaporins. 
Aquaglyceroporins of protozoan parasites have also been reported to be bifunctional 
and thus serve to improve the conduction of glycerol and water at reasonable rates 
(Beitz et al., 2005). 
 
1.4.1. Role of AQPs in drug response in Trypanosoma brucei: Human African 
Trypanosomiasis (HAT) 
In the T. brucei genome there exist three aquaglyceroporins, namely TbAQP1, 
TbAQP2 and TbAQP3 (Uzcategui et al., 2004; Beitz, 2005). These aquaglyceroporins 
are differentially involved in the regulation of the localization and abundance of the 
different AQPs depending on the unique developmental stages of T. brucei (Baker 
et al., 2012). In the case of TbAQP1, it is localized in the flagellar membrane, 
whereas the localization of TbAQP3 occurs in the pellicular membrane, independent 
of the developmental stage (Bassarak et al., 2011; Baker et al., 2012). Interestingly, 
the situation is different when it comes to the case of TbAQP2, whose redistribution 
occurs over the pellicular membrane in insect stage form but it is located to the 
flagellar pocket in bloodstream forms (Baker et al., 2012). The characterized AQPs 
from T. brucei are aquaglyceroporins, and as a result, they are explicitly responsible 
for the transportation of water in addition to other small molecules that are 
uncharged as trivalent metalloids, urea, and glycerol (Uzcategui et al., 2004; 2013). 
Unlike the cases of other aquaglyceroporins, TbAQP2 has been implicated in the 
transportation of larger compounds such as melarsoprol (398 Da) and pentamidine 
(340 Da). Both melarsoprol (398 Da) and pentamidine (340 Da) are trypanocides, 
which are three-fold larger than glycerol, widely considered as the largest substrate 
of TbAQP2 (Baker et al., 2012). The arsenical and diamidine resistant parasites are 
reported to be cross-resistant and have shown reduced uptakes of both drugs in HAT. 
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Many studies have found that there is that the TbAT1 (purine transporter 2 - P2) and 
TbAQP2 transporters (Baker et al, 2013; Figure 1.8) are implicated in determining 
the rate of uptake of pentamidine and melarsoprol, as well as in the emergence of 
MPXR in T. brucei (Mäser et al., 1999; Munday et al., 2014; Munday et al., 2015b; 
Carter & Fairlamb, 1993; Baker et al., 2012, 2013).  
       
 
 
Figure 1.8: A depiction of the model explaining the pentamidine and melarsoprol transport in T. 
brucei.  
There is the linkage of four T. brucei transporters to the pentamidine susceptibility and melarsoprol 
control. The entrance of both drugs into the cell occurs through AQP2 (Tb927.10.14170) and AT1/P2 
(Tb927.5.286b). HAI-3 (Tb927.10.12500-10, with only two of them reflected through annotation in the 
reference genome) has been specifically associated with the susceptibility of pentamidine. It is 
suggested that there is requirement for pentamidine symport via AQP2 for the generation of the proton 
motive force (De Koning, 2001). MRPA (Tb927.8.2160) is the channel through which the efflux of the 
Mel T, a toxic melarsoprol-trypanothione adduct. AQP2 and AT1/P2 channels are responsible for the 
transportation of the drugs with different efficiencies, indicated by the weight arrows in the figure. (Baker 
et al., 2013). 
 
There is a close relation between TbAQP2 and TbAQP3, which have close sequence 
similarity and are adjacent to each other on the chromosome. In comparison to 
TbAQP3, TbAQP2 is characterized by unusual selectivity filter amino acids residues 
in comparison with TbAQP3. The TbAQP2 exhibits unusual selectivity pore amino 
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acids residues, (NSA/NPS/IVLL) in the pore, unlike the latter which has the usual 
motifs (NPA/NPA/WGYR) (Baker et al., 2012; Figure 1.9). TbAQP2 also does not have 
the aromatic/arginine (a/R) motif in comparison with TbAQP3 (Baker et al., 2012).  
Aquaporins usually have a selectivity filter which usually defined by two constrictions 
in the channel: one formed by extremely conserved of two of "NPA" motifs within the 
half helices, the other one is usually narrower, created by an "aromatic arginine" (ar/R) 
motif (de Groot et al., 2001; Sui et al., 2001). These two regions have been suggested 
as filters that block solutes larger than water and charged molecules from moving 
through. The two NPA motifs in the narrow central constriction of the pore, according 
to crystallographic studies, contribute to a monomeric pore structure that enables 
selective, bi-directional, and single-file transport of water in classical AQPs (Sui et al., 
2001) and water and glycerol in aquaglyceroporins (Jensen et al., 2001). The 
aromatic-arginine region, which is narrower than the central NPA constriction and acts 
as a selectivity filter on the extracellular side of the AQP channel, blocks the entry of 
molecules larger than water (de Groot & Grubmu; 2005, 2001). (The selectivity filter 




Figure 1.9: Schematic representation of AQP2 (Tb927.10.14170) and AQP3 (Tb927.10.14160). 
The selectivity filter residues are indicated; the unique NSA/NPS/IVLL in AQP2 and the classical 
NPA/NPA/WGYR in AQP3 (adapted from Baker et al., 2012). 
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It has been demonstrated that the genetic knockout of TbAQP2 results in MPXR, 
while the re-expression of this gene causes a full reversal of the phenomenon. 
However, the expression or deletion of TbAQP3 did not have any measurable effects 
on the uptake of (or sensitivity to) pentamidine or melaminophenyl arsenicals. 
Therefore, these findings show that TbAQP2 is undeniably a genetic determinant of 
MPXR. Thus, owing to the unique selectivity of its filter functions, TbAQP2 is not 
only a water channel but also a potential drug transporter (Baker et al., 2012). The 
area of dispute remains the specific translocation mechanism for the TbAQP2-
mediated internalisation of pentamidine. The study by Song et al. (2016) challenged 
the drug uptake model through the uniquely permissive aquaglyceroporin by positing 
the argument that instead of traversing the pore of TbAQP2, there is the mere 
binding of pentamidine to an aspartate residue (Asp265) above the selectivity filter 
and close to the pore’s extracellular end, followed by the process of endocytosis 
(Song et al., 2016). Based on this understanding, it is necessary to conduct further 
studies with the specific aim tailored towards determining the TbAQP2-mediated 
drug transport mechanisms in the trypanosomes.  
 
1.4.2. Role of AQPs in drug response and resistance in Leishmania spp.: 
Leishmaniasis  
Drugs containing pentavalent antimony, such as meglumine antimonate 
(Glucantime) and stibogluconate (Pentostam), are used as the first treatment choice 
against all leishmaniasis forms. There have been reports of clinical resistance from 
diverse parts of the world when it comes to this class of drugs (Guerin et al., 2002). 
As membrane support proteins, aquaglyceroporins play critical functions in the life 
cycle of parasites as they serve roles in controlling transmembrane nutrient (or 
waste product) flux, alleviating osmotic stress, and releasing metabolites (Verkman 
et al., 2014; Brochu et al., 2003; Gourbal et al., 2004; Freźard et al., 2014; Nilsen 
et al., 2016). One of markers that is commonly linked to antimonial resistance and 
most frequently identified in Leishmania is AQP1 (Marquis et al., 2005; Decuypere 
et al., 2005; Mandal et al., 2010; Maharjan et al., 2008; Kazemi-Rad et al., 2013). 
Pentavalent antimonials [SbV] chiefly serve as pro-drugs and in order for the drugs 
to be in its active form, they are usually reduced to trivalent antimony [SbIII] (Ephros 
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et al., 1999). Shaked et al. (2001) acknowledges that the process of how pentavalent 
antimony is reduced to a trivalent compound in the parasites is still not known, and 
also, it has not yet been determined how the entry of antimonials mechanisms into 
macrophages and from there into the phagolysosomes takes place. 
However, Gourbal, et al. (2004) suggested that the first SbIII facilitator that has been 
identified in Leishmania is aquaglyceroporin 1 (LmAQP1) (Figure 1.10) and 
determined that it embodies a direct relationship to both the resistance and uptake 
of antimonite [SbIII] (Gourbal et al., 2004; Marquis et al., 2005). The level of 
expression of AQP1 in cultured promastigotes and intra-macrophage amastigotes in 
vitro was found to correlate with the levels of susceptibility exhibited in different 
Leishmania species; AQP1 of L. major was reported to facilitate the highest level of 
sensitivity to Sb (III) (Mandal et al., 2015). It was found that five different aquaporins 
are expressed by the genome of Leishmania major species: LmAQP1, LmAQPα, 
LmAQPβ, LmAQPγ, and LmAQPδ. LmAQP1 showed a strong degree of similarity to 
human AQP9 and to bacterial aquaglyceroporin GlpF, while the remaining water-
transporting proteins (LmAQP α-δ) operated as classic aquaporins, reflecting 
similarity to the ones that are found in plants (Figarella et al., 2007; Biyani et al., 
2011; Maurel et al., 2015).There has been proof supporting the permeability of 
LmAQP1 to glycerol and how it effectively functions as a route of drug-delivery for 
antimonial compounds as well as performing a critical role in osmotaxis (Figarella et 
al., 2007). 
In promastigotes there is the exclusive localisation of LmAQP1 to the flagellum, 
while in amastigotes, its presence is within the contractile vacuoles, the 
rudimentary flagellum, and the flagellar pocket. LmAQP1 serves a significant 
physiological role in osmotaxis, volume regulation, and the transportation of solutes 
and water. Resistance to SbIII could be increased when one of the two LmAQP1 alleles 
in L. major is disrupted (Marquis et al., 2005). There are significantly lower levels 
of LmAQP1 mRNA in As (III) or Sb (III) resistant Leishmania tarentolae and L. major 
cells, which is an indication of how drug resistance is caused by the downregulation 
of LmAQP1 (Marquis et al., 2005). Later there was a corroboration of these findings 
in the field isolates from Nepal (Decuypere et al., 2005) and India (Mandal et al., 
2010). The drug resistance and cellular physiology of Leishmania were amongst the 
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major roles played by the LmAQP1. As a result of all findings, there is the need for 
further work to be conducted with the specific goal focused on understanding the 




Figure 1.10: Representation of proposed antimonial transport mechanism diagrammatically for 
an infected macrophage in Leishmania.  
The figure shows a potential mechanism of antimonial transport an infected macrophage in Leishmania. 
There is transportation of pentavalent antimony [Sb (V)] into the macrophage, which is then 
subsequently reduced to trivalent antimony [Sb (III)] prior to its transportation into the phagolysosome. 
Finally, the transportation of Sb (III) into the cytoplasm of the parasite is facilitated by LmAQP1 (adapted 
from Mandal et al., 2013). 
 
 
1.5. Objectives and aims of the project: 
Neglected parasitic diseases (NPD) include some of the worst human infections and 
are caused by pathogens including T. brucei (human African trypanosomiasis or 
sleeping sickness), Leishmania spp (leishmaniasis), which lead to large disease 
burden, high mortality and morbidity rates in afflicted countries. In the absence of 
effective vaccines against any trypanosomatid diseases, chemotherapy takes the 
centre stage to combat them. Many anti-protozoal drugs are inherently cytotoxic 










the host. Conversely, loss of the specific drug transporters is a main cause of drug 
resistance.  
Identification of parasite-specific targets and uptake mechanisms is critical for the 
development of new agents. Within two decades of discovery, significant 
advancement has been achieved with regard to mammalian AQPs. However, 
knowledge about AQPs from other living systems, especially in protozoa is lagging 
far behind. Therefore, further exploration of parasite AQP structures and functions, 
including their regulatory mechanisms, will eventually reveal their real potential for 
novel chemotherapeutic approaches and/or transmission intervention(s). The 
general aim of my research is to understand the roles of kinetoplastid AQPs in 
trypanosomatid parasites with respect to drug resistance and transport. For 
Leishmania AQP1 there have been credible reports of its involvement in antimony 
(stibogluconate, pentostam) resistance and for T. brucei spp the hypothesis is that 
AQP2 is involved in pentamidine and melaminophenyl sensitivity. In both cases, 
mutations in the AQPs are believed to be responsible, at least in part, for resistance 
to the drugs. 
The first and largest aim of my project was to determine how the structure of 
TbAQP2 allows it to transport pentamidine, whereas the closely related TbAQP3 does 
not. The working hypothesis was that the pore of TbAQP2 was wider than that of 
TbAQP3 and that the cation filter in the form of a pore-located arginine must be one 
of the determining factors, the hypothesis was tested by conducting mutational and 
functional analyses of TbAQP2 including: 
• Swapping residues of TbAQP2 and TbAQP3, particularly in the selectivity filters 
with the goal of determining their effects on the uptake of pentamidine drug by 
Trypanosoma brucei.  
• Investigating the effect of the size of amino acids at the cytoplasmic end of the 
TbAQP2 pore to test the hypothesis that bulky residues would block the passage 
of pentamidine.  
• Testing whether the constructed variants of TbAQP2 exhibited different abilities 
to transport, and sensitise to, pentamidine and melaminophenyl-arsenicals. 
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• To determine the degree of their functional effectiveness as aquaglyceroporins, 
especially the ability to transport glycerol. 
• To investigate whether the alternative hypothesis, of pentamidine uptake via 
endocytosis of a pentamidine-AQP2 complex, is compatible with all available 
data. 
 
The second and last aim of my project is to get insight in the role of Leishmania 
major AQP1 in drug transport. Here, the hypothesis is that Sb(III) traverses the pore 
of AQP1 and that loss of functionality of this aquaporin contributes to antimonial 
resistance, which is a first-line treatment of leishmaniasis but is not used against 
any of trypanosomiasis. For this, a systematic examination on the LmAQP1 was 
achieved by: 
Cloning, functional expression, and characterisation of LmAQP1 in appropriate 
trypanosomatidae cells, with the aim of obtaining insights in the explicit role that 








2.1.1. Media and growth chemicals 
T. b. brucei bloodstream was cultured in Hirumi's modified Iscove’s (HMI-9) powder, 
obtained from Gibco (Life Technologies, Paisley, United Kingdom). Heat-inactivated 
Fetal Bovine Serum (FBS) was obtained from PAA Laboratories (Linz, Austria). Sodium 
bicarbonate (NaHCO3) and β-mercaptoethanol were obtained from BDH and Sigma 
respectively (Dorset, United Kingdom).  
Leishmania promastigotes were cultured in Eagle’s Minimal Essential Medium 
(HOMEM) purchased from Gibco (Paisley, United Kingdom). Penicillin/Streptomycin 
antibiotic was also purchased from Gibco. 
2.1.2. Radiolabelled compounds 
Three radiolabelled drugs were used throughout the project, which enabled the 
characterisation of our transporters of interest. [3H]-pentamidine was custom-made 
by GE Healthcare Life Sciences (Cardiff, UK) with a specific activity of 88 Ci/mmol. 
[3H]-suramin; 20 Ci/mmol, and [3H]-glycerol; 40Ci/mmol were both obtained from 
American Radiolabeled Chemicals, Inc (Arc Drive, St. Louis, USA). 
2.1.3. Chemicals and compounds 
Most chemicals and compounds, as well as antibodies, were obtained from Sigma. 
However, Potassium chloride, Sodium dihydrogen phosphate hydrate and (4-(2-
hydroxyethyl)-1- piperazineethanesulfonic acid (HEPES) were all purchased from 
BDH Prolabo Chemicals (United Kingdom). Scintillation fluid [Optiphase HiSafe III] 
was purchased from Perkin-Elmer. 2-Thiouridine and 4-thiouridine were both 
obtained from Carbosynth Limited (Berkshire, United Kingdom).  
The pGEM-T Easy sub-cloning vector, Go-Taq polymerase and dNTPs were all 
obtained from Promega (Madison, WI, USA). All primers used in the study were 
synthesized by Sigma-Aldrich Limited (Dorset, UK). The Q5 Site-Directed 
Mutagenesis Kits (#E0554S), High-fidelity proofreading polymerase Phusion and 
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Restriction enzymes were acquired from New England Biolabs (Hitchin, United 
Kingdom). The ultra-pure agarose was sourced from Invitrogen (Paisley, United 
Kingdom). All the extraction kits for plasmid, gel, DNA and RNA were obtained from 
Macherey-Nagel (Du ̈ren, Germany). 
The Nanodrop ND 1000 spectrophotometer was obtained from ThermoFisher 
Scientific (UK), and was used to measure the concentrations of DNA and RNA in 
solution. The XL1-Blue competent cells of E. coli were supplied by Agilent 
Technologies (United Kingdom), while the 5-alpha competent cells of E. coli were 
supplied by New England BioLabs. A Neubauer haemocytometer was sourced from 
Weber Scientific (Teddington, Middlesex, United Kingdom). 
2.2. Methods 
 
2.2.1. Parasite cultures 
2.2.1.1. Culturing of T. b. brucei bloodstream forms (BSF)  
T. b. brucei 2T1 cells (Alsford et al., 2005) were used for all the work as control cell 
line. The tbaqp2/tbaqp3 null cells (Baker et al., 2012) and tbaqp1-2-3 null cells 
(Jeacock et al., 2017) (both obtained from David Horn, University of Dundee, UK) 
are derived from the 2T1 strain of T. b. brucei (Alsford & Horn, 2008). The CRK12 
RNAi cell line (Monnerat et al., 2013) was obtained from Dr. Tansy Hammarton 
(University of Glasgow, UK) and is also based on the 2T1 cell line; RNAi expression 
was induced with 1 µg/ml tetracycline in the medium. All experiments were 
performed with bloodstream form (BSF) trypanosomes grown in vitro in HMI-9 
medium supplemented with 10% FBS and 2 mM β-mercaptoethanol (pH 7.4) at 37 ºC 
and 5% CO2 as described (Bridges et al., 2007) and maintained in the log-phase of 
growth. Cultures were routinely grown in 10 ml of this medium, being seeded at 1 × 
105 cells/ml and passed to fresh medium at reaching approximately 1.5 – 2 × 106 
cells/ml. The 2T1 strain was grown in the media under two selective pressure of 
antibiotics (0.5 µg/ml phleomycin) and (0.2 µg/ml of puromycin) to maintain the 
tetracycline repressor (TetR) constructs for selection of correct integration. The 
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CRK12 RNAi cell line was routinely grown in the media with two antibiotics 
(phleomycin 0.5 ug/ml & hygromycin .2.5 ug/ml).  All the AQP mutant cell lines 
were routinely maintained with a selection antibiotic (2.5 µg/ml hygromycin) and 
were induced with 1 µg/ml of tetracycline for 24 hours prior to the sensitivity and 
transporter assays to ensure expression of the test construct. For transport 
experiments 150 or 200 ml of culture was seeded, again at ~5×104 cells/ml, in large, 
vented tissue culture flasks and incubated until the culture reached late-log phase.  
The growth curves of bloodstream form trypanosomes were performed in the HMI-9 
standard medium. Dilution of a preliminary culture was made to achieve a density 
of 1 × 105 cells/ml. Counting of cells was done using a haemocytometer in triplicate, 
every 4 h for CRK12 RNAi and every 24 h for 2T1 and all mutant cell lines. 
2.2.1.2. Culturing of L. major promastigotes 
Wild type L. major strain LV39, L. major AQP1 null mutant (Plourde et al., 2015) 
(kind gift from Professor Marc Ouellette, Laval University, Quebec, Canada), and our 
mutant cell lines (L. major AQP1 null + L. major AQP1) were used in this project. 
The promastigotes of L. major strains were cultured in HOMEM medium obtained 
from Gibco (Paisley, United Kingdom) with 10% FBS and 1% Streptomycin antibiotic 
at a pH of 7.4. The culturing was performed in non-vented plastic flasks 25 cm² at 
temperature of 25 ºC according to Al-Salabi et al. (2003). Every 3 days, the growing 
cells were passaged and exposed to antibiotics whenever necessary. The selection 
of antibiotics included: Hygromycin at 100 µg/ml for L. major AQP1 null, and 
Neomycin (G418) at 50 µg/ml for mutant cells.  
To perform the growth curves of Leishmania promastigotes strains, 1×105 cells/ml 
were seeded in HOMEM medium added with the required antibiotics. Using a 
haemocytometer, the cells were counted in triplicate every 24 hours. 
2.2.1.3. Establishing stabilates  
Stabilates were made from cells in the log phase. For T. brucei, for each cryovial 
0.5 ml of log phase culture was added to 0.5 ml of HMI-9 supplemented with 10% 
FBS and 30% glycerol (resulting in a final concentration of 15% glycerol). For L. 
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major, 0.8 ml of log phase culture was added to 0.8 ml of HOMEM supplemented 
with 10% FBS and 30% of glycerol per cryovial (resulting in a final concentration of 
15% glycerol). The cryovials were stored at -80 ºC for a period of 24-48 hours before 
transferring them to a liquid nitrogen storage tank. 
2.2.1.4. Preparation and recovery of stabilates 
Stabilates were recovered by removing cryovial tubes from the liquid nitrogen where 
they were stored and defrosting the cells rapidly in the hood at room temperature. 
For T. brucei, the cells were first transferred from stabilate into 5 ml of pre-warmed 
media, followed by centrifugation at 1300 x g for 5 min at room temperature. This 
process enabled the removal of glycerol which may otherwise affect the recovery of 
cells. The supernatant was very carefully decanted off, and the pellet re-suspended 
and transferred into a vented flask with 5 ml of fresh HMI-9/10% FBS. Flasks were 
then incubated in a 5% CO2 atmosphere at a temperature of 37 ºC during the study. 
For Leishmania spp, the cells were transferred into non-vented plastic flasks 
containing 5 ml pre-warmed (25 ºC) HOMEM medium with 10% FBS. The flasks were 
then incubated horizontally at 25 ºC. Cells were renewed after about 20 passages by 
taking another stabilates from the liquid nitrogen storage tank. 
2.2.2. Bacterial cultures 
2.2.2.1. Bacterial components and culturing 
XL1-Blue competent cells (Agilent Technologies®, UK), and 5-alpha competent cells 
(New England BioLabs, E0554S) of E. coli were used for plasmid amplification 
throughout the project. The XL1-Blue competent cells were used for routine cloning, 
while the NEB 5-alpha competent cells were used after site-directed mutation, in 
order to obtain high efficiency transformation. Both types of E. coli cells were 
cultured overnight at 37 ºC, either in LB broth (Appendix 1) (shaking incubator) or 
on LB agar (Appendix 1) (incubator).  
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2.3. Molecular techniques  
2.3.1 Genomic DNA Extraction 
Genomic DNA from T. brucei and L. major cells was extracted using the Nucleospin 
Tissue kit (Macherey-Nagel) according to the manufacturer’s instructions. Briefly, 5 
ml of cell culture was transferred to a 15-ml tube and centrifuged for 10 min at 1000 
x g. The medium was discarded by inversion and the rim of the tube was cleaned 
with tissue paper. The cell pellet was then resuspended in 200 µl of buffer T1, 
followed by addition of 20 µl of Proteinase solution from the kit. 200 µl of buffer B3 
was added and the tube was vigorously vortexed and incubated at 70 ºC for 10 
minutes. 210 µl of absolute ethanol was then added to the mixture, vortexed and 
then transferred onto the NucleoSpin® tissue column followed by centrifugation at 
11,000 x g for 1 min. The column was washed with 500 µl of buffer BW, centrifuged 
and then washed again with 600 µL of buffer B5 and centrifuged at 11,000 x g for 1 
min. The column was then transferred to a new 1.5 ml tube and incubated at 70 ºC 
for 5 min. Finally, the DNA was eluted with 50 µl of elution buffer at room 
temperature for 20 min and the eluate collected by centrifugation at 11,000 x g for 
2 min. The DNA concentration was measured on the NanoDrop ND 1000 
spectrophotometer (ThermoFisher Scientific), and the samples were stored at -20 
ºC until use. 
2.3.2. Primer design 
All the primers used in the study for PCR amplification for the purpose of screening 
and cloning were designed to flank the gene of interest with 18 to 25 nucleotide 
regions using the CLC Genomic workbench software (version 7.0, developed by CLC 
bio). Restriction sites were introduced in the primer 3’ flank whenever it was 
necessary, preceded by six random nucleotides, so that the PCR product could be 
directly digested by restriction enzymes, and ligated into the relevant vector. For a 
point mutation, NEBaseChanger tools were used in the production of primer series 
and an annealing temperature for the anticipated mutation. 
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2.3.3. Polymerase chain reaction (PCR)  
Prior to the amplification of a DNA fragment, the annealing temperatures were 
usually optimized for each pair of primers by evaluating 12 PCR reactions using 
different annealing temperatures ranging from 50 ºC to 70 ºC (Gradient PCR) 
(Appendix 2). All PCR reactions were performed on G-Storm thermocyclers (Gene 
Technologies).  
Q5 Hot Start High-Fidelity (NEB) was used to generate the desired mutations. The 
25 µl PCR mixtures contained 12.5 µl 2× Q5 Hot Start High-Fidelity Master Mix, 1.25 
ul of each primer (taken from a 10 µM stock solution), 1 ul template DNA (conc. 1–
25 ng/µl), and 9 ul nuclease-free water. The cycling conditions included an initial 
denaturation for 30 s at 98 ºC, followed by 24 cycles of denaturation for 10 s at 98 
ºC, annealing for 20 s at 61 ºC, an extension for 4:05 min at 72 ºC, and a final 
extension at 72 ºC for 2 min.  
The GoTaq polymerase (Promega) was used for routine PCR screening. The 50 µl PCR 
mixtures contained 10 µl Go Taq Reaction buffer (5 x), 5 ul MgCl2 (25 mM), 1ul dNTPs 
mix (10 mM), 1 ul of each primer (taken from a 10 µM stock solution), 0.5 ul template 
DNA (conc. ~200 ng/µl), and 31 ul distilled water. The cycling conditions included 
an initial denaturation for 3 min at 95 ºC, followed by 34 cycles of denaturation for 
40 s at 95 ºC, annealing for 30 s at melting temperatures (Tm) based on the gradient 
PCR, an extension for 1 min at 72 ºC, and a final extension at 72 ºC for 10 min.   
The High-fidelity Phusion polymerase (NEB) was employed when high fidelity 
amplification was required to amplify the gene of interest (GOI) from a genome. The 
50 µl PCR mixtures contained 10 µl Phusion GC buffer (5 x), 2 ul dNTPs mix (10 mM), 
2 ul of each primer (taken from a 10 µM stock solution), 0.5 ul template DNA (conc. 
~200 ng/µl), and 33.3 ul distilled water. The cycling conditions included an initial 
denaturation for 30 s at 98 ºC, followed by 34 cycles of denaturation for 10 s at 98 
ºC, annealing for 20 s at melting temperatures (Tm) based on the gradient PCR, an 
extension for 30 s at 72 ºC, and a final extension at 72 ºC for 10 min.   
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2.3.4. Plasmids constructions 
2.3.4.1. Generation of AQP2 mutants 
All mutations in the TbAQP2 gene were introduced to the backbone WT pRPaGFP-AQP2 
vector (Baker et al., 2012), by Site-Directed Mutagenesis Kit (New England BioLabs), 
according to manufacturer’s instructions.  
To generate the named TbAQP2 mutations into WT pRPaGFP-AQP2 vector, the primer 
pairs (itemised in Table 2.1) were used and amplified by PCR using Q5 site-directed 
mutagenesis kit protocol (New England BioLabs, E0554), following the 
manufacturer’s instructions. The plasmids were then introduced into NEB 5-alpha 
Competent E. coli cells by transformation, exactly as described in the Q5 Site-
Directed Mutagenesis Standard Protocol (E0554). Briefly, NEB 5-alpha Competent E. 
coli cells were thawed on ice in an Eppendorf tube, for approximately 15 min. 5 µl 
of the Kinase, Ligase & DpnI (KLD) mix were added to the tube for assembling. The 
tube was gently flicked 4-5 times to mix. The mixture was placed on ice for 30 min, 
followed by a heat shock for 30 s at 42 ºC. The mixture was then placed on ice for 5 
min. A volume of 950 µl of Super Optimal broth with Catabolite (SOC) repression 
medium was added into the mixture, which was then incubated at 37 ºC for 1 h with 
shaking at 250 rpm. The tubes were carefully flicked and a volume of 50-100 µl was 
spread onto a selection plate and incubated at 37 ºC overnight. The next day, 
colonies from the overnight transformation were screened by PCR using GoTaq 
polymerase (PCR mixture and programme conditions in section 2.3.3), with HDK529 
and HDK209 primers (Table 2.2) to confirm the presence of the AQP2 gene. Positive 
colonies with the correct band size were incubated overnight in LB containing 100 
µg/ml ampicillin, at 37 ºC. The plasmid extraction kit (Macherey-Nagel) was used to 
purify the plasmid DNA from the culture according to the manufacturer’s 
instructions. Using the primers of HDK1011 and HDK430 (both present in the plasmid; 
table 2.2), the whole gene sequence checked by Sanger Sequencing by Source 
BioScience (Nottingham, UK) to check for additional unwanted mutations, the 
presence of the correct mutation(s) and correct cassette for integration. Plasmids 
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produced (Figure 2.1) were digested with AscI (NEB, Hitchin, UK) prior to 
transfection into the tbaqp2/tbaqp3 null cells and tbaqp1-2-3 null cells. 
 
Table 2.1: Primers used to create mutations in TbAQP2. 
 





































Table 2.2: Primers for confirmation of pRPaGFP-AQP2 mutant constructs used before and after 
transfection. 
Primer 
name Direction Position Sequence (5’ – 3’) 
HDK529 Forward  TbAQP2 gene CAGCTGCGAACTGACGGAAGTTGGT 
HDK209 Reverse TbAQP2 gene AAGCTTCGTAGTGTCCAACTGTGCAC 
HDK1011 Forward 
located 143 bp 
upstream of the open 
reading frame (ORF) of 
the gene of interest 




located 83 bp 
downstream of the open 
reading frame (ORF) of 
the gene of interest 




located 989 bp 
upstream of the AscI 




located 90 bp 
downstream of the AscI 




located 338 bp 
downstream of the AscI 





Figure 2.1: Plasmid map of T. brucei expression vector pRPaGFP-TbAQP2 WT (pHDK80).  
The map shows the TbAQP2 WT gene and the vector confers hygromycin resistance to the transfected 
cells. The rRNA targeting fragment and Hygromycin B phosphotransferase ensures that the constructs 
are located to the tagged locus in the T. brucei genome. This plasmid was used throughout the study 
as an original template to generate mutation(s) in the TbAQP2WT. The positions of used primers and 
restriction sites are highlighted. The plasmid maps were generated by the CLC Genomics Workbench 
program (QIAGEN Bioinformatics). 
 
2.3.4.2. Cloning of PCR products into pGEM-T Easy vector (subcloning vector) 
In order to clone the Leishmania major aquaglyceroporin 1 wild-type (LmAQP1 WT) 
into the final destination vectors (either pRPa or pNUS), the gene was initially 
subcloned into pGEM-T Easy subcloning vectors (Promega). The LmAQP1 WT gene 
(LmjF.31.0020) was amplified from gDNA using primers with the required restriction 
sites using High-fidelity proofreading polymerase Phusion (NEB) (Primers in table 
2.3). The PCR product was A-tailed using 2 µl 10 mM dATP, 10 µl GoTaq reaction 
buffer and 0.2 µl GoTaq polymerase (Promega). A-tailing was achieved by incubating 
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the reaction mix at 72 ºC for 15 min. After incubation, the product was then 
separated by electrophoresis, using a 1% agarose gel, and visualized with SYBR Safe 
DNA gel stain (Invitrogen) under a UV light transilluminator (UVP Inc). The expected 
band size at 959 bp (LmAQP1 WT) was cut out from the agarose gel under ultraviolet 
(UV) light. The DNA was purified using the NucleoSpin Gel and PCR clean-up Kit 
(Macherey-Nagel) exactly as recommended by the manufacturer, and ligated into 
the pGEMT Easy in 10 µl reaction for a ratio of 3:1 insert:vector using the following 
conditions: 5 µl 2× rapid ligation buffer, 1 µl vector (50 ng), 1 µl T4 DNA Ligase (3 
Weiss units/µl), 3 µl insert DNA (50 ng). The mixture was incubated overnight at 4 
ºC.  
Following ligation, the pGEM-T Easy subcloning vector containing our gene of 
interest (GOI) was transformed into XL1-Blue competent E. coli cells using a heat 
shock, as follows. The XL1-Blue competent E. coli cells were thawed on ice in a 1.5 
ml tube (Eppendorf) for ~15 min. 5 µl of the ligation production was added to the 
tube. The tube was gently flicked 4-5 times to mix. The mixture was placed on ice 
for 30 min, following by a heat shock for 45 s at 42 ºC. The mixture was then placed 
on ice for 2 min. 200 µl of room temperature SOC was added into the mixture and 
was incubated at 37 °C for one h with shaking at 250 rpm. The cells were gently 
flicked and a volume of 50-100 µl was spread onto a selection plate (LB agar 
containing 100 µg/ml ampicillin) and incubated at 37 ºC overnight. Next day, 
colonies from the overnight transformation were screened by PCR using forward 
primer M13F (5’-CAGGAAACAGCTATGAC-3’) and reverse primer M13R (5’-
GTAAAACGACGGCCAG-3’) to confirm the presence of the target gene. Positive 
colonies with the correct band size were incubated overnight at 37 ºC in LB 
containing 100 µg/ml ampicillin. The plasmid extraction kit (Macherey-Nagel) was 
used to purify the plasmid DNA from the culture according to the manufacturer’s 
instructions, and was sent for Sanger sequencing (Source BioSciences, Glasgow, UK) 
for sequence confirmation.  
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Table 2.3: Primers used for cloning of LmAQP1 gene into pGEM-T Easy vector. 
 
Lower case sequence: Random nucleotides, to facilitate directly digestion by restriction enzymes. 
Underlining sequence: Restriction site. 
Upper case sequence: Gene of interest primer. 
 
2.3.4.3. Generation of pRPa construct (final vector) for T. b. brucei expression 
The verified, correct DNA sequences of the inserted LmAQP1 gene in the pGEM-T 
Easy subcloning vector were digested using appropriate restriction enzymes and 
ligated into the expression vector pRPa (final vector). LmAQP1 was digested out 
from the plasmid pHDK269 (Appendix 3) (based on the pGEM-T subcloning vector) 
and was ligated to the backbone of pRPa vector after dropping out the TbAQP2 gene 
from the plasmid pHDK80 to give pHDK271 (Figure 2.2). The procedure was 
performed as follows: from bacterial cultures, the vector DNA obtained by miniprep 
was digested with the required restriction enzymes HindIII and Xbal (NEB, Hitchin, 
UK) overnight at 37 ºC. The reaction was made in a total volume of 100 µl, containing 
approximately 25 µg of purified DNA, 1× restriction buffer and 2 µl of restriction 
enzyme and ddH2O. The digested products were run on a 1% agarose gel and 
separated by electrophoresis, at 120 V for 45 min. The desired bands were identified 
by viewing the gel under ultraviolet (UV) light. Bands of the correct size for the DNA 
fragments for each of the backbone (pRPa) and the gene (LmAQP1) were cut out 
Gene Primer Direction 
Res. 
Site 
Sequence 5’ – 3’ 
LmAQP1 HDK1515 Forward BglII ggccAGATCTATGAACTCTCCTACAAC 
LmAQP1 HDK1516 Reverse Xhol CTCGAGCTAACAGCTGGGCGGAA 
LmAQP1 HDK1517 Forward HindIII ggccAAGCTTATGAACTCTCCTACAAC 
LmAQP1 HDK1518 Reverse Xbal aatcTCTAGACTAACAGCTGGGCGGAA 
LmAQP1 HDK1519 Forward - ATGAACTCTCCTACAACCATGCC 
LmAQP1 HDK1520 Reverse - CTAACAGCTGGGCGGAATGAT 
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from the agarose gel and the DNA was purified using the NuceoSpin gel extraction 
kit. The ligation reactions were performed exactly as described in section (2.3.4.2) 
keeping the same ratio (3:1 insert:vector). Ligation productions were then 
transformed into E. coli XL1-Blue cells exactly as explained in section (2.3.4.2). 
Colonies were screened by PCR using forward primer HDK1011 and HDK430 (Table 
2.4) to confirm insertion. Positive clones were cultured in 10 ml LB broth at 37 ºC 
overnight in the shaking incubator. For confirmation of correct integration in the 
vector, plasmids were extracted by miniprep (Macherey-Nagel) according to the 
manufacturer’s instructions, and sent for sequencing with primers HDK1519 and 
HDK1520 (Table 2.4). After sequence confirmation, positive clones of the plasmid 
were linearised with AscI (NEB, Hitchin, UK) prior to transfection into the tbaqp1-2-
3 null cells. For this, the DNA samples were run on a 1% agarose gel in order to 
extract the desired band. The samples were cleaned up using the NucleoSpin Gel 
extraction kit (Macherey-Nagel) according to the manufacturer’s instructions, and 
kept at – 20 ºC until use.  
Table 2.4: Primers for confirmation of the pRPaLmAQP1 WT expression construct used before and 
after the transfection. 
 
Primer name Direction Position Sequence (5’ – 3’) 
HDK1519 Forward LmAQP1 WT gene ATGAACTCTCCTACAACCATGCC 
HDK1520 Reverse LmAQP1 WT gene CTAACAGCTGGGCGGAATCAT 
HDK1011 Forward 
located 205 bp upstream 
of the open reading 
frame (ORF) of the gene 




located 100 bp 
downstream of the open 
reading frame (ORF) of 
the gene of interest 






Figure 2.2: The pHDK271 (pRPa+LmAQP1) plasmid map.  
The map shows the full LmAQP1 gene, primers, restriction sites and the hygromycin antibiotic cassette. 
 
2.3.4.4. Generation of pNUS-HcN plasmid (final vector) for L. major expression 
The pNUS-HcN is a non-integrative vector (episomal) and was used to express gene 
of interest into the LmAQP1 null strain. After verification of the pHDK270 (Appendix 
4) (pGEMT containing LmAQP1 WT) by Sanger sequencing, the LmAQP1 gene was 
digested from the pHDK270 using the BglII and XhoI restriction enzymes (NEB), and 
cloned into pNUS-HcN using the restriction enzymes BglII on the 5′ end and XhoI on 
the 3′. The gene was then ligated into the pNUS-HcN backbone to give pHDK272 
(Figure 2.3). The procedure of the digestion, ligation and transformation was 
performed exactly as described in (section 2.3.4.2), except for the digestion with 
the BglII and XhoI restriction enzymes. Colonies of transformants (containing 
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plasmids) were confirmed by PCR using HDK1519 and HDK1520 primers (Table 2.5) 
to confirm insertion. Positive clones were cultured in 10 ml LB broth overnight in 
the shaking incubator at 37 ºC. The generated plasmids were extracted by miniprep 
(Macherey-Nagel) according to the manufacturer’s instructions, and sent for Sanger 
sequencing (Source BioScience, Nottingham, UK) with HDK851 and HDK340 primers 
(Table 2.5) to check the sequence and correct integration in the vector. 
 
Table 2.5: Primers for confirmation of the pNUSLmAQP1 WT expression construct used before 
and after the transfection. 
Primer 
name Direction Position Sequence (5’ – 3’) 
HDK1519 Forward  LmAQP1 WT gene ATGAACTCTCCTACAACCATGCC 
HDK1520 Reverse LmAQP1 WT gene CTAACAGCTGGGCGGAATCAT 
HDK851 Forward  
located 152 bp 
upstream of the open 
reading frame (ORF) of 
the gene of interest 





located 71 bp  
downstream of the open 
reading frame (ORF) of 
the gene of interest 





Figure 2.3: The pHDK272 (pNUS+LmAQP1) plasmid map. 
The map shows the full LmAQP1 gene, primers, restriction sites and the neomycin antibiotic cassette.  
 
2.4. DNA sequencing 
2.4.1. Preparation of sample for sequencing 
In order to prepare samples for sequencing, DNA samples were cleaned up using the 
purification kit (Macherey-Nagel). Volume of the sample 1-2µl was placed onto the 
pedestal of a Nanodrop spectrophotometer (ThermoFisher Scientific) to measure the 
purity and the concentration of the DNA. The DNA samples were then prepared 
exactly as recommended by Source Bioscience as following. For sequencing of 
plasmid, 5 µl per reaction of both primers at 3.2 pmol/µl and plasmid DNA at 100 
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ng/µl was used. For PCR product sequence confirmation, 5 µl per reaction was also 
sent for both primers, at 3.2 pmol/µl, and DNA at 10 ng/µl per 500 bp of the PCR 
product.  
2.4.2. Sequence analysis and alignments  
The nucleotide and amino acid sequences for gene of interest (GOI) were imported 
from TriTrypDB (tritrypdb.org/tritrypdb) or GeneDB (genedb.org) databases. The 
CLC Genomic workbench software (version 7.0, developed by CLC bio) was routinely 
used to create alignments and sequence analysis.  
2.5. Transfection 
2.5.1. In Trypanosoma brucei 
Prior to transfection, the generated expression construct pRPa (containing our gene 
of interest and a hygromycin resistance cassette) was digested with AscI (NEB) to 
linearize the plasmid. Following the digestion, the products were run on 1% agarose 
gels to confirm the correct length of the desired fragment of the plasmid which was 
estimated to be around 5.3 kb for the DNA expression cassette. The DNA samples 
(expression cassette) were extracted from the gel and cleaned up using the 
NucleoSpin Gel extraction kit (Macherey-Nagel) according to the manufacturer’s 
instructions. The samples were then precipitated with ethanol overnight at 20 ºC, 
dried and resuspended in 10 µl of sterile water. Bloodstream form of the desired cell 
line either aqp2/aqp3 null or aqp1/aqp2/aqp3 null were cultured and density of 
1×107 cells/ml were washed in 100 µl Human T-Cell solution and resuspended in 10 
µg of the digested plasmid. The mixture was transferred into a cuvette (Amaxa) for 
transfection. Using an Amaxa Nucleofector (Amaxa AG, Cologne, Germany), the 
program X-001 was used for electroporation of the cells, which were immediately 
transferred to a warm medium of HMI-9 and left to recover for 6-18 hours at 37 ºC 
and 5% CO2. Appropriate antibiotic (2.5 µg/ml hygromycin) was added before the 
cells were cloned out using limiting dilutions of (1/10, 1/25 and 1/100) into 96-well 
plates into 96-well. After around seven days of incubation with the selection 
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antibiotic, clones (surviving cells) were picked up from the plates, cultured in 5 ml 
fresh media with the antibiotic (2.5 µg/ml hygromycin). After several passages (3 - 
5 passage), the gDNA of clones was extracted using the standard protocol and the 
Nucleospin tissue kit (Macherey-Nagel). The positive clones were assessed by PCR to 
confirm correct integration, and to check for the presence of the desired gene. The 
PCR products cleaned up using the PCR purification kit (Macherey-Nagel). Sanger 
Sequencing was used to confirm the sequence (SourceBioscience, Glasgow, Scotland, 
UK). 
2.5.2. In Leishmania major  
Since the plasmid pNUS-HcN was for episomal expression, the generated plasmid 
DNA (pHDK272) was directly transfected without digestion (As circular plasmid). 20 
µg of plasmid DNA was precipitated with ethanol and resuspended in 20 µl of sterile 
water. Log phase cells of L. major AQP1 null promastigotes (5×107 cells) were 
pelleted by centrifugation at 1000 × g for 10 min. The pellet was then resuspended 
in 100 µl Human T-cell buffer, and mixed with the 10 µl precipitated DNA. To 
electroporate the cells, the program U-033 of the Amaxa Nucleofector II 
electroporator (Amaxa Biosystems) was used to create the desired strains. Cells 
were then transferred to pre-warmed HOMEM medium containing 10% FBS and were 
left to recover overnight in 25 ºC incubator. In the following day, Neomycin G418 
(50 µg/ml) was added and the cells were plated out using limited dilutions (1:20, 
1:100, 1:200) to generate individual clones. Positive clones produced from this 
transfection were cells that were resistant to antibiotic Neomycin (G418). The gDNA 
of the generated clones were extracted using Nucleospin Tissue kit (Macherey-Nagel) 
according to the manufacturer’s instructions. PCR confirmations were performed to 
confirm correct integration, and to check for the presence of the desired gene. 
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2.6. Quantitative real-time PCR (qRT-PCR) 
2.6.1. Preparation of RNA from T. brucei 
Following the instructions provided by the manufacturer of the NucleoSpin RNA kit, 
RNA purifications were prepared from T. brucei 2T1 and CRK12 cell lines. Briefly, 5 
x 106 cells were centrifuged for about 10 minutes at 1300 × g, and the supernatant 
was discarded. This was followed by lysing the cells by addition of 350 µl Buffer RA1 
and 3.5 µl β-mercaptoethanol reducing agent, before vortexing vigorously. In order 
to adjust the RNA binding conditions, 350 µl of 70% ethanol was added to the samples 
and the contents were pipetted up and down to homogenize. This was followed by 
loading the samples onto the NucleoSpin column for DNA binding, by centrifuging 
the contents at 11,000 × g for about 30 s. To prevent contamination with DNA, it 
was necessary to intermittently change gloves and collection tube. To desalt the 
silica membrane, 350 µl of Membrane Desalting Buffer was added into the tube, and 
centrifuged at 11,000 × g for one minute. The remaining DNA in the mix were 
removed by applying rDNase reaction mixture on the column, followed by incubation 
at room temperature for about 15 minutes. A washing buffer was used to clean the 
column before leaving it to dry. Elution of the RNA was done using nuclease-free 
water, and placing the tubes on ice to prevent RNA degradation. The concentration 
of RNA was then checked using the NanoDrop spectrophotometer (ThermoFisher 
Scientific). All samples were collected and stored at -20 ºC for later use. 
2.6.2. Complementary DNA synthesis from RNA 
Conversion of RNA to complementary DNA (cDNA) was accomplished by the use of 
SuperScript III Reverse Transcriptase (RT, Invitrogen) as described by Ali and Field 
(2013). Control samples in which there was no RT added were performed in parallel. 
There were three phases involved in the production of cDNA. In the first phase, 500 
ng of Random primers (Invitrogen), 2 µl of 10 mM dNTPs, 1 µg RNA template and 
sterile water were mixed to a volume of 29 µl for hot mixing at 65 ºC for 5 minutes. 
In the second phase, 8 µl of 5× First-Strand Buffer, 1 µl of SuperScript III RT and 2 µl 
0.1 M DTT were added to the mixture. Water was added to samples without RT 
instead of SuperScript III RT. All the samples were then incubated at a temperature 
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of 25 ºC for 5 min, followed by incubation at 50 ºC for 45 minutes, and then at 70 ºC 
for 15 minutes. In the third phase, any remaining template of RNA were removed by 
adding 1 µl (2U) of E. coli RNase H, followed by incubation at a temperature of 37 
ºC for 20 minutes. This resulted in pure cDNA that was stored at -20 ºC until use.  
2.6.3. Quantitative RT-PCR 
Upon generating the required cDNA, quantitative real time PCR (qRT-PCR) was 
performed using the GoTaq qPCR Master mix (Promega). Using Primer3®, primers 
were designed (Table 2.6), and efficiency evaluated using the previously described 
method (Pfaffl, 2001). Endogenous gene GPI8 (housekeeping gene) with its primers 
was deployed as control (Table 2.6). The reaction was performed in 25 µl, made up 
of 12.5 µl of GoTaq master mix, 3.5 µl of water, 2 µl each of 2.5 mM forward and 
reverse primer, and 5 µl of cDNA where the ratio of dilution of the converted cDNA 
is 1:10. The samples were then subjected to a very brief vortex and centrifuge 
before putting them into the machine. The DNA amplification was done in a 7500 
Real Time PCR System (Applied Biosystems). The specific reaction conditions were 
as follows: 50 ºC for 2 min, 95 ºC for 10 min, 45 cycles of 95 ºC for 15 sand 60 ºC for 
1 min. A dissociation curve was used to show the amplification of only one product 
at a time. Samples in which reverse transcriptase was not added or lacked cDNA 
served as controls. The whole experiment was performed independently on three 
occasions, from culturing of the cell lines to isolation of RNA.  
Table 2.6: Primers used to quantify gene expression by qRT-PCR. 
Gene Primer Direction Sequence 
CRK12 HDK1779 Forward 5’-AGCGGTCTTGGTCTGTGAAC-3' 
CRK12 HDK1780 Reverse 5’-GACATCCAACGGTTTATCTG-3' 
GPI8 HDK131 Forward   5’-CGAAGCGCATTTGGATAG-3' 
GPI8 HDK132 Reverse 5’-AGCGGTCTTGGTCTGTGAAC-3' 
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2.7. Drug sensitivity assay 
As described by Gould et al. (2008), sensitivity assays of both Trypanosoma and 
Leishmania species to various drugs using the viability dye resazurin (Alamar Blue) 
are based on the reduction of resazurin sodium salt (blue, non-fluorescent) to 
resorufin (pink, fluorescent) by surviving but not by dead cells.  
For T. brucei strains, in 96-well plates containing doubling dilutions of test 
compounds were set up in 100 µl HMI-9/FBS medium, each over 2 rows (23 
concentrations) The top concentrations were usually 100 µM in culture medium; the 
last well received 100 µl medium as no- drug control. To each well, 100 µl of 2×105 
cells/ml were added, and the plates were incubated for 48 h at 37 ºC in 5% CO2, 
after which 20 µl of 0.5 mM of resazurin was added and the plates incubated under 
the same conditions for a further 24 h. Fluorescence intensity was read using a 
FLUOstar OPTIMA (BMG Labtech, Germany) at wavelengths of 544 nm for excitation 
and 620 nm for emission.  
For Leishmania promastigotes strains, cultured in HOMEM/10% FBS, the procedure 
was identical, except that 100 µl of 2×106 cells/ml was added per well, the 
incubation time before addition of resazurin was 72 h at 25 ºC, and incubation with 
resazurin was for a further period of 48 hours. Data was plotted to a sigmoid curve 
with variable slope using Prism 6.0 (GraphPad) and 50% effective concentrations 
(EC50) were determined for all compounds in 3 – 5 independent experiments. 
 
2.8. Transport Assay 
Transport assays - Transport of [3H]-pentamidine was performed exactly as 
previously described for various permeants (Wallace et al., 2002; Bridges et al., 
2007; Teka et al., 2011) in a defined assay buffer (AB; 33 mM HEPES, 98 mM NaCl, 
4.6 mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2PO4, 0.3 mM MgCl2, 23 mM 
NaHCO3, 14 mM glucose, pH 7.3). [3H]-pentamidine was custom-made by GE 
Healthcare Life Sciences (Cardiff, UK) with a specific activity of 88 Ci/mmol. 
Incubations of bloodstream form trypanosomes with 30 nM of this label (unless 
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otherwise indicated) were performed in AB at room temperature for 60 s (unless 
otherwise indicated) and terminated by addition of 1 ml ice-cold ‘stop’ solution (1 
mM unlabelled pentamidine (Sigma) in AB) and immediate centrifugation through oil 
(7:1 dibutylphthalate:mineral oil v/v (both from Sigma)) to separate the cells from 
the aqueous buffer. Transport was assessed in the presence of 1 mM adenosine to 
block uptake through the P2 aminopurine transporter; adenosine does not affect 
HAPT1-mediated transport (De Koning, 2001a; Bridges et al., 2007). This mixture 
was incubated for predetermined times. The reaction was stopped by the addition 
of 750 µl of an ice-cold 1 mM solution of unlabelled permeant. The tubes were 
centrifuged at 13,000 ×g for 1 min. The microfuge tube was then placed in liquid 
nitrogen for flash freezing; the bottom of the frozen tubes, containing the cell 
pellet, was cut off and collected in a scintillation vial. 250 µl of 2% sodium dodecyl 
sulphate (SDS) was added to the vial to solubilise the cells. The scientillation vials 
with cell pellets and SDS were left at room temperature for 30 min. A volume of 3 
ml scintillation fluid (Optiphase HiSafe III) was added to each vial, which were then 
incubated overnight at room temperature. Inhibition assays were performed 
routinely with 6 - 10 different concentrations of inhibitor over the relevant range, 
diluting stepwise by one third each time, in order to obtain a well-defined and 
accurate sigmoid plot and IC50 value (inhibitor concentration giving 50% inhibition of 
pentamidine transport; calculated by non-linear regression using Prism 6.0 
(GraphPad), using the equation for a sigmoid curve with variable slope). Highest 
concentration was usually 1 mM unless this was shown to be insufficient for good 
inhibition, or when limited by solubility. Ki values were obtained from IC50 values 
using: Ki = IC50/[1 + (L + Km), in which L is the [3H]-pentamidine concentration and 
Km the Michaelis-Menten constant for pentamidine uptake by HAPT1 (Wallace et al, 
2002). The Gibbs Free energy of interaction ΔG0 was calculated from ΔG0 = -RTlnKi, 
in which R is the gas constant and T is the absolute temperature (Wallace et al, 
2002).  
Transport of [3H]-glycerol and [3H]-suramin was performed essentially as for [3H]-
pentamidine. For [3H]-glycerol (American Radiolabeled Chemicals, 40.0 Ci/mmol), 
107 BSF T. brucei were incubated with radiolabel at a final concentration of 0.25 
µM, for one minute. When the effect of Carbonyl cyanide m-chlorophenyl hydrazone 
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(CCCP) was studied, CCCP was added 3 minutes prior to the addition of the 
radiolabel. [3H]-suramin (American Radiolabeled Chemicals, 20.0 Ci/mmol) was also 
used at 0.25 µM final concentration, using 15 min incubations I the presence and 
absence of 100 µM unlabelled suramin (used as saturation) control. 
2.9. Protein Model  
To facilitate visualisation of the TbAQP2 channel and the relative proximity of amino 
acid residue sites to the selectivity filter (Baker et al., 2013), a 3D homology model 
of the TbAQP2 protein structure was generated.  The FASTA format of the protein 
sequence was obtained from the NCBI database (https://www.ncbi.nlm.nih.gov/). 
Best representation of the protein was sought considering the FASTA sequence using 
the NCBI BLAST tool (https://blast.ncbi.nlm.nih.gov/), with ‘chimeric 
aquaglyceroporin 2/3 [Trypanosoma brucei gambiense]’ selected as the most similar 
template to the TbAQP2 protein based on a zero ‘e-value’, and the highest sequence 
percentage identity and query coverage. Cross-reference with the SWISS-MODEL 
software (Waterhouse et al., 2018) ensured that a model had already been 
generated for this homologous protein structure (UniProtKB AC: U5NJF5). The model 
was then visualised with PyMOL 2.2 (Schrödinger), with only the original FASTA 
sequence highlighted in the images produced. Amino acid residue sites were 
highlighted, along with residue sites that have already been established to 
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Species belonging to the Trypanosoma brucei-group can lead to severe infections 
such as sleeping sickness (humans) and nagana (animals) (Giordani et al., 2016); 
Bu ̈scher et al., 2017). The treatment is determined by the trypanosome subspecies 
that causes the disease, the host, and the stage of the disease (Giordani et al., 2016; 
De Koning, 2020). However, various anti-protozoan medications are considered 
intrinsically cytotoxic, and they are believed to obtain their selectivity through 
favoured uptake by the pathogen rather than of the host cells (Munday et al., 2015a; 
De Koning, 2020). In contrast, drug resistance is attributed to the loss of specific 
drug transporters (Barrett et al., 2011; Baker et a.l, 2013; Munday et al., 2015a; and 
De Koning, 2020). Drug resistance has been observed in a wide range of trypanocides, 
such as the fluorinated amino acid analog eflornithine used to treat human cerebral 
trypanosomiasis (Vincent et al, 2010), melaminophenyl arsenicals (melarsoprol for 
cerebral stage human and cymelarsan for animal trypanosomiasis (Carter & 
Fairlamb, 1993; Bridges et al., 2007), and diamidines (pentamidine, diminazene) 
(Carter et al., 1995; De Koning, 2001a; De Koning et al., 2004; and Bridges et a.l, 
2007). Consequently, it is imperative to explore transporters when studying the anti-
protozoal drug discovery, as well as when investigating drug resistance (Lu ̈scher et 
al., 2007; Munday et al., 2015a). 
 
Several researchers have conducted various studies to gain more insights into anti-
protozoal drug resistance. For instance, Rollo & William (1951) first identified 
melarsoprol-pentamidine cross-resistance (MPXR) in Trypanosoma brucei, and was 
connected MPXR to decreased uptake instead of shared intracellular target(s) 
(Frommel & Balber, 1987). The aminopurine transporter TbAT1/P2 was the first 
transporter associated with the MPXR (Carter & Fairlamb, 1993; Ma ̈ser et al., 1999; 
Munday et al., 2015b). However, two other transporters have been affiliated with 
melarsoprol-pentamidine cross-resistance to include Low-Affinity Pentamidine 
Transporter (LAPT1) and High-Affinity Pentamidine Transporter (HAPT1) (De Koning, 
2001a; De Koning & Jarvis, 2001; Bridges et al., 2007). HAPT1 is considered the main 
determinant of MPXR and was identified as Aquaglyceroporin 2 (TbAQP2) through an 
RNAi library screen (Baker et al., 2012, 2013; Munday et al., 2014). The two motifs 
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of the asparagine-proline-alanine sequences (NPA), and the aromatic-arginine 
(ar/R), in the aquaporin water channel family, are the most important structural 
domains that play a crucial role in water-selective permeation. These two regions 
have been proposed as filters that block solutes larger than water and charged 
molecules from moving through. According to crystallographic studies, the two NPA 
motifs in the narrow central constriction of the pore, contribute to a monomeric 
pore structure that enables selective, bi-directional, and single-file transport of 
water in classical AQPs (Sui et al., 2001) and water and glycerol in aquaglyceroporins 
(Jensen et al., 2001). The aromatic-arginine region, which is narrower than the 
central NPA constriction and acts as a selectivity filter on the extracellular side of 
the AQP channel, blocks the entry of molecules larger than water (de Groot & 
Grubmu; 2005, 2001). Uniquely, TbAQP2 allows substance with high molecular 
weight due to its highly unusual selectivity filter that is deemed to lack the canonical 
aromatic/arginine (ar/R) and full NPA/NPA motifs, which make it become a much 
wider pore (Baker et al., 2012; Munday et al., 2014, 2015a). Introducing TbAQP2 
into Leishmania promastigotes significantly increased their sensitivity to 
pentamidine and melarsen oxide (Munday et al., 2014). Moreover, studies have 
demonstrated various MPXR laboratory strains of T. brucei to have deleted the AQP2 
gene and strains with a chimeric AQP2/TbAQP3 gene that is regarded to be different 
from the AQP2 gene (Munday et al., 2014).  This chimeric AQP2/TbAQP3 gene 
consists of the full, classical ar/R and NPA/NPA selectivity filter motifs, in addition 
to lacking the capability of transporting either pentamidine or melaminophenyl 
arsenicals (Munday et al., 2014). Correspondingly, such deletions and chimeric genes 
have been noted and isolated from individuals with sleeping sickness resistant to 
melarsoprol treatment (Graf et al., 2013; Pyana Pati et al., 2014). These chimeric 
genes and deletions also failed to show pentamidine sensitivity when expressed in a 
tbaqp2-tbaqp3 null cell line (however, the wild-type TbAQP2 conferred sensitivity) 
(Munday et al., 2014; Graf et al., 2015). Nevertheless, the mechanism associated 
with TbAQP2-mediated drug transport in the trypanosomes is still unclear. 
Therefore, this study aimed to conduct a mutational analysis to determine any role 
of amino acids along the TbAQP2 pore in assisting in sensitivity and/or uptake of 
pentamidine. To resolve this, mutation(s) related to TbAQP2 and TbAQP3 genes were 
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synthesized, expressed, and preserved for characterization focusing on drug 




3.2.1. Positive selection for investigation of the structural determinants of AQP2 
for pentamidine transport 
Three aquaglyceroporins (TbAQP1-3) exist in the T. brucei and are deemed to 
contribute to the transport of various small solutes, including urea, glycerol, and 
water (Benga G, 2009; Jeacock et al., 2017). The TbAQP2 and TbAQP3 are 74% amino 
acids identical and appear as a tandem pair on chromosome 10. However, TbAQP2 
facilitates the uptake of pentamidine, which is not observed in TbAQP3 (Baker et 
al., 2012; Munday et al., 2014) and in a variety of chimeric AQP2/3 changes that 
result in pentamidine resistance (Munday et al., 2014; Graf et al., 2015). A 
phylogenetic analysis of AQPs in African trypanosomes was conducted (kindly 
created by Dr. Mark Carrington, University of Cambridge). Based on the tree 
considered consistent with the four species' evolutionary history (Hutchinson & 
Gibson, 2015) (Figure 3.1), APQ1 was found to be the ancestral AQP as it was 
expressed in all trypanosome species. A duplication was observed in the common 
ancestor of T. suis and T. brucei, following divergence from T. congolense and a 
further duplication to form AQP2 and AQP3 in the ancestor of T. brucei after 
divergence from T. suis. On the other hand, there was a variation in the number of 
aquaporins, where one aquaporin was noted in T. vivax and T. congolense, two in T. 
suis, and three in T. brucei and its derivatives. 
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Figure 3.1: Phylogenetic tree of AQPs in African trypanosomes; T. congolense, T. b. brucei and 
T. suis. The tree is a Neighbour-joining tree produced with the lengths of the horizontals proportional 
to the differences. (Created by Dr. Mark Carrington). 
 
With the exception of T. brucei AQP2, all other APQs were found to have the classical 
NPA/NPA and ar/R AQP selectivity filter elements, indicated by multiple alignments 
(Figure 3.2). The TbAQP2 and TbAQP3 were observed to be closely related except 
that TbAQP2 lacks the “aromatic/arginine (a/R)” motif and contains unusual 
selectivity pore amino acids residues (NSA/NPS/IVLL), unlike TbAQP3 
(NPA/NPA/WGYR) (Baker et al., 2013; Figure 3.3). The NPA/NPA is one highly 
conserved motif of aquaporins and is found in TbAQP3 (not in TbAQP2), where they 
are deemed to play a significant role in permeant selectivity. The ar/R motif is found 
in both TbAQP1 and TbAQP3 and is argued to be a part of the larger selectivity filter, 
mainly WGYR, and distinctively contains I110V249L258L264 in TbAQP2 (Baker et al., 
2013). In contrast, the AQP3 Tyr-250 accounts for half of the highly conserved 
aromatic/arginine (ar/R) motif and plays a role in pore restriction as well as proton 









Tco       MTSPTVPNPMSTVPMTEM----TE-ANGTTNPPIPDAGERTAV---NFDTEQCK-TKEIL 51 
Tbr1      MSD--EKINVHQYPSETDVRGLKARNGGACEVPFEENN-EPIPNRSANPQEKNE--NELV 55 
Tsu1      MSS--EPVNVHRYTAEGDRSGLKDRHGKTCEVCVGDESAAAVPSAVYNPQEQSGDGPEVK 58 
Tsu2      MQN--QPDAMTH-STAVQMV-NKNPEDGTGGADTERSDEMTAP--------TTRTGDAQK 48 
Tbr2      MQS--QPDNVAY-PMELQAV-NKDGT---VEVRVQGNVDNSSN--------ERWDADVQK 45 
Tbr3      MQS--QPDNVAY-PMELQAV-NKDGT---VEVRVQGNDDSS----------------NRK 37 
          * .      :            .                                      
 
 
Tco       -AGEGEAPHGPMDINYWPLRNLRMDFREYVGEFLGTFVLLFMGNGVVATTLLDNNLGFLS 110 
Tbr1      GDNADNEAHDAVDVNYWAPRQLRLDYRNYMGEFLGTFVLLFMGNGVVATTILDKDLGFLS 115 
Tsu1      AGGGEAEVQNAADVNNWAPRRLRLDYRDYMGEFLGTFVLLFMGNGVVATTMLDDGLGFLS 118 
Tsu2      CETTNTPKEGAGGINYWAPRELRLKYRDYMGELLGTFVLLLMGNGVVATVVVDGKLGFLS 108 
Tbr2      HEVAEAQEKPVGGINFWAPRELRLNYRDYVAEFLGNFVLIYIAKGAVITSLLVPDFGLLG 105 
Tbr3      HEVAEAQEEVPGGINFWAPRELRLNYRDYMGELLGTFVLLFMGNGVVATVIIDGKLGFLS 97 
                  .   .:* *  *.**:.:*:*:.*:**.***: :.:*.* * ::   :*:*. 
 
 
Tco       ITFGWGIAVTMGLYVSLGTSSGHLNPAVTVANAFFGGFPWKKVPGYIAMQMLGAFVGAAC 170 
Tbr1      ITLGWGIAVTMGLYISLGISCGHLNPAVTLANAVFGCFPWRRVPGYIAAQMLGAFVGAAC 175 
Tsu1      ITLGWGIAVTMGLYISLGTSCGHLNPAVTVANAVFGCFPWKKVAGYIAMQMLGAFVGAAC 178 
Tsu2      ITLGWGIAVTMALYISLGISSGHLNPAVTVGNAVFGDFPWRKVPGYIAAQMFGAFLGAAC 168 
Tbr2      LTIGIGVAVTMALYVSLGISGGHLNSAVTVGNAVFGDFPWRKVPGYIAAQMLGTFLGAAC 165 
Tbr3      ITLGWGIAVTMALYVSLGISSGHLNPAVTVGNAVFGDFPWRKVPGYIAAQMLGAFLGAAC 157 
          :*:* *:****.**:*** * **** ***:.**.** ***::* **** **:*:*:**** 
 
 
Tco       AYGVYADLLNKKVSDG----EIEDYAGMFSTYPRDGNSLFSCIFGEFICTAMLTFCVCGI 226 
Tbr1      AYGVYADLLKQHSGG-LVGFGDKGFAGMFSTYPREGNRLFYCIFSEFICTAILLFCVGGI 234 
Tsu1      AYGVFADLLKQHSGG-LIPFGDKGFAGMFSTYPRDGNRLFYCIFGEFICTAMLLFCVSGI 237 
Tsu2      AYGVFADLLKEYCGGKLLAFGAKGIAGVFSTYPKEANSVFACVFGEFICTAILLFCVCGI 228 
Tbr2      AYGVFADLLKAHGGGELIAFGEKGIAWVFAMYPAEGNGIFYPIFAELISTAVLLLCVCGI 225 
Tbr3      AYGVFADLLKAHGGGELIAFGEKGTAGVFSTYPRDSNGLFSCIFGEFICTAMLLFCVCGI 217 
          ****:****:   ..       :. * :*: ** :.* :*  :*.*:*.**:* :** ** 
 
Tco       FDTHNAPATGHEPLAVGALVFAIGNNVGYATGYAINPARDFGPRVFSAILYGSTVFTRGD 286 
Tbr1      FDPNNSPAKGHEPLAVGALVFAIGNNIGYASGYAINPARDFGPRVFSAILFGSEVFTTGN 294 
Tsu1      FDANNSPAKGHEPLAVGALVFAIGNNIGYATGYAINPARDFGPRLFSAILFGSEVFTAGN 297 
Tsu2      FDPNNSPAKKHEPLAVGSLIFAIGNNIGYSTGYAMNPARDFAPRVFSALLLGGEVFSHGN 288 
Tbr2      FDPNNSPAKGYETVAIGALVFVMVNNFGLASPLAMNPSLDFGPRVFGAILLGGEVFSHAN 285 
Tbr3      FDPNNSPAKGHEPLAVGALVFAIGNNIGYSTGYAINPARDFGPRVFSSFLYGGKVFSHAN 277 
          ** :*:**. :* :*:*:*:*.: **.* ::  *:**: **.**:*.::* *. **: .: 
Tco       YYFWVPLFIPLLGGIFGIILYKYFVPH 313 
Tbr1      YYFWVPLFIPFLGGIFGLFLYKYFVPY 321 
Tsu1      YYFWVPLFIPFLGGIFGLLLYKYFVPH 324 
Tsu2      YYFWVPLFIPFLGAIFGLFLYKYFVPH 315 
Tbr2      YYFWVPLVVPFFGAILGLFLYKYFLPH 312 
Tbr3      YYFWVPLVIPLFGGIFGLFLYKYFVPH 304 
          *******.:*::*.*:*::*****:*: 
 
Figure 3.2: Amino acid sequence alignment of aquaporins in African trypanosomes; T. 
congolense, T. b. brucei and T. suis. 
 
The figure shows the classical AQP selectivity filter elements that present in all of AQPs in African 
trypanosomes compared to the unique selectivity filter amino acids residues that present in T. brucei 
AQP2. The turquoise highlighting indicates the highly conserved motifs of aquaporins (NPA/NPA), and 
the red highlighting indicates the unusual motifs (NSA/NPS) present in T. brucei AQP2. The pink 
highlighting indicates the usual residues (WGYR) present in all aquaporins, and the bright green 
highlighting indicates the uniquely residues (IVLL) in TbAQP2. The yellow highlighting indicates the N-
terminus of the sequences used to determine non-synonymous v synonymous ratios (Table 3.1).  
*, indicates perfect alignment (fully conserved residue); :, indicates a strong similarity; ., indicates a 





Figure 3.3: Homology models of the TbAQP2 and TbAQP3 protein structures.  
 
The figures show the selectivity filter residues in TbAQP2 (Tb927.10.14170) and TbAQP3 
(Tb927.10.14160). (A) top and side views of TbAQP2; the unique selectivity filter IVLL/NSA/NPS motifs 
are indicated. (B) top and side views of TbAQP3; the classical selectivity filter NPA/NPA/WGYR motifs 
are indicated. (adapted from Baker et al., 2012). 
 
Investigations were conducted to determine the divergence of T. brucei AQP2 and 
AQP3, which was achieved by calculating the non-synonymous/synonymous codon 
ratio (dN/dS) for different AQPs, as indicated in Table 3.1. For T. brucei versus T. 
suis AQP1, the dN/dS was found to be 0.21, while that of AQP3 to be 0.30, 
demonstrating purifying selection. Nonetheless, regarding T. brucei AQP2 versus T. 
brucei AQP3, the dN/dS was observed to be 2.0, signifying intense selection pressure 
for divergence on AQP2 towards an increased size aquaporin’s pore. 
 
Table 3.1: The non-synonymous/synonymous codon ratio (dN/dS) calculated for selected 









The ratios were calculated using a region of high confidence alignments from ~amino acid 60 






Trypanosoma species dN/dS 
T. brucei AQP1 v T. suis AQP1 0.21 
T. brucei AQP3 v T. suis AQP3 0.30 
T. brucei AQP2 v T. brucei AQP3 2.00 
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3.2.2. Introduction of AQP3 selectivity residues in AQP2 disables pentamidine 
(and melarsoprol) uptake. 
3.2.2.1. Confirmation of the construction and transfection of AQP2 mutants 
Selected residues of the classical selectivity filter motifs of the TbAQP3 (ar/R and 
NPA/NPA) were introduced into the corresponding residues in the selectivity filter 
of the TbAQP2 pore to test the possible role of these in guiding pentamidine and 
cymelarsan. The NPA/NPA (TbAQP2S131P/S263A), WGYR (TbAQP2I110W/L264R) and the 
AQP3 Tyr-250 (TbAQP2L258Y) mutants were constructed and expressed into 
tbaqp2/tbaqp3 null cells by Dr. Jane Munday at the De Koning laboratory. To 
characterise these mutant(s), cells were retrieved from stabilates in liquid nitrogen 
storage, the presence of the TbAQP2 gene was verified by PCR and confirmed by 
sequencing for the correct mutation(s). For this, genomic DNA from each cell line 
was extracted and purified, followed by two PCR reactions that were set up for the 
confirmation. The first PCR was performed to solely amplify the full TbAQP2 gene 
using primers HDK529 and HDK209. The second was designed to amplify the gene 
with a partial fragment of the expression cassette using primers HDK1011 (located 
143 bp upstream of the open reading frame of the gene in the plasmid backbone) 
and HDK430 (located 83 bp downstream of the open reading frame the gene in the 
plasmid backbone). PCR products were then run on 1% an agarose gel with DNA 
staining. From the first reaction PCR products were at 950 bp (Figure 3.4 A-B), 
approximately the size of the TbAQP2 gene (936 bp). Product-sized bands from the 
second PCR reaction were at ~1250 bp, corresponding to the expected size of the 
gene with the partial plasmid fragment (1212 bp) (Figure 3.4 C-D). The expected 
amplification products from the two PCR reactions were indicating successful 
transfections (See plasmid map (figure 2.1) in section 2.3.4.1; for primers sites). 
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Figure 3.4: Agarose gel electrophoresis of PCR products reveals the presence of the integrated 
tbaqp2 (AQP3 selectivity residues) in transfected tbaqp2/tbaqp3 null cells.  
(A) and (B) amplified PCR products at ~939 bp present the full TbAQP2 gene. (A) L: 1kb DNA ladder; 
1: TbAQP2 (WT) positive control; 2: TbAQP2 (KO) negative control; 3: TbAQP2 (S131P/S263A); 4: 
TbAQP2 (L258Y); 5: TbAQP2 (I110W). (B) L: 1kb DNA ladder; 1: TbAQP2 (WT) positive control; 2: 
TbAQP2 (KO) negative control; 3: TbAQP2 (L264R); 4 (I110W/L264R). Bands in (C) and (D) display 
fragments at ~1250 bp (TbAQP2 and parts of the expression cassette neighbouring the gene). The 
order of the samples in (C) are as same as in (A). The order of the samples in (D) are as same as in 
(B). The positive control (lane 1) in C and D is pRPaGFP-AQP2 WT plasmid. 
 
 
Prior to performing the sensitivity and uptake assays, cell lines were also checked 
by sequencing. For this, the full TbAQP2 gene was amplified from the genomic DNA 
of each cell line using a high-fidelity DNA polymerase (New England BioLabs). The 
products from PCR reactions were purified using a DNA purification kit (Macherey-
Nagel) and were then sent for sequencing (SourceBioscience, Glasgow, Scotland, UK) 
using forward primer (HDK1011) and reverse primer (HDK340). Correct mutation(s) 
were checked by creating alignments of the amino acid of TbAQP2 WT and the 
generated TbAQP2 mutant(s) (Appendix 5). 






























3.2.2.2. Molecular characterization of the introduction of AQP3 residues into 
the AQP2 selectivity filter. 
To assess the effect of introducing the classical selectivity filter motifs of TbAQP3 
(ar/R and NPA/NPA) into the TbAQP2 on the pentamidine and cymelarsan 
susceptibility, the standard protocol of 48 h incubation with the drug, followed by a 
further 24 h in the presence of the resazurin indicator dye (Alamar blue assay), was 
performed to determine EC50 values. The assay was performed in parallel with the 
tbaqp2/tbaqp3 null strain (drug-resistant control) and the tbaqp2/tbaqp3 null strain 
possessing the re-expressed TbAQP2 WT cells (drug-sensitive control). Pentamidine 
and the melaminophenyl arsenical cymelarsan were the drugs assessed whilst 
diminazene aceturate and phenylarsine oxide (PAO), which are not TbAQP2 
permeants (Graf et al., 2015), were used as positive controls throughout the 
assessment. The TbAQP2S131P/S263A-expressing cells were strongly sensitised to 
pentamidine (P<0.0001 vs tbaqp2/tbaqp3 null) but the EC50 was again also 
significantly different from the TbAQP2WT control (P<0.05) (Figure 3.5A). A similar 
effect was observed for the melaminophenyl arsenical drug cymelarsan (Figure 
3.5A), but there was no change in sensitivity to diminazene or PAO. Diminazene is 
taken up by the TbAT1/P2 transporter (De Koning, 2004) whereas PAO is believed to 
diffuse directly across the membrane (Fairlamb et al., 1992) (Figure 3.5A). The EC50 
values of pentamidine and cymelarsan in the mutant L258Y, which has the AQP3 Tyr-
250 in the highly conserved aromatic/arginine (ar/R) motif, were also significantly 
different from both the TbAQP2WT and the tbaqp2/tbaqp3 null controls (Figure 
3.5B). Cell lines expressing mutations AQP2I110W and AQP2L264R, either alone or in 
combination, displayed pentamidine and cymelarsan EC50 values that were not 
significantly different from the tbaqp2/tbaqp3 null controls but highly significantly 

























Figure 3.5: Sensitivity assay of TbAQP2 mutants cell lines (the introduction of TbAQP3 residues 
into the TbAQP2 selectivity filter). 
The figures of (A-E) show the EC50 values for the indicated test drugs; pentamidine, cymelarsan, and 
the control drugs diminazene and phenylarsine oxide (PAO), expressed as a percentage of the 
tbaqp2/tbaqp3 null (resistant control), against cell lines either expressing the indicated TbAQP2 mutant 
or TbAQP2WT (sensitive control). Red stars and green stars: comparison with tbaqp2/aqp3 null or 
TbAQP2WT-expressing cells, respectively, which were assessed in parallel in each experiment. (A-E) 
Shows the drug susceptibility of the indicated TbAQP2 mutants. (A) double mutants (S131P/S263A). 
(B) single mutant (L258Y). (C) single mutant (I110W). (D) single mutant (L264R). (E) double mutants 
(I110W/L264R). All experiments are the average and SEM of at least 3 independent experiments.  
*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001 by unpaired Student’s t-test, two-tailed. (Alghamdi 




Next, transport assays, using radiolabelled [3H]-pentamidine were performed to all 
derivative and control strains from the Alamar Blue assay over the course of a 
minute, to determine if the significant loss of pentamidine sensitivity in the cell 
lines expressing mutants were associated with alterations to pentamidine uptake 
into the cell. In the TbAQP2S131P/S263A cell line, the calculations recorded a reduction 
in the rate of uptake of 30 nM [3H]-pentamidine by 4.40 ± 0.71% (n=4) compared to 
the rate of the control cell line expressing TbAQP2WT (P<0.05, Student’s unpaired 
t-test). Correspondingly, this uptake of [3H]-pentamidine in the TbAQP2S131P/S263A cell 
line was also observed to be significantly different from the rate calculated in the 
tbaqp2/tbaqp3 null cells (P<0.01). Introducing L258Y into the TbAQP2 pore gave the 
drug transporter the phenotype similar to TbAQP2S131P/S263A. This led to a reduction 
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of the [3H]-pentamidine transport rate to 6.6 ± 1.4% of TbAQP2WT (P<0.01) but 
stayed considerably above the rate observed in the tbaqp2/tbaqp3 null cells 
(P<0.05) (Figure 3.9). However, cell lines with mutations AQP2I110W and AQP2L264R, 
showed pentamidine transport rates that were not significantly different from those 
observed in the tbaqp2/tbaqp3 null controls but highly significantly different from 
the TbAQP2WT drug-sensitive controls, showing that their ability to uptake 




Figure 3.6: Transport of 30 nM [3H]-pentamidineby tbaqp2/aqp3 null cells expressing TbAQP2-
WT or one of the TbAQP2 mutants (TbAQP3 selectivity filter residues) as indicated (blue bars). 
The corresponding brown bars are pentamidine transport in the control tbaqp2/aqp3 null cells assessed 
in parallel in each experiment. Transport was determined. Bars represent the average and SEM of at 
least three independent experiments, each performed in triplicate. Blue stars: statistical significance 
comparison, by two-tailed unpaired Student’s tests, between the cells expressing TbAQP2WT and 
mutants; red stars: statistical comparison between the AQP2-expressing cells and control cells; NS, not 
significant.  *, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001 by unpaired Student’s t-test, two-tailed. 
(Alghamdi et al., 2020). 
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3.2.3. Introduction of TbAQP2 selectivity filter residues into the AQP3 pore 
enables pentamidine transport. 
3.2.3.1. Confirmation of the construction and transfection of AQP3 mutants 
The effects of introducing some of the critical TbAQP2 residues in TbAQP3 were 
determined to see whether these mutants would give the latter the capability for 
pentamidine uptake. The mutants TbAQP3W102I/R256L and TbAQP3W102I/R256L/Y250L were 
constructed and expressed in tbaqp2/tbaqp3 null cells by Dr. Jane Munday at the 
De Koning laboratory. To characterise these generated mutants, I therefore followed 
Munday’s work by obtaining the cell lines from stabilate storage and maintaining the 
cells (3-5 passage) in the standard medium (HMI-9 with 10% FBS) with the addition 
of the right antibiotic for the transfectants (0.2 µg/ml hygromycin). Next, genomic 
DNA was extracted from each cell line, and two PCR reactions were then performed 
for confirmation. Forward primer HDK529 and reverse primer HDK329 (5’-
AGGATCTTAGTGTGGCACAAA-3’) were used to amplify the presence of the full 
TbAQP3 gene in the first PCR reaction, whereas the primer HDK1011 (located 143 bp 
upstream of the open reading frame of the gene in the plasmid backbone) and 
HDK430 (located 83 bp downstream of the open reading frame the gene in the 
plasmid backbone) were used to amplify the gene with a partial fragment of the 
expression cassette in the second PCR reaction. The PCR products were then run on 
an 1% agarose gel with DNA staining to confirm the correct size of the amplified 
fragments. PCR products from the first reaction were ~950 bp (Figure 3.7A), i.e. 
displayed the full size of the TbAQP3 (912 bp). The product-sized bands from the 
second PCR reaction were at ~1250 bp (Figure 3.7B) corresponding to the expected 
size of the gene with the partial plasmid fragment (1212 bp). The sizes of the PCR 





Figure 3.7: Agarose gel electrophoresis of PCR products reveals the presence of the integrated 
TbAQP3 mutants (TbAQP2 selectivity filter residues) in transfected tbaqp2/tbaqp3 null cells.  
(A) Amplified PCR products at ~950 bp show the full TbAQP3 gene. L: 1kb DNA ladder; 1: TbAQP3 
(WT) positive control; 2: TbAQP3 (KO) negative control; 3: TbAQP3 (W102I/R256L); 4: TbAQP3 
(W102I/R256L/Y250L). (B) The bands at ~1250 bp displayed fragments containing TbAQP3 gene and 
part of the expression cassette neighbouring the gene. L: 1kb DNA ladder; 1: (pHDK70) positive control; 




Prior to use the cell lines for drug sensitivity and uptake assays, confirmation for 
correct mutation was verified by sequencing. The gDNA of the clones that exhibited 
successful transfection were used to amplify the full TbAQP3 gene using a high-
fidelity DNA polymerase (New England BioLabs). The products from PCR reactions 
were purified using a DNA purification kit (Macherey-Nagel) and were then sent for 
sequencing (SourceBioscience, Glasgow, Scotland, UK) with forward primer 
(HDK1011) and reverse primer (HDK430). Correct mutation(s) were checked by 
creating alignments of the amino acid sequences of TbAQP3 WT and the TbAQP3 




3.2.3.2. Molecular characterization of the introduction of TbAQP2 selectivity 
filter residues into the AQP3 pore  
The aim of this study was to test the impacts of the unique selectivity filter elements 
of the TbAQP2 when introduced into the TbAQP3 selectivity filter on the drug's 
sensitivity and transport. The Alamar Blue assay was performed to test whether 
tbaqp2/tbaqp3 null cells transfected with these mutant aquaporins were able to 
sensitise expressing cells to pentamidine. The strain possessing the re-expressed 














TbAQP3 WT cell line (drug-resistant control) was used in parallel with the mutant 
cell lines. In this study pentamidine was assessed and phenylarsine oxide (PAO) was 
used as positive control throughout the assays. There was no significant difference 
between the sensitivity to PAO for the cell lines expressing mutations 
TbAQP3W102I/R256L and TbAQP3W102I/R256L/Y250L and the TbAQP3 (control cell line) 
(Figure 3.8). But, when tested with pentamidine, TbAQP3W102I/R256L/Y250L conveyed 
significant sensitisation into tbaqp2/tbaqp3 null cells (P<0.0001; Figure 3.8). This 
indicates that this particular triple mutant (W102I, R256L and Y250L) in the 
TbAQP3WT can confer increased pentamidine sensitivity. 
 
 
Figure 3.8: Sensitivity assay of TbAQP3 mutants cell lines (the introduction of AQP2 selectivity 
filter residues).  
The figure shows the EC50 values of the pentamidine (red bars) and the control drug phenylarsine oxide 
(blue bars) against tbaqp2/aqp3 null cells expressing either TbAQP3 or a mutant thereof, expressed as 
percentage of tbaqp2/aqp3 null. All experiments are the average and SEM of at least 3 independent 
experiments. ****, P<0.0001 by unpaired Student’s t-test, two-tailed. (Alghamdi et al., 2020). 
 
Next, transport assays of [3H]-Pentamidine were performed to test whether 
tbaqp2/tbaqp3 null cells transfected with these mutant aquaporins were able to 
take up 30 nM [3H]-pentamidine in the presence of 1 mM adenosine (which blocks 
uptake via TbAT1/P2). Over a time course of 2 minutes, the pentamidine uptake in 
 110 
the AQP3WT and mutant cell lines was very low compared to the same cells 
expressing TbAQP2WT (Figure 3.9).  
 
                     
Figure 3.9: The uptake of 30 nM [3H]-Pentamidine over 2 minutes by tbaqp2/aqp3 null cells 
expressing TbAQP2WT in comparison with the TbAQP3WT and the TbAQP3 mutant cell lines. 
Pentamidine uptake in the mutant cell lines, in the presence of 1 mM adenosine, when incubation time 
points at 0, 5, 10, 15 and 20 seconds for AQP2, and 0, 30, 60 and 120 seconds for the other strains.  
 
The [3H]-pentamidine uptake was reliably and reproducibly determined by 
measuring its accumulation in every cell line for 30 minutes (Figure 3.10 A,B). The 
results indicated uptake of TbAQP3W102I/R256L to trend to some extent upwards 
(P>0.05). On the other hand, the mutant AQP3 with all three AQP2 W(G)YR residues 
(W102I, R256L, and Y250L) had a significantly increased [3H]-pentamidine uptake 
compared to the tbaqp2/tbaqp3 null cells (P<0.01) or the null cells expressing 
TbAQP3WT (P=0.011). These results showed that introduction of the AQP2 filter 
residues in AQP3 expressively led to sensitization towards pentamidine in addition 





Figure 3.10: Transport of 30 nM [3H]-pentamidine by tbaqp2/aqp3 null cells expressing TbAQP3 
or an TbAQP3 mutant as indicated.  
Pentamidine transport performed in 30 min incubation in the control tbaqp2/aqp3 null cells and 
assessed with the TbAQP3 mutant cell lines in parallel in each experiment. Transport was determined 
in the presence of 1 mM adenosine to block the TbAT1/P2 transporter. (A) Representative transport 
assay shows the accumulation of radiolabelled pentamidine in each cell line when incubation over 30 
minutes. (B) Bars represent the average and SEM of at least three independent experiments, each 
performed in triplicate. Red stars: statistical significance comparison, by two-tailed unpaired Student’s 
tests, between the cells expressing TbAQP2WT and mutants**, P<0.01 by unpaired Student’s t-test, 
two-tailed. (Alghamdi et al., 2020). 
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3.2.4. Mutations of amino acids modelled to potentially bind pentamidine or 
melarsoprol dramatically reduce pentamidine transport. 
3.2.4.1. Confirmation of the construction and transfection of AQP2 mutants  
 
Previous attempts made at the De Koning laboratory focusing on modelling the 
binding of pentamidine and melarsoprol into TbAQP2 pore led to identifying various 
residues associated with this activity (Munday et al., 2015a). Among these residues, 
two residues, Ile190 and Trp192, (Position shown in Figure 3.11) were chosen at the 
extracellular end of the channel and were predicted to interact with the substrate 




Figure 3.11: Homology models of the predicted binding of pentamidine and melarsoprol in 
complex with a single TbAQP2 subunit (green).  
(A) Binding of pentamidine (cyan carbon atoms). (B) Binding of melarsoprol (orange carbon atoms). 
Key polar interactions are shown for both (A, B). The Ile190 and Trp192 (red) were the two selected 
residues which predicted to interact with the substrate(s) with main-chain carbonyl oxygen atoms. 
Models obtained from (Munday et al., 2015a). 
 
 113 
To swap with the corresponding residues of TbAQP3, mutants of TbAQP2I190T, 
TbAQP2W192G and TbAQP2I190T/W192G were generated. These mutants were created and 
expressed into tbaqp2/tbaqp3 null cells by Dr. Jane Monday at the De Koning 
laboratory. This part was followed by characterising generated mutants. Firstly, the 
cell lines were retrieved form the stabilate storage and were growin in culture 
medium (HMI-9 + 10% FBS) supplemented with 2.5 µg/ml hygromycin. After passaging 
the cells (3-5 passages), genomic DNA from each cell line was extracted and two 
PCR reactions were performed for more confirmation prior to the sensitivity and 
transport assays. In the 1st PCR, the TbAQP2 gene from each cell line was amplified 
using the forward and reverse primers (HDK529 & HDK209) to check for the presence 
of the full TbAQP2 gene. Whilst, the 2nd PCR was used to amplify the gene with a 
partial fragment of the expression cassette using the primers HDK1011 & HDK430. 
The PCR products were then run on an agarose gel with DNA staining to confirm the 
correct size of the amplified fragments. PCR products from the first reaction were 
~950 bp (Figure 3.12A), indicating to the expected size of the full TbAQP2 gene (939 
bp). Whereas, product-sized bands from the second PCR reaction were ~1,250 bp 
presented the gene with the partial plasmid fragment (1212 bp) (Figure 3.12B). The 
correct product-sized bands of the amplified PCR products presenting correct 








Figure 3.12: PCR screening of the TbAQP2 mutant cell lines (TbAQP2 residues I190 and W192).  















PCR products were separated by gel electrophoresis on 1% agarose gel. The expected size of each 
band was obtained with respect to the standard sizes of the 1kb molecular weight size Ladder (Left 
columns). (A) amplified PCR products at ~950 bp show the full TbAQP2 gene. (B) Bands at ~1250 bp 
displayed fragments containing TbAQP2 and part of the expression cassette neighbouring the gene. L: 
1kb DNA ladder; 1: TbAQP2 (WT) positive control; 2: TbAQP2 (KO) negative control; 3: TbAQP2 
(I190T); 4: TbAQP2 (W192G); 5: TbAQP2 (I190T/ W192G). 
 
 
The I190T and W192G mutations were verified using Sanger Sequencing (Source 
BioScience, Nottingham, UK). The TbAQP2 gene was amplified from the genomic 
DNA of cell lines that displayed successful transfections using a high-fidelity DNA 
polymerase (New England BioLabs). The products from PCR reactions were purified 
using a DNA purification kit (Macherey-Nagel) and were then sent for sequencing 
(SourceBioscience, Glasgow, Scotland, UK) with forward primer (HDK1011) and 
reverse primer (HDK430). Correct mutation(s) were checked by creating alignments 
of the amino acid sequences of TbAQP2WT and the TbAQP2 mutants (Appendix 8). 
 
 
3.2.4.2. Molecular characterizations of mutations of the amino acids modelled 
to potentially bind pentamidine or melarsoprol. 
 
The Alamar blue assay was performed to determine the EC50 values of the mutant 
cell lines (TbAQP2I190T), (TbAQP2W192G) and (TbAQPI190T/W192G) in parallel with the 
resistant control cell line (tbaqp2/tbaqp3 null), and the strain possessing the re-
expressed TbAQP2WT (drug-sensitive control). In this study, pentamidine and 
cymelarsan drugs were used to investigate the predicted binding model. 
Phenylarsine oxide (PAO) was used as positive control throughout the study. As 
previously noted from the information provided above regarding the selectivity of 
filter mutants, TbAQP2I190T was observed to show high pentamidine sensitivity in the 
standard resazurin test (P<0.0001) but with significantly less sensitization compared 
to TbAQP2WT (P<0.001). Besides, an intermediate sensitivity for pentamidine was 
also noted for cymelarsan (Figure 3.13A). The substitution of W192G resulted in 
producing intermediate sensitivity to both pentamidine and cymelarsan (Figure 
3.13B). However, the double substitution of TbAQPI190T/W192G led to no significant 








Figure 3.13: Sensitivity assay of TbAQP2 mutant cell lines (TbAQP2 residues I190 and W192). 
(A) EC50 values for the indicated drugs against tbaqp2/tbaqp3 null cells, and against TbAQP2WT and 
TbAQP2 mutant cell lines; values were expressed as % of the tbaqp2/tbaqp3 null (resistant) control. 
Red stars, comparison with the resistant control; green stars, comparison with the internal sensitive 
control (TbAQP2WT). The assays for all three strains and all three drugs were done simultaneously on 
at least 3 different occasions. (B) As A but for TbAQP2W192G. (C) As A but for TbAQP2I190T/W192G.  




          The TbAQP2I190T presented intensely decreased uptake of [3H]-pentamidine at 
2.7 ± 0.7% (P<0.0001) of the TbAQP2WT control. However, this uptake rate was still 
significantly higher compared to the rate observed in the tbaqp2/tbaqp3 null 
negative control (P<0.05) (Figure 3.14). In contrast, the double substitution of 
TbAQPI190T/W192G demonstrated no significant uptake of pentamidine with reference 




Figure 3.14: Transport of 30 nM [3H]-pentamidine by tbaqp2/tbaqp3 null cells or TbAQP2 variants 
(residues I190 and W192) expressed therein.  
Transport was expressed as a percentage of the rate of the TbAQP2WT control, performed in parallel. 
Blue stars are comparison with TbAQP2WT, red stars, comparison with the tbaqp2/tbaqp3 null control. 
NS, not significant. The assays for all three strains and all three drugs were done simultaneously on at 
least 3 different occasions. *, P<0.05; ****, P<0.0001 by unpaired Student’s t-test. (Alghamdi et al., 
2020). 
 
The I190T mutant was further investigated to see whether this substitution might 
have altered the Km of the high affinity pentamidine transport, as might be expected 
if the substitution disrupted a specific interaction with the substrate. Because of 
the very low rate of uptake in this mutant a 15 min incubation time was used to 
obtain a reproducible inhibition curve. (Figure 3.15) shows a biphasic double-
sigmoidal inhibition curve for a high affinity component with an average IC50 of 30.9 
± 12.2 nM (n=3) and a low affinity component. The latter could be converted to a 
Michaelis-Menten curve (Figure 3.15A., inset), yielding an average Km of 59.9 ± 9.1 
µM. Figure 3.15B., inset shows the corresponding experiment with the same cells, 
but expressing TbAQP2WT instead of the mutant and using 20 s incubations. In this 
case the high affinity component, although showing a very similar IC50 in the biphasic 
plot (41 ± 17 nM; P>0.05), was much more prominent, showing that the rate of 
TbAQP2-mediated transport, rather than the transporter affinity was altered in the 
mutant. The low affinity component was statistically identical in the two strains 




Figure 3.15: The determination of Km and Vmax values for the TbAQP2I190T mutant and the 
tbaqp2/tbaqp3 null cells expressing TbAQP2WT.  
(A) Transport of 30 nM [3H]-pentamidine by TbAQP2I190T, in the presence of unlabelled pentamidine at 
the indicated concentrations. Incubation time was 15 min, required to ensure sufficient radiolabel for 
accurate quantification, and uptake was linear and through zero over this period. The inhibition data 
were plotted to a double sigmoidal curve (Prism 7.0) with the bottom value fixed at 0. The high affinity 
component displayed IC50 of 30.9 ± 12.2 nM (n = 3) and the lower affinity segment could be converted 
to a Michaelis-Menten plot for determination of Km and Vmax (inset), yielding an average Km of 59.9 ± 
9.1 µM (n = 3), consistent with the Low Affinity Pentamidine Transporter (LAPT1; Bridges et al, 2007). 
The plot shown is one representative experiment in triplicate of three independent experiments. (B) Like 
(A) but with tbaqp2/tbaqp3 null cells expressing TbAQP2WT. Incubation time was 20 s. The inset shows 
a zoom-in on the low-affinity part of the curve, with the dotted line representing a theoretical sigmoid 
plot for one inhibitor, with the upper limit fixed at the value obtained for 10 μM pentamidine. Note that 
the amount of [3H]-pentamidine taken up by the low affinity component is highly similar for the mutant 
(A) and control (B) cell lines, at approximately 0.0005 pmol(107 cells)-1s-1. 
Both frames show one representative experiment of three repeats, each performed in triplicate. Error 
bars are SEM, when not shown, fall within the symbol. (Alghamdi et al., 2020). 
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3.3. Discussion 
A vast agreement exists that the expression of TbAQP2 is related to the 
extraordinary sensitivity of T. brucei towards pentamidine, as well as towards 
melaminophenyl arsenicals, and that mutations and deletions associated with this 
locus can result in drug resistance (Baker et al., 2012, 2013; Graf et al., 2013, 2015, 
2016; Pyana Pati et al., 2014; Munday et al., 2014, 2015a; Unciti-Broceta et al., 
2015). However, the mechanisms explaining these phenomena are still unclear, and 
no current document exists outlining other examples of aquaporins in the 
transportation of such large molecules. TbAQP2 has evolved through positive 
selection, as indicated by the high dN/dS ratio, to eliminate all significant 
constriction points, such as the aromatic amino acids, cationic arginine of the 
selectivity filter, and the NPA/NPA motif, leading to enlarged pore size. The 
advantage of this phenomenon in T. b. brucei is still not known, but the adaptation 
is considered to be stable in the brucei group of trypanosomes, where it is found in 
T. b. rhodesiense (Munday et al., 2014; Graf et al., 2016), T. b. gambiense (Graf et 
al., 2013, 2015; Munday et al., 2014; Pyana Pati et al., 2014), T. equiperdum, and 
T. evansi (Philippe Bu ̈scher and Nick Van Reet, unpublished). Consequently, it is not 
incongruous to speculate that this enlarged TbAQP2 pore (i) permits the passage of 
materials that TbAQP1 and TbAQP3 do not transport; (ii) provides a yet unknown 
advantage to the cell; and (iii) that uptake of pentamidine is a by-product of this 
evolvement.  
 
In the current study, I demonstrated that modifications in the TbAQP2 WGYR and 
NPA/NPA motifs provide a passageway for these drugs into the cell, thereby 
supporting the parasite's very high sensitivity towards the drugs. The introduction of 
the AQP3 Arg residue in position 264 (TbAQP2L264R) disables the transport of 
pentamidine, which we concluded was due to the positively charged arginine located 
in the middle of the pore blocking all cations from passing through the pore (Beitz 
et al, 2006; Wu et al, 2009). Certainly, the W(G)YR filter residues seem to be critical 
determinants for pentamidine uptake by AQPs, and introducing all three TbAQP2 
residues into TbAQP3 (AQP3W102I/R256L/Y250L) was needed to generate an TbAQP3 with 
mild sensitization to pentamidine, and which enabled a measurable level of 
pentamidine uptake. On the other hand, any mutation (I110W, L258Y, or L264R) was 
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appropriate to all but abolish pentamidine transport by TbAQP2. Likewise, the 
conserved NPA/NPA motif (predominantly the Asp residues) found in TbAQP3 (but 
NSA/NPS in TbAQP2) is also affiliated with the blocking of the cations passage (Wree 
et al, 2011). The unique serine residues found in the TbAQP2 motif, halfway down 
the pore, might have the capacity to make hydrogen bonds with pentamidine 
because the reestablishment of the NPA/NPA motif created a TbAQP2 variant that 
demonstrated a 93.5% reduced rate of [3H]-pentamidine uptake. 
 
To conclude, the selectivity filter differences between TbAQP2 and TbAQP3 are 
largely responsible for their differences in pentamidine sensitivity and transport 
rates. The unique TbAQP2 replacement of the NPA/NPA motif and all of the WGYR 
selectivity filter mutations are necessary for the observed pentamidine and 





















Chapter 4 Mutagenesis of leucine residues at the 
cytoplasmic end of the TbAQP2 pore affects the protein’s 




The drug uptake model suggests that pentamidine traversed through the uniquely 
permissive aquaglyceroporin (Munday et al., 2015a). However, this model was 
challenged by a study proposing that pentamidine does not traverse the TbAQP2 but 
binds to an aspartate residue (Asp265) located near the pore's end on the 
extracellular side, above the selectivity filter, before it is internalized through 
endocytosis (Song et al., 2016). Furthermore, the study supported their argument 
by showing the inability of TbAQP2 to transport organic cations, such as ammonium 
ions, when expressed in yeast. The study also went further to eliminate size as a 
factor affecting the transport of organic cation substrates; even for the 
pentamidine’s 44 Da end moiety known as formamidine (HN=CH=NH2), the 
transporter exhibited no permeability. Therefore, the authors of the study 
concluded that TbAQP2 does not directly transport pentamidine but acts as a high-
affinity receptor for this drug in addition to facilitating its passage in trypanosomes 
through non-selective endocytosis. This non-selective endocytosis was noted due to 
D265 residue significance, which is considered to have a strong electrostatic 
interaction with pentamidine, as indicated by figure 4.1. The flagellar pocket is the 
only site associated with endocytosis in trypanosomatids (Field & Carrington, 2009). 
TbAQP2 location in the flagellar pocket (Baker et al., 2012), has led to speculations 
that pentamidine is transported into the cell through a receptor-mediated 
endocytosis mechanism. However, no further experimental evidence has been 
presented or published to support these speculations. It is not typical for such a 
small-sized channel to control and facilitate the transport of relatively large drug 
molecules like pentamidine. Hence, more exploration regarding this gene would be 
imperative to comprehensively understand the mechanism behind this phenomenon 
and probably at the same time improve the associated treatments.  
 
The question thus remained whether to determine whether TbAQP2 is a fixed 
transmembrane transporter, with pentamidine acting as a permeant, or a receptor 
for pentamidine, which is then transported by other mean. Therefore, the 
hypothesis that the TbAQP2 channel allows the translocation of pentamidine through 
its pore was tested by investigation of a substitution of small and uncharged amino 
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acid residues L84, L118 and L218, which reside in the transport channel below the 
unique T. brucei selectivity filter and are not interfering with the D265 residue, for 
tryptophan and methionine (Figure 4.2). In this study, the purpose of substituting 
L84, L118, and L218 with tryptophan residues near the pore's cytoplasmic end was 
to determine if the presence of bulky amino acids in that end would block the 
transport of pentamidine through the TbAQP2 pore. This study was followed by 
introducing a medium sized residue (methionine) instead of tryptophan into the 
same three selected positions of the leucine to allow further discrimination between 
the models of binding to the extracellular end of the pore (followed by endocytosis) 
and the requirement for the drug to traverse the full length of the channel.  
 
Site-directed mutagenesis was performed to code an amino acid substitution at the 
three selected positions of the leucine, expressed the mutant(s) into tbaqp2/tbaqp3 
null cells, assessed the sensitivity of the mutant cell lines to cymelarsan and 




Figure 4.1: Model of the TbAQP2 protein structure.  
The figure shows the positions of the D265 residue, central to the theory that TbAQP2 acts as a 
pentamidine receptor (Song et al., 2016), relative to the selectivity filter (orange). The Song et al. model 
predicts that the pentamidine binds to the Aspartic Acid (D265) with high affinity which likely results 




the residue (negatively charged). This model suggested that the pentamidine internalised via 
endocytosis of TbAQP2 and the D265 binding is a starting point of receptor-mediated endocytosis. The 
model was generated using SWISS-MODEL software from the FASTA sequence of TbAQP2 
(TriTrypDB Gene ID: Tb927.10.14170) and images created with PyMOL 2.2 (Schrödinger). 
 
 
Figure 4.2: Schematic of our predicted model of pentamidine traversal through the TbAQP2 
channel.  
The model shows the positions of L84, L118 and L218 residues (red) at the cytoplasmic end relative to 
the selectivity filter (orange), and not interfering with the D265 residue (black). These Leucine residues, 
lining the pore, were selected for site-specific mutation and were investigated for effects on T. brucei 
sensitivity and pentamidine uptake. The model was generated using SWISS-MODEL software from the 





4.2.1. Introduction of a large sized amino acid (tryptophan) at the cytoplasmic 









4.2.1.1. Successful construction and transfection of AQP2 L-W mutants 
The L84W, L118W, and L218W were created by exchanging three leucine residues, 
each with tryptophan. This was aimed to determine the impact of bulky amino acids 
at the cytoplasmic end of TbAQP2 on pentamidine transport. Plasmid vectors 
containing (single or multiple amino acid substitutions) in the TbAQP2 were 
constructed. The plasmids pHD210 (TbAQP2L84W), pHD208 (TbAQP2L118W), pHD209 
(TbAQP2L218W) and pHDK227 (TbAQP2L84W/L118W) were all constructed by Q5 Site-
Directed Mutagenesis Kit (NEB), following the kit’s protocol. The single mutants 
were introduced by PCR (mixture and programme conditions in section 2.3.3; 
primers in table 2.1) using the pRPaGFP-AQP2 plasmid, which is under the control of a 
Tet-regulated RRNA promoter (Baker et al., 2012). The combination L84W/L118W 
mutants were generated based on template pHDK208, producing pHDK227. All the 
indicated plasmids were verified by Sanger Sequencing to check for the presence of 
full gene sequence, additional unwanted mutations, and the correct mutation(s), as 
well as the correct cassette for integration, using the primers HDK1011 and HDK430. 
Prior to the transfection, plasmids were linearised with AscI restriction enzyme to 
allow for correct integration of the expression cassette into the genome of 
tbaqp2/tbaqp3 null cells (Alsford et al., 2005). Products of the digested plasmid 
along with undigested plasmid (as control) of each of the generated plasmids were 
run on 1% agarose gel to confirm the correct fragment of the DNA expression cassette 
which should be around 5.3 kb long (Figure 4.3). (See plasmid map (figure 2.1) in 
section 2.3.4.1; for AscI restriction sites). 
 
Figure 4.3: Digestion of the produced plasmids (pRPaGFP-AQP2 L-W mutant) by AscI enzyme.  
















The figure shows a successful digestion of the produced plasmids by AscI enzyme prior to the 
transfection. The bands at ~ 5.3 kb represent the fragments (blue arrows indicate desired bands) of the 
DNA expression cassette that contain the TbAQP2 (L-W mutant) gene and a selection marker of the 
plasmid (hygromycin). The bands at ~ 2.6 kb represent the remaining (unwanted) part of the plasmid 
which containing only B-lactamase. Bands at ~ 7.9 kb represent the undigested plasmid (as control) of 
each generated plasmid. L: 1kb DNA ladder; 1: pHDK210 (digested plasmid); 2: control (pHDK210 
undigested); 3: pHDK208 (digested plasmid); 4: control (pHDK208 undigested); 5: pHDK209 (digested 
plasmid); 6: control (pHDK209 undigested); 7: pHDK227 (digested plasmid); 8: control (pHDK227 
undigested). 
 
Following the linearization, DNA cassettes (bands of approximately 5.3 kb) were 
extracted from the gel and cleaned up using the NucleoSpin Gel extraction kit 
(Macherey-Nagel) according to the manufacturer’s instructions, and were 
transfected into tbaqp2/aqp3 cells (Baker et al., 2012). Transfected cells were then 
selected and cloned out with the presence of hygromycin, and genomic DNA was 
extracted from the new cell lines using the NucleoSpin Tissue kit (Macherey-Nagel) 
following the manufacturer’s instructions. Clones were screened by PCR 
amplifications using Go Taq DNA polymerase (Promega) for the presence of the 
TbAQP2 gene and for the correct integration of the plasmid into the genome (Figure 
4.4). Three PCR reactions were set up to confirm this: the first PCR was used to 
amplify the TbAQP2 gene using primers HDK529 and HDK209. The second PCR was 
performed to amplify the gene with surrounding parts of the expression cassette 
using primers HDK1011 and HDK430. The third PCR was to assess whether the 
expression cassette was correctly linearised, thus integrated into the T. brucei 
genome using primers HDK713 and HDK991. PCR products were separated on a 1.5% 
agarose gel and visualised with SYBR™ Safe DNA gel stain. Figure 4.4A shows PCR 
products from the first reaction of ~950 bp, the expected size of the full-length 
TbAQP2 gene (939 bp). Product-sized bands from the second PCR reaction were 
~1250 bp corresponding to the expected size of gene with the partial plasmid 
fragment (1212 pb) (Figure 4.4B). The amplified PCR products of the clones from 
the third PCR reaction showed no bands to that of the undigested plasmid control 
(~1100 bp), suggesting correct linearization by AscI restriction enzyme, thus correct 
integration into the genome (Figure 4.4C) (See plasmid map (figure 2.1) in section 



















Figure 4.4: Agarose gel electrophoresis of PCR products reveals the presence of the integrated 
TbAQP2 mutants (L-W) transfected in aqp2/aqp3 null cells.  
Amplified PCR products shown of (A) the full TbAQP2 gene at ~950 bp, (B) shows fragment at ~1250 
bp containing TbAQP2 and parts of the expression cassette neighbouring the gene, (c) represent a 
fragment containing an AscI restriction site (~1100 bp). (A-B) L: 1kb Ladder; 1: pRPaGFP-AQP2 (positive 
control); 2: TbAQP2 (KO) negative control; 3: TbAQP2 (L84W); 4: TbAQP2 (L118W); 5: TbAQP2 
(L218W); 6: TbAQP2 (L218W/L118W). (C) L: 1Kb Ladder; 1: no DNA (negative control); 2: TbAQP2 
(L84W); 3: TbAQP2 (L118W); 4: TbAQP2 (L218W); 5: TbAQP2 (L218W/L118W); 6: pRPaGFP-AQP2 
(undigested). 





























































Following the PCR confirmations, the TbAQP2 gene was then amplified from the 
genomic DNA of each strain using Phusion High-Fidelity DNA Polymerase (NEB). The 
PCR products were purified using the NucleoSpin PCR kit (Macherey-Nagel), and were 
sent for sequencing using the forward (HDK1011) and reverse primer (HDK430), to 
confirm that the generated cell lines have the correct introduction of the tryptophan 
residues into the three selected positions of leucine in the AQP2 (L84, L118, L218) 




4.2.1.2. Molecular investigation of the AQP2 L-W mutants  
After introducing all the mutants successfully into tbaqp2/tbaqp3 null cells, the L-
W mutants were tested for drug susceptibility and transport assays. The L-W mutants 
were initially evaluated through the standard Alamar Blue assay just as described 
(Wallace et al., 2002; Bridges et al., 2007) to determine their impact on the drug's 
sensitivity at the cytoplasmic end of TbAQP2. On the other hand, the resistant cells 
(tbaqp2/tbaqp3 null) and the sensitive cells (tbaqp2/tbaqp3 null re-expressed 
TbAQP2WT) were employed as controls of the experiment. This study used four drugs 
throughout the assay: pentamidine, cymelarsan, diminazene aceturate, and 
phenylarsine oxide (PAO). AQP2/HAPT1 transports both pentamidine and 
cymelarsan, and in this study were used for the drug susceptibility (Bridges et al., 
2007; Baker et al., 2012). In contrast, diminazene aceturate and phenylarsine oxide 
were used as positive controls because they are not AQP2’s substrates (Munday et 
al., 2014). The expression of each of the L-W mutants in tbaqp2/tbaqp3 null cells 
resulted in cells reducing their sensitivity to pentamidine compared to similar cells 
expressing TbAQP2WT, as shown by Figure 4.5A. Additionally, all the L-W mutants 
were observed to be more resistant to cymelarsan compared to resistance observed 
in the expressed TbAQP2WT cell line control, but not that different from the 
tbaqp2/tbaqp3 null control, as indicated by Figure 4.5B. On the other hand, none 
of the L-W mutants demonstrated any sensitivity to diminazene or PAO (Figure 4.5C-
D). Nonetheless, the L218W mutant showed slight sensitivity towards diminazene, 
which was considered to be less (~2-fold, P<0.05) compared to that of pentamidine 


















































































































Figure 4.5: Sensitivity assay of TbAQP2 mutants (L-W) cell lines.  
(A-D) EC50 values of the tested drugs; pentamidine, cymelarsan, diminazene and phenylarsine oxide 
(PAO), against tbaqp2/tbaqp3 null (resistant control) and cell lines either expressing the TbAQP2 L-W 
mutants or TbAQP2WT (sensitive control). Red stars and green stars: comparison with tbaqp2/aqp3 
null or TbAQP2WT-expressing cells, respectively, which were assessed in parallel in each experiment 
showing the drug susceptibility of the indicated cell lines to; (A): pentamidine; (B): cymelarsan; (C): 
diminazene; (D): phenylarsine oxide (PAO). All experiments are the average and SEM of three 




















































































The [3H]-pentamidine transport assays were carried out to confirm the drug 
susceptibility phenotypes towards pentamidine with respect to control cell lines 
tbaqp2/tbaqp3 null, the re-expressed TbAQP2WT, as well as the L-W mutants. Also, 
these transport assays were conducted in the presence of 1 mM adenosine, which is 
considered to block the TbAT1/P2 transporter (De Koning and Jarvis, 1999). The data 
obtained were plotted to equations for linear regression using Prism 7.04 (GraphPad 
software). The two control cell lines were used to present the highest and the lowest 
slope rates for pentamidine uptake over up to 60 s as shown in (Figure 4.6A). The 
rate of transport of [3H]-pentamidine was measured in all mutants and showed 
strong reductions upon introduction of the tryptophan residues (Figure 4.6B). The 
L84W, L118W and L84W/L118W mutants showed a strongly diminished rate of 
pentamidine transport compared to the TbAQP2WT and the uptake rates of these 
cell lines were almost equal to the control resistant tbaqp2/tbaqp3 null cell line 
(Figure 4.6B). The L218W mutant showed a very low uptake rate of the radiolabelled 









































Figure 4.6: Transport of 25 nM [3H]-pentamidine by aqp2/aqp3 null, the expressing TbAQP2WT 
and the L-W mutant cell lines.  
Transport was determined in the presence of 1 mM adenosine to block the TbAT1/P2 transporter. (A) 
Pentamidine uptake over a time course of 60s. Uptake rate of re-expressed wild-type TbAQP2 strain 
plotted only to 30s due to depleted [3H]-pentamidine. Slope calculated based on linear regression using 
Prism 7.04 (GraphPad). (B) Bars represent the average and SEM Pentamidine uptake rates in mutant 
strains, relative to wild-type levels (set to 100%). Averages and SEM of three independent replicates. 
Significance determined by two-tailed unpaired Student’s tests in comparison to TbAQP2WT (green 





4.2.2. Introduction of a medium sized amino acid (methionine) at the cytoplasmic 
end of the AQP2 pore restores sensitivity to pentamidine (and melarsoprol) 
uptake 
4.2.2.1. Successful construction and transfection of AQP2 L-M mutants 
Based on the previous results of introducing bulky residues (tryptophan) to the 
cytoplasmic end of the AQP2 pore, I thought that it would be interesting to introduce 
a medium sized amino acid such a methionine, which is relatively similar in size to 
leucine, into the same selected positions (L84, L118 and L218). The combination of 
the effects of the Trp and Met mutations potentially allow to distinguish between 
an endocytosis model and a channel model for pentamidine. Therefore, genetic 


























































following the kit’s protocol. The TbAQP2 L-M mutants were generated by PCR 
(mixture and programme conditions in section 2.3.3; primers in table 2.1) using 
three plasmid vectors: pHDK210, pHDK208 and pHDK209 as template plasmids to 
give pHDK234 (TbAQPL84M), pHDK235 (TbAQPL118M) and pHDK236 (TbAQPL218M), 
respectively. All the plasmids were originally based on the vector pRPaAQP2-WT which 
is under the control of a Tet-regulated RRNA promoter (Baker et al., 2012). The 
indicated plasmids were then verified by Sanger sequencing for the existence of the 
expected mutation using the primers HDK1011 and HDK430. Before transfecting the 
expression cassettes into the genome of tbaqp2/tbaqp3 null cells, plasmids were 
digested overnight with the AscI restriction enzyme (NEB) for linearization, to ensure 
correct integration in a prepared locus in the ribosomal rRNA spacer region of the 
(Alsford et al., 2005). The digested products along with undigested plasmids 
(control) were run on 1% agarose gel. (Figure 4.7) shows band- sized at around 5.3 
kb indicating to correct digestions. (See plasmid map (figure 2.1) in section 2.3.4.1 
for AscI restriction sites). 
 
 
Figure 4.7: Digestion of the produced plasmids (pRPaAQP2 L-M mutants) by AscI enzyme.  
The figure shows a successful digestion of the produced plasmids by AscI enzyme prior to the 
transfection. The bands at ~ 5.3 kb represent the fragments (blue arrows indicate desired bands) of the 
DNA expression cassette that contain the TbAQP2 (L-M mutant) gene and a selection marker of the 
plasmid (hygromycin). The bands at ~ 2.6 kb represent the remaining unwanted part of the plasmid 
which contain only B-lactamase. Bands at ~ 7.9 kb represent the undigested plasmid (as control) of 
each plasmid. L: 1kb DNA ladder; 1: pHDK234 (digested plasmid); 2: control (pHDK234 undigested); 
3: pHDK235 (digested plasmid); 4: control (pHDK235 undigested); 5: pHDK236 (digested plasmid); 6: 
control (pHDK236 undigested). 
 
















After the linearisation, DNA was extracted and transfected into tbaqp2/aqp3 null 
cells. Clones were grown up in the presence of hygromycin, gDNA from each cell 
lines were extracted using the NucleoSpin Tissue kit (Macherey-Nagel) following the 
manufacturer’s instructions, and PCR confirmation were carried out. Three PCR 
amplifications were performed using GoTaq polymerase (Promega), for the existing 
of the TbAQP2 gene and for the correct integration of the expression cassette into 
the genome (Figure 4.8A-C). 1st PCR was used to amplify the full TbAQP2 gene using 
forward primer (HDK529) and reverse primer (HDK209). Whereas, the forward primer 
(HDK1011) and the reverse primer (HDK430) both from the vector were used in the 
2nd PCR to amplify parts of the expression cassette containing the TbAQP2 gene. The 
3rd PCR was to confirm the correct integration of the expression cassette into the 
genome of the T. brucei using (HDK713) and (HDK991) primers. PCR products were 
then run on an 1% agarose gel with DNA staining to validate the correct size of the 
DNA amplified. From the first reaction, PCR products were ~950 bp (Figure 4.8A) 
displayed the full size of the TbAQP2 (939 bp). Whilst, product-sized bands from the 
second PCR reaction were at ~1250 bp (Figure 4.8B) indicating to the expected size 
of the gene with the partial plasmid fragments (1212 bp). (Figure 4.8C) presents PCR 
products from the 3rd PCR reaction showing no bands to that of the undigested 
plasmid control (~1110bp), suggestion a correct linearization and integration to the 
genome. The expected bands sizes of the PCR products that were obtained from the 
amplifications of the three PCR indicate to successful transfections (See plasmid 
































Figure 4.8: PCR evidence of plasmid integration of the TbAQP2 (L-M) mutants into the 
tbaqp2/tbaqp3 null cells.  
(A) is a gel using forward primer (HDK529) and revers primer (HDK209), shown the full TbAQP2 gene 
at ~950 bp. While (B) is gel using forward primer (HDK1011) and revers primer (HDK430) presents 
bands around 1250bp, indicated to fragments of the expression cassette containing the AQP2 gene. 
(C) is gel using forward primer (HDK713) and revers primer (HDK991), shown no bands to that of the 
undigested plasmid control at ~1100bp indicated to correct linearization and integration. (A-B) L: 1Kb 
Ladder; 1: pRPaAQP2WT (positive control); 2: TbAQP2 (KO) negative control; 3: TbAQP2 (L84M); 4: 
TbAQP2 (L118M); 5: TbAQP2 (L218M). (C) 1: no DNA (negative control); 2: TbAQP2 (L84M); 3: 
TbAQP2 (L118M); 4: TbAQP2 (L218M); 5: pRPaAQP2WT (undigested). 
 
Before testing the generated cell lines for drugs sensitivity and transport assays, the 
correct substitutions of leucine to methionine were confirmed by sequencing. The 
TbAQP2 gene was amplified from the genomic DNA of each cell lines using Phusion 
High-Fidelity DNA Polymerase (NEB); using the forward (HDK1011) and reverse 
primer (HDK430). The amplified products from the PCR reaction were purified using 
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a DNA purification kit (Macherey-Nagel) and were then sent for sequencing 
(SourceBioscience, UK) using the mentioned primers. The DNA sequencing represent 
that the mutant cell lines contain TbAQP2 gene and carry the correct mutations (L-
M) at right positions (Appendix 10). 
4.2.2.2. Molecular investigation of the AQP2 L-M mutants 
To confirm the importance of the three selected positions of the leucine residues, 
substitution mutations to a medium-sized amino acide, L84M, L118M and L218M were 
created and expressed in the null-background strain tbaqp2/tbaqp3 (Baker et al., 
2012) using the tetracycline-inducible pRPa vector (Alsford et al., 2005). Sensitivity 
of the L-M mutants to pentamidine and the melaminophenyl arsenical cymelarsan 
was assessed using the Alamar Blue assay. Additionally, the mutant strains were 
assessed against diminazene and the control drug PAO, which is not a TbAQP2 
permeant (Graf et al., 2015). EC50 values obtained with the mutants were compared 
with values obtained with the tbaqp2/tbaqp3 null strain (drug-resistant control) and 
the strain possessing the re-expressed wild-type TbAQP2 (drug-sensitive control). 
Substituting the same leucine residues with methionine rather than tryptophan, 
variants L84M and L218M show no difference compared to TbAQP2WT in terms of 
pentamidine sensitivity with a significant difference with regards to tryptophan 
variants (Figure 4.9A). However, replacing Met at position 118 led to developing the 
same effects as observed with the Trp variant (Figure 4.9A). The L84M and L218M 
mutants also sensitised to cymelarsan (P<0.01) (Figure 4.9B). By the same 
comparison, there was no significant difference between the sensitivity of all the 
mutants to diminazene (Figure 4.9C) and PAO (Figure 4.9D), with exception of the 
L218M mutant that was, surprisingly, somewhat sensitised to diminazene (~2-fold, 
P<0.05). Thus, an amino acid substitution to the cytoplasmic end of L84, L118 and 













































































































Figure 4.9: Sensitivity assay of TbAQP2 mutants (L-M) cell lines. 
The controls and the L-M mutant cell lines and tbaqp2/tbaqp3 null (resistant control) and cell line 
expressing the TbAQP2WT (sensitive control) were assessed against a serial dilution of (a) 
pentamidine (b) cymelarsan (c) the control drug diminazene and (d) the control drug phenylarsine oxide 
(PAO). Bars represent the average and SEM of three independent replicates. Significance was 
determined by two-tailed unpaired Student’s tests in comparison to tbaqp2-tbaqp3 null cell line (red 
star), TbAQP2WT (green star) and tryptophan variants (black star), respectively: *, P<0.05; **, P<0.01; 

















































































In order to determine whether the significant changes of pentamidine sensitivity in 
the mutants expressing L-M were associated with alterations to pentamidine uptake 
into the cell, direct uptake assays of [3H]-pentamidine were performed to all 
derivative and control strains over the course of a minute. The transport assessment 
was conducted in triplicate and on three independent occasions in the presence of 
1 mM adenosine (for blocking the TbAT1/P2 transporter, De Koning and Jarvis, 1999). 
Observations indicated all expressed L-M mutants exhibited higher pentamidine 
uptake rates compared to the rate observed in the tbaqp2/tbaqp3 null strain in 60 
s (Figure 4.10A). The introduction of methionine residues into the L84, L118 and 
L218 sites in the TbAQP2 showed that in two out of the three cases (L84M and 
(L218M), the pentamidine uptake was largely restored, whereas L118M showed a 
very low uptake rate of the [3H]-pentamidine but still above the level of the 
knockout cell line (Figure 4.10A). The rate of [3H]-pentamidine uptake for the L84M 
and L218M mutants was significantly increased compared to the previous results of 
the (L-W) mutants, and were nearly normal to the rate of the TbAQP2WT, with an 









L 1 1 8M
L 2 1 8M
A Q P 2 /3 -K O
+  A Q P 2  W .T

























R e p r e s e n ta t iv e  U p ta k e  o f  [3H ]-P e n ta m id in e  b y  A Q P 2 /3 -K O  a n d  A Q P 2  (L -M ) m u ta n ts












L 1 1 8M
L 2 1 8M
A Q P 2 /3 -K O
+  A Q P 2  W .T

























R e p r e s e n ta t iv e  U p ta k e  o f  [3H ]-P e n ta m id in e  b y  A Q P 2 /3 -K O  a n d  A Q P 2  (L -M ) m u ta n ts









Figure 4.10: Transport of 25 nM [3H]-pentamidine by tbaqp2/aqp3 null cells, expressing TbAQP2 
WT and the L-M mutant cell lines as indicated.  
Transport was determined in the presence of 1 mM adenosine to block the TbAT1/P2 transporter. (A) 
Pentamidine uptake over a time course of 60s. Uptake rate of re-expressed wild-type TbAQP2 strain 
plotted only to 30s due to depleted [3H]-pentamidine. Slopes were calculated by linear regression using 
Prism 7.04 (GraphPad). (B) Bars represent the average and SEM Pentamidine uptake rates in mutant 
strains, relative to wild-type levels (set to 100%); averages and SEM of three independent replicates. 
Significance was determined by two-tailed unpaired Student’s tests in comparison to TbAQP2WT 
(green star), tbaqp2/aqp3 null (red star) and tryptophan variants (black star), respectively: *, P<0.05; **, 
P<0.01; ***, P<0.001, ****, P<0.0001; ns, non-significant. 
 
 
4.2.3. The TbAQP2 (L-W) and (L-M) variants are still functional 
aquaglyceroporins 
In aerobic conditions, the bloodstream-form trypanosomes (BSF) can survive by 
utilizing glycerol as a carbon source (Bakker et al, 1997). However, the accumulation 
of higher glycerol levels can result in harmful conditions to the parasites, need to 
be disposed from the cells through aquaglyceroporins (Jeacock et al, 2017). In 
contrast, T. brucei is considered to have a mitochondrial protein called the 
trypanosome alternative oxidase (TAO), which is believed to facilitate the 
respiration of the BSF parasites (Clarkson et al., 1989). It has proposed that the 
trypanosome parasites tend to produce large quantities of glycerol to survive 


























































Acid (SHAM) is a known TAO inhibitor that can simulate the case of growing 
trypanosomes under anaerobic conditions (Opperdoes et al.,1976). A very recent 
study noted that trypanosomes could not efficiently dispose glycerol in the absence 
of aquaglyceroporins, leading to higher SHAM susceptibility (Jeacock et al., 2017). 
The same study continued to propose that TbAQP2 has a more significant 
contribution to glycerol utilization and efflux compared to TbAQP1 and TbAQP3. 
 
 
From the above experiments, the results clearly showed that introducing large 
amino acids at the cytosolic end can block the pentamidine transport. The data also 
show the Leu-Met substitution mutants to be more sensitive towards pentamidine 
but not cymelarsan. In order to check whether these variants were still functional 
aquaglyceroporins, the observation of Jeacock et al. (2017) was used, that when T. 
brucei cells lack all three APQs, they become sensitized to (SHAM) Trypanosome 
Alternative Oxidase inhibitor (TAO) due to cellular glycerol accumulation. Here in 
this study, the TbAQP2 (L-W) and (L-M) mutants were assessed for their ability to 
transport glycerol as aquaglyceroporins. This was achieved by expressing the 
mutants into the T. brucei AQP null background (tbaqp1-3 null) and test them for 
SHAM sensitivity and glycerol uptake. 
 
4.2.3.1. Successful transfection of TbAQP2 variants into tbaqp1/tbaqp2/tbaqp3 
null cells 
 
In order to verify whether the L-W and L-M AQP2 mutants are still functional, the 
AQP2 variants were expressed in the tbaqp1-2-3 null cell line (Jeacock et al., 2017) 
(made available by David Horn, University of Dundee, UK). E. coli containing each 
of the plasmid constructs of the AQP2 (L-W) and (L-M) mutants, including the 
pRPaGFP-TbAQP2WT vector, were cultured overnight in LB broth and plasmids were 
isolated by miniprep kits (Macherey-Nagel) according to the manufacturer’s 
instructions. Prior to the transfection, the vectors were digested using AscI 
restriction enzyme (NEB) to linearise the expression cassette for correct integration 
into the T. brucei genome (Alsford et al., 2005). After the linearisation, the digested 
products, along with undigested plasmids (control), were loaded onto a 1% agarose 
gel. Figure 4.11 shows bands of the digested plasmids sized at 5.3 kb and 2.6 kb, 
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indicating the correct digestions of the DNA expression cassette. (See plasmid map 
(figure 2.1) in section 2.3.4.1 for AscI restriction sites). 
 
 
Figure 4.11: Confirmation of correct linearisation of the plasmids of (pRPaAQP2L-W) and 
(pRPaAQP2L-M) prior to the transfection.  
The plasmids were digested with AscI restriction enzyme, resulting in two distinct bands refenced to 1 
kb DNA ladder (L). Band at ~ 5.3 kb represent fragment of the DNA expression cassette that contain 
the gene of interest and the hygromycin resistance marker (blue arrows indicate desired band). The 
band at ~ 2.6 kb represent the remaining unwanted fragment of each plasmid that containing only B-
lactamase. (C) as a control (undigested plasmid of each L-W and L-M mutant) band at ~ 7.9 kb. 
 
For each of the digested plasmids, the DNA expression cassette (band at 5.3 kb) was 
extracted from the gel using the NucleoSpin Gel extraction kit (Macherey-Nagel) and 
was transfected into tbaqp1/tbaqp2/tbaqp3 null cells. The produced clones were 
grown up in the presence of hygromycin (2.5 µg /ml; selection for the expression 
cassette), followed by gDNA extraction from each cell line (after 5 passages with 
the selection marker) using the NucleoSpin Tissue kit (Macherey-Nagel). In order to 
use for the sensitivity and uptake assays, the positive clones were verified by PCR. 
Two PCR amplifications were set up using GoTaq polymerase (Promega), one to 
verify the existence of the TbAQP2 gene and one for the correct integration of the 
expression cassette into the genome. The 1st PCR was used to amplify the full 
TbAQP2 gene using forward primer HDK529 and reverse primer HDK209, whereas, 
for the 2nd PCR reaction forward primer HDK713 (located 989 bp upstream of the 
AscI site in the plasmid backbone) and the reverse primer HDK535 (located 338 bp 


















































then run on a 1% agarose gel with DNA staining to validate the correct size of the 
DNA amplified. From the 1st PCR reaction, PCR products were at ~950 bp (Figure 
4.12A), i.e. approximately the full size of the TbAQP2 gene (939 pb). Figure 4.12B 
represents PCR products from the 2nd PCR reaction showing no bands other than that 
of the undigested plasmid control (1384 bp), suggestion a correct linearization and 
integration into the genome. The PCR products of the two PCR reactions indicate a 
successful transfection of the TbAQP2 WT gene and its variants into the genome of 






Figure 4.12: Gel images show the result of the PCR confirmation for the presence and the correct 
integration of the linearized expression constructs of the TbAQP2WT, the TbAQP2 L-W and L-M 
mutants into the tbaqp1/aqp2/aqp3 null cells.  
(A) PCR products of ~1 kb indicates the presence of the full TbAQP2 gene using primers HDK529 and 
HDK209. (B) No bands indicate to the complete linearisation of the circular plasmids that were 
confirmed by PCR using the primers HDK713 and HDK535. Bands at ~1400 bp represent the positive, 





























































































4.2.3.2. Expressing the TbAQP2 variants into aqp1-3 null cells correlates with 
reversal of sensitisation to SHAM 
The assessment of both AQP2WT and the variants sensitivities towards the TAO 
inhibitor SHAM was conducted as a proxy for glycerol transport after the expression 
in tbaqp1-2-3 null cells (Jeacock et al., 2017). For this, the Alamar blue assays were 
used to determine the EC50 of the L-W and L-M mutants to verify whether these cells 
are resistant to SHAM. The assay was performed in parallel with the sensitive 
(tbaqp1-2-3 null) and the resistant (expressing TbAQP2WT) strains, which were used 
as controls (Jeacock et al., 2017). The sensitivity of these cells to pentamidine 
(control drug) was also determined throughout the assessment for more validation. 
For pentamidine, we found that all the mutants expressed in the triple 
tbaqp1/tbaqp2/tbaqp3 null cells behave almost in a same manner to that when they 
were previously expressed in the tbaqp2/tbaqp3 null cells (Figure 4.5A, 4,9A), 
showing similar EC50 profiles (Figure 4.13). This observation is consistent with 




Figure 4.13:  Sensitivity assay of pentamidine by TbAQP2 variants with a leucine-to-tryptophan 
or leucine-to-methionine substitution near the cytoplasmic end of the pore.  
Pentamidine (control drug) EC50 values (nM) for mutant and WT TbAQP2 expressed in 
tbaqp1/tbaqp2/tbaqp3 cells (aqp1-3 null), performed in parallel with the determination of EC50 values 






















































































































bars) substitution at the indicated positions. The resistant control (aqp1-3 null) and sensitive control 
(AQP2WT) for the separate datasets (Trp or Met) are indicated as hatched bars in the same colours. 
All bars represent the average and SEM of at least three independent replicates. *, P<0.05; **, P<0.01; 
***, P<0.001, ****, P<0.0001 by unpaired Student’s t-test; ns, not significant; nd, not determined. 
 
 
On the other hand, cells expressing the variants all displayed highly significant 
reversal of the sensitisation to SHAM seen in the tbaqp1/tbaqp2/tbaqp3 null cells, 
although some showed an intermediate phenotype indicating a somewhat reduced 
ability to mediate glycerol efflux (Figure 4.14). This is not surprising considering the 
introduction of tryptophan at the narrow cytoplasmic end. At position 118 the 
substitutions with Trp and Met produced, surprisingly, a very similar, intermediate 
effect, which may indicate a particularly important role for this residue. All the Trp 
and Met mutants at positions 84, 118, and 218 were noted to have the capacity to 
transport glycerol as indicated by SHAM EC50 values that appear to be much higher 
than those observed in the tbaqp1-2-3 null cells (Figure 4.14). These mutants 
demonstrated an intermediate SHAM EC50, which was considerably different from 
that observed in TbAQP2WT, showing some reduction in those mutants' glycerol 
efflux capacity.  
 
 
Figure 4.14: Sensitivity assay of SHAM by TbAQP2 variants with a leucine-to-tryptophan or 
leucine-to-methionine substitution near the cytoplasmic end of the AQP2 pore.  
The figure shows SHAM EC50 values (µM) for mutant and WT TbAQP2 expressed in 













































































































substitution at the indicated positions. The resistant control (aqp1-3 null) and sensitive control 
(AQP2WT) for the separate datasets (Trp or Met) are indicated as hatched bars in the same colours. 
All mutants effectively reversed the increased SHAM-sensitivity of the aqp1-2-3 null cell line. All bars 
represent the average and SEM of at least three independent replicates. *, P<0.05; **, P<0.01; ***, 
P<0.001, ****, P<0.0001 by unpaired Student’s t-test; ns, not significant; nd, not determined. 
 
4.2.3.3. Expressing the TbAQP2 variants into aqp1-3 null cells displayed ability 
to mediate glycerol transport 
We then sought to determine if the mutant cells (both L-W and L-M) displayed 
measurable glycerol uptake capacity and the glycerol-efflux capability as observed 
from the above experiments. As a result, the assessment was conducted on the rate 
of radiolabelled glycerol uptake in aqp1/aqp2/aqp3 null cells expressing AQP2 
variants. Then, this rate was presented as a percentage of the transport rate of [3H]-
glycerol recorded in the TbAQP2WT control cells. The aqp1-2-3 cells were noted to 
have a low glycerol uptake rate (Figure 4.15), which was considered consistent with 
reduced glycerol diffusion across the plasma membrane. Based on this measure, 
glycerol's transport occurred in all Trp and Met mutants at 84, 118, and 218. 
However, this glycerol transport did not happen in the double mutants of 
L84W/L118W due to bulky residues (tryptophan) at the pore's lower point. Certainly, 
our results demonstrate the uptake of [3H]-glycerol reflected what was observed in 


























































































































Figure 4.15: [3H]-glycerol uptake by TbAQP2 variants with a leucine-to-tryptophan or leucine-to-
methionine substitution near the cytoplasmic end of the pore.  
The figure shows uptake of 0.25 µM [3H]-glycerol by aqp1/aqp2/aqp3 null cells expressing TbAQP2WT 
or an TbAQP2 variants as indicated, expressed as percentage (100%) of the transport rate in the 
TbAQP2 control cells. The resistant control (aqp1-3 null) and sensitive control (AQP2WT) for the 
separate datasets (Trp or Met) are indicated as hatched bars in the same colours. All bars represent 
the average and SEM of at least three independent replicates. *, P<0.05; **, P<0.01; ***, P<0.001, ****, 




TbAQP2 plays an essential role in pentamidine uptake in T. brucei. However, the 
mechanism by which it mediates and facilitates this uptake is still unclear. No 
adequate information has been provided to understand better whether TbAQP2 has 
direct transporter activity (Munday et al., 2014; Baker et al., 2013; Graf et al., 2013) 
or acts as a receptor with a high affinity for pentamidine (Song et al., 2016). Here, 
several genetic mutations (single or multiple amino acid substitutions) were 
constructed in the TbAQP2 pore to assess their effects on the ability of the gene for 
drug sensitivity and drug transport. This study replaced leucine residues with 
tryptophan and methionine at positions L84, L118, L218 near the cytoplasmic end of 
TbAQP2, potentially allowing to distinguish between an endocytosis model and a 
channel model for pentamidine.  
Introducing tryptophan in the selected three sites (L84, L116, and L218) at the 
cytoplasmic end of the TbAQP2 resulted in a loss of pentamidine sensitivity in L84 
and L118 mutants compared to the wild-type cells. On the other hand, the L218 
mutant demonstrated a sensitivity similar to that of the wild-types. The double 
mutant of L84W/L118W displayed an even greater loss of pentamidine susceptibility. 
In addition, the transport rates of [3H]-pentamidine were measured in all mutants 
and showed strong reductions upon introduction of the tryptophan residues. Thus, 
it can be concluded that the introduction of the bulky amino acids in the three 
selected positions at a low point in the aquaporin duct could block the passage of 
pentamidine through the TbAQP2 channel.  
In contrast, introduction of the methionine residues into the same three positions 
showed that in two out of three cases, L84M and L218M were significantly sensitive 
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to pentamidine, as well as these two mutants were restored near-normal rates of 
pentamidine uptake of the AQP2 wild type. All L-W mutants were affiliated with 
reduced pentamidine and cymelarsan sensitivity with a >90% decrease in [3H]-
pentamidine uptake. This effect was dependent on size because the pentamidine 
transport rate associated with L84M and L218M was statistically similar to that 
observed in TbAQP2 cells. Besides, L118M demonstrated a higher transport rate 
compared to L118W (P<0.0001). 
From the homology protein model, the outcomes of the specific mutations of L84, 
L118 and L218 residues appear far below down the selectivity filter, indicating that 
pentamidine must traverse through the constriction points of the channel. The AQP2 
(L-W) and (L-M) mutants were also investigated for their ability to transport glycerol 
as aquaglyceroporins. The introduction of large amino acid residues at AQP2 
cytoplasmic end resulted in reducing the entry of pentamidine but maintained the 
glycerol flux. This implies that even though the TbAQP2 mutants lost their ability to 
transport pentamidine, they were still functional aquaglyceroporins because their 
expression in tbaqp1-2-3 null cells increased glycerol uptake and decreased 
sensitivity towards the TAO inhibitor SHAM. 
Together with the data from all mutants presented previously in chapter 3, these 
observations stand up for the conclusion that TbAQP2 is a conduit for pentamidine 
and the principal determinant of pentamidine and melarsoprol resistance (Munday 
et al., 2014).  
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Chapter 5 Partially blocking endocytosis does not alter 
the rate of pentamidine transport and pentamidine does 





There are few licensed drugs for the treatment of Human African Trypanosomiasis 
(HAT): pentamidine, suramin, melarsoprol, eflornithine and nifurtimox (Migchelsen 
et al., 2011). The choice of the drug to treat sleeping sickness in humans is mainly 
based on the stage of the disease and the causative organism (Burri et al., 2010). 
The WHO recommends pentamidine for the treatment of the initial stage of sleeping 
sickness caused by T. b. gambiense. Pentamidine has the ability to access 
trypanosomes via different routes (Figure 5.1). The aminopurine transporter P2, also 
known as Trypanosoma brucei AT1 (TbAT1), facilitates partial transport as 
evidenced by reduction in knockout studies involving pentamidine sensitivity with 
encoding gene (TbAT1) (Matovu et al., 2003), as well as partial inhibition of 
pentamidine transport by adenine, a known substrate of TbAT1 (Carter and 
Fairlamb, 1993). The bulk of pentamidine transport is facilitated by two other 
channels discovered in 2001: a High Affinity Pentamidine Transporter (HAPT1) and a 
Low Affinity Pentamidine Transporter (LAPT1). This has been further supported by 
competitive inhibition work using radiolabelled [3H]-pentamidine with increasing 
concentrations of unlabelled pentamidine substrate, causing significant biphasic 
uptake inhibition in tbat1-null mutants (de Koning, 2001; Matovu et al., 2003). It has 
been documented that knock-down of the HA1–3 plasma membrane proton pumps of 
T. brucei (which are vital for preserving the potential of plasma membrane), confers 
the resistance against pentamidine (Alsford et al., 2012; Baker et al., 2013). The HA1-
3 pumps are thought to provide the proton motive force necessary for HAPT1 activity 
and pentamidine uptake (De Koning, 2001). The former channel, HAPT1, has since 
been identified as Trypanosoma brucei aquaglyceroporin 2 (TbAQP2), located at the 







Figure 5.1: Overview of the transporters implicated in uptake of pentamidine in Trypanosoma 
brucei.  
Model shows known and putative mechanisms of the T. brucei AQP2 and P2 transporters thought to 
facilitate the uptake of pentamidine. Adenosine competitively inhibits pentamidine uptake by P2. The 
presence of the TbAQP2 gene appears to correlate with HAPT1 activity. The P-type H+ ATPases (HA1–
3) generates a proton motive force that could drive pentamidine uptake. (adapted from Molla-Herman 





Suramin is one of the few drugs available for treating sleeping sickness in humans, 
exclusively to treat T. b. rhodesiense infections that occur at early stages (De 
Koning, 2001). The drug is relatively large in size and possesses a six-fold negative 
charge, which hinders passive cell transport into the parasite cells (De Koning, 
2020). Suramin was proposed to be taken up by T. brucei via receptor-mediated 
endocytosis (Stewart et al., 2005; Damper et al., 1967). Many pieces of evidence 
show that the drug enters the parasite cell by endocytosis mechanism facilitated by 
its receptor, the Invariant Surface Glycoprotein (ISG75) (Alsford et al., 2012; Pal et 
al., 2002). These findings were supported by later studies that revealed the current 






endocytosis process starting from the binding of the drug to the ISG75, until the 
release of the drug in the cytoplasm via a Major Facilitator Superfamily Transporter 




Figure 5.2: A simplified schematic model of the trypanosome endosomal system.  
The figure shows the way in which the suramin drug enters the T. brucei cell via endocytosis 
mechanism. ISG75 has been proposed as the major surface receptor for suramin uptake but other cell-
surface proteins may make some contribution as well, since suramin is a prolific binder. The drug enters 
the cell by binding to ISG75 followed by uptake into the endosome by endocytosis (relies on four protein 
subunits that form adaptor protein complex 1, AP1) and transfers to the lysosome where it is broken 
down by proteolysis (involving the proteins UbH1, CatL, CBP1 and p67). The free drug is then released 
into the cytoplasm with the aid of transport protein MFST. (adapted from Alan et al., 2012).   
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In trypanosomes, endocytosis occurs rapidly, and is even more rapid in the flagellar 
pocket zone than in the mammalian cells (Allen et al., 2003). The knockdown of 
CRK12 kinase, an essential protein kinase (Mackey et al., 2011), is reported to cause 
a highly reproducible endocytosis defect in T. brucei (BSF) that affects approximately 
twenty percent of cells 12 hours after induction of RNAi and is eventually lethal 
(Monnerat et al., 2013). Therefore, to examine the conceivable existence of a 
connection between pentamidine transport and endocytosis, the CRK12 RNAi cell line 
was utilized. Parallel uptake experiments were performed involving [3H]-pentamidine 
and [3H]-suramin, with suramin as a positive control because it is known to bind to the 
ISG75 surface protein and enter bloodstream forms of T. brucei through endocytosis 
(Zoltner et al., 2016, 2020). This approach was chosen because no stable T. brucei 
cell lines with endocytosis defects are possible, as this rapidly leads to gross 
distortions of the cell (swelling of the flagellar pocket) and cell death (Monnerat et 
al., 2013; Allen et al., 2003; Field et al., 2009; García et al., 2004). However, 
induced knockdown of CRK12 is a relatively mild method to progressively reduce the 
endocytosis rate, and unambiguously distinguishes between endocytosis and 
secondary-active transporters.  
 
5.2. Results 
5.2.1. Growth analysis of CRK12 RNAi cells 
To determine the earliest time points at which endocytosis becomes disrupted, and 
without causing excessive cellular pathology or affecting cell viability when carrying 
out transport assays, growth analysis of the CRK12 RNAi cell line (Monnerat et al., 
2013), was performed in the presence and in the absence of tetracycline. Therefore, 
the initial step was to test the effect of the tetracycline based on varying 
concentrations of the antibiotic (tet 0.1 µg/ml, 0.5 µg/ml and 1 µg/ml) on the cell 
growth, in parallel with corresponding control (-tet). For the purpose of this test, 
the bloodstream parasites were seeded at 1 × 105 cells ml-1 both in the presence and 
in the absence of tetracycline, followed by incubation at 37 ºC with 5% carbon 
dioxide. After every 24 hours, a cell count was done using a haemocytometer, for 
three consecutive days. The experiments were conducted independently on three 
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separate occasions. It was observed that there was continued normal growth of 
CRK12 RNAi cell line when there was no addition of tetracycline to the media over 
the 72 hours (Figure 5.3). On the other hand, the rate of growth of the induced cells 
was lower in the first 24 hours in the presence of tetracycline in comparison to 
growth rate in the control (-tet). After day 1, there was a steep decline in cell 
density caused by cell death. Mackey et al., (2011) notes that this observation is 
because CRK12 is an important protein kinase in bloodstream form T. brucei. The 
growth curve indicates that the varying concentrations of tetracycline have a very 
similar effect on the cell growth.  
 
 
Figure 5.3: CRK12 RNAi cell growth curve in full HMI-9 medium by incubated at 37 ºC with 5% 
carbon dioxide, with and without tetracycline (tet).  
From this graph, there is no considerable difference in the CRK12 RNAi growth phenotype when 
induced with three different concentrations of 0.1 μg/ml tet, 0.5 μg/ml tet or 1 μg/ml tet. In the absence 
of tetracycline (-tet), CRK12 RNAi acted as a control. The results presented in the graph are based on 
the data obtained from three similar but independent experiments. (Alghamdi et al., 2020). 
 
Bloodstream Trypanosoma cells normally divide after about every 6 h under standard 
culture conditions, and reach a cell density of 1.5 - 2 × 106 cells/ml at late log phase 
after every 48 h, when seeded at 1 x 105 cells/ml (Vassella et al., 1997). Based on 
this, and on the growth analysis shown in figure 5.3, an additional growth analysis 
was performed on the CRK12 cells to determine the peak growth rate so that viable 
cells are harvested prior to apparent growth arrest. Hence, the cells were induced 





























hours to ensure as much inhibition from endocytosis as possible without affecting 
cell viability. The experiments were independently conducted on three different 
occasions. Cell induction with tetracycline 1 µg/ml was performed, followed by cell 
counts after every 4 h. For controls, un-induced CRK12 RNAi cells were used 
throughout the assay. From figure 5.4, it is evident that the induction of CRK12 blood 
stream form RNAi cell line using tetracycline arrested cell growth in the first 12 
hours, causing cell death after longer RNAi induction. These experimental findings 
were consistent with previous data published under the investigation of the function 
of CRK12 (Monnerat et al., 2013). Culture samples collected at this time point reveal 
an increased abundance of swelling cells, which is a characteristic of endocytosis 
defects in T.  brucei. However, it was difficult to quantify this characteristic since only 
a minority of cells was affected and to varying degrees, as intended at the 12 h time 
point selected for that very reason.  Our subsequent experiments of drug uptake were 
optimized on the basis of these growth assay. 
 
 
Figure 5.4: CRK12 RNAi cell growth curve in full HMI-9 medium at 37 ºC with 5% carbon dioxide, 
with or without 1 μg/m tetracycline (tet).  
The graph shows the growth curve of the CRK12 RNAi cells within a period of 24 hours, when induced 
with 1 μg/ml tetracycline. In the absence of tetracycline (-tet), CRK12 RNAi acted as a control. The cells 
were counted using a haemocytometer and the mean of duplicate determinations has been shown. 
(Alghamdi et al., 2020) 






















5.2.2. Quantitative RT-PCR on the CRK12 RNAi cell line 
Based on the growth analysis assay in figure 5.4, it was evident that in the presence 
of tetracycline, the cells experienced a steady growth until after 12 hours when a 
decline in growth was observed. Therefore, the mRNA expression of CRK12 was 
determined 12 h after induction with 1 µg/ml tetracycline. For the quantification of 
RNA, 5 x 106 cells were harvested from CRK12 RNAi cells induced with tetracycline 
and un-induced 2T1 parental cells which acted as the control. RNA was extracted 
from the cells by use of the NucleoSpin RNA extraction kit. After the extraction of 
RNA, the RNA was converted to cDNA by use of SuperScript III Reverse Transcriptase 
(Invitrogen). The RT-PCR process was performed using qRT-PCR primers specific for 
CRK12 gene, and using cDNA to measure the levels of mRNA normalized to GPI8 
expression which is usually used as a standard reference gene in T. brucei cell (Kang 
et al, 2002). The 2T1 cell line contains the two endogenous alleles of the CRK12 
gene and is therefore set to 100%. The levels of CRK12 mRNA were reduced by 42% 
(P<0.001) compared to un-induced controls as shown by qRT-PCR (Figure 5.5). Our 
analysis of the CRK12 transcript is closely consistent with the observations made by 
Monnerat et al, (2013) that mRNA transcript reduces by nearly 67% 18 hours after 
induction with tetracycline.  
 
 
Figure 5.5: Relative gene expression for the CRK12 RNAi cell line using qRT-PCR.  
Gene expression is normalised to housekeeping gene GPI8 (n=3) and the 2T1 parental cells (control) 
set at 100. Induction with 1 μg/ml tetracycline for 12 h. The error bar shows ± standard deviation. **, 





























5.2.3. Knockdown of CRK12 slows down endocytosis and suramin uptake but 
not pentamidine transport in T. brucei 
A study previously done on CRK12 kinase by Monnerat et al. (2013) showed that 
about 20% of population of the CRK12 RNAi cells in T. brucei tend to have 
enlargement of the flagellar pockets 12 hours after inducing the cells with 
tetracycline. Allen et al. (2003) also showed that there is a link between the 
enlarged T. brucei parasite flagellar pocket and defects in endocytosis. Therefore, 
this system was used to inhibit endocytosis in order to demonstrate that this does 
not impact pentamidine uptake. [3H]-suramin and [3H]-pentamidine were performed 
in two parallel experiments. [3H]-suramin was used as a positive control since, upon 
binding to the protein ISG755, it can reach T. brucei bloodstream forms via 
endocytosis (Zoltner et al, 2016, 2020). Transport of 0.025 μM [3H]-pentamidine, after 
12 h of CRK12 RNAi induction, was the same as that observed in the control (non-
induced) and was linear for at least 30 s at 0.00658 ± 0.00061 pmol (107 cells)-1 s-1 
and 0.00650 ± 0.00067 pmol (107 cells)-1 s-1, respectively. After 12 h of CRK12 RNAi 
induction, transport of 0.025 µM [3H]-pentamidine in the presence of 1 mM adenosine 
(to block the P2 transporter) was the same as that observed in the control (non-
induced) and was linear for at least 30 s at 0.00658 ± 0.00061 pmol (107 cells)-1 s-1 
and 0.00650 ± 0.00067 pmol (107 cells)-1 s-1, respectively. (Figure 5.6 A). The 
addition of 200 µM unlabelled pentamidine inhibited the uptake of [3H]- pentamidine 
for all the cells and was not significantly greater than 0 (P > 0.05). This indicates 
that [3H]-pentamidine uptake is transporter-mediated and is completely saturated 
at 200 µM pentamidine. There was no significant reduction in the rate of uptake of 
pentamidine (n=5) by the RNAi cells in comparison to the control cells (Figure 5.6 










Figure 5.6: Transport of 0.025 µM [3H]-Pentamidine measured in control (non-induced) and 
CRK12 RNAi cell after exactly 12 h of tetracycline induction.  
Transport was measured over a course of 30 seconds in the presence of 1 mM adenosine to block 
P2/TbAT1 transporter. [A] Representative pentamidine uptake experiment, the slope was determined 
using linear regression with Prism 7.04 (GraphPad). [B] The bars represent the mean and SEM rates 
of pentamidine uptake in CRK12 RNAi, relative to the control. The means and SEM of five independent 
experiments were determined in triplicate. Using unpaired Student’s t-test, NS is not significant. 
 
 
The uptake of 0.25 µM [3H]-suramin was evaluated in a way similar to the [3H]-
pentamidine experiment above, only that suramin was determined in over 15 





































































minutes. [3H]-suramin is a drug accumulated by endocytosis via the flagellar pockets 
in T. brucei (Zoltner et al., 2016), thus, it was used as a positive control. After 12 
hours of CRK12 RNAi induction, it was shown that the rate of labelled suramin was 
lower (0.001656 ± 0.00067 pmol (107 cells)-1 s-1) than in the control cells (0.00237 ± 
0.00061 pmol (107 cells)-1 s-1) (Figure 5.7A). 100 µM unlabeled suramin was used as 
a saturation control but did not fully out-compete the radiolabel, indicating that 
suramin binds with quite low affinity to its receptor, ISG75.  Hence, the uptake of 
0.25 µM [3H]-suramin by the two cells was significantly greater than zero, but not 
significantly different from each other. Considering the mean of five repeats, the 
[3H]-suramin uptake was inhibited by 32% in comparison to the control cells 
(P=0.019, n=5) (Figure 5.7B). Although this approach is limited to partially inhibited 
endocytosis in BSF T. brucei, the results obtained from these experiments show that 
inhibition on endocytosis has no impact on the uptake of pentamidine, but does 






































Figure 5.7: Measurement of 0.25 µM [3H]-suramin over a time period of 15 minutes in the control 
and in CRK12 RNAi cells after exactly 12 h of tetracycline induction.  
(A) representative experiment of suramin uptake, the slope is determined by linear regression in Prism 
7.04 (GraphPad). (B) Bars represent the mean and SEM rates of suramin uptake in CRK12 RNAi in 
relation to the control. Means and SEM of five independent experiments were performed in 
quadruplicate. Using Student’s unpaired, two-tailed t-test, p =0.0027.  
 
5.2.4. The protonmotive force drives uptake of AQP2-mediated pentamidine 
uptake in bloodstream forms of T. brucei 
Studies by Alsford et al. (2012) and Baker et al. (2013) have reported that knock-
down of the HA1–3 proton pumps in T. brucei confers the resistance to pentamidine. 
The HA1–3 proton pumps are important in maintaining a stable plasma membrane 
potential. An interesting fact is that this locus conferred resistance to only 
pentamidine (dicationic), and not to melaminophenyl arsenicals (neutral), unlike 
the case with the knockdown of the TbAQP3/TbAQP2 locus, which gave resistance 
to both drugs (Alsford et al., 2012). Previous studies by De Koning (2001a) have 
reported that the uptake of pentamidine in T. brucei procyclics, mediated by HAPT 
has a strong correlation with the proton-motive force (PMF) in procyclic T. brucei. 
Many T. brucei transporters are associated with proton symporter-mediated nutrient 
uptake (De Koning & Jarvis, 1997a, b, 1998; De Koning et al., 1998). However, it is 
uncertain if this dependence means that pentamidine uptake is mediated by a proton 
symporter or is simply a result of the energetics of cationic pentamidine uptake being 

































on sensitivity to neutral melaminophenyl arsenicals, a claim that strongly goes against 
a proton symport mechanism for HAPT1/AQP2, but if the substrate crosses the 
channel, there would be a partial dependence on HAPT1/AQP2-mediated dicationic 
pentamidine uptake on Vm or PMF, as opposes to a single Asp residue, according to 
the endocytosis model, binding on the extracellular side of the protein (Song et al, 
2016). Alghamdi et al. (2020) show that in T. brucei the same ionophores that dose-
dependently inhibit the uptake of hypoxanthine in procyclic (De Koning and Jarvis, 
1997a) and in BSF (De Koning and Jarvis, 1997b) also inhibit the transport of [3H]-
pentamidine in BSF and HAPT1-mediated pentamidine in procyclic cells. This is a 
confirmation that, as expected by the reliance on the HA1–3 proton pumps, a 
membrane potential must be present for rapid uptake of pentamidine. 
Zoltner et al. (2016) observe that [3H]-suramin, an endocytosed substrate, was also 
inhibited by 20 µM carbonyl cyanide m-chlorophenyl hydrazone (CCCP), by about 
32.6% (P=0.029; 3 minutes pre-incubation, and suramin accumulation of more than 
10 minutes) (Figure 5.8). Although this means that the ionophore does not absolutely 
discriminate between trans-channel transport and endocytosis for di-cationic 
pentamidine, the inhibition of transport did not occur for neutral melaminophenyl 
arsenicals. That is, these neutral TbAQP2 substrates do not depend on the proton 
gradient as noted by Alsford et al. (2012), an indication that they are not 





Figure 5.8: The 0.25 µM [3H]-suramin uptake by T. b. brucei s427WT cells in just over 10 minutes. 
































































































































Cells were incubated in the presence or in the absence of 20 µM CCCP (additional 3 minutes of pre-
incubation) and in parallel. The 100 µM unlabelled suramin (shown by the blue bars) was included to 
demonstrate saturation of the suramin-receptor interaction. The bars represent the mean and SEM of 
the three experiments which are independent of each other, all performed in quadruplicate. Following 
the Student’s unpaired t-test: *P<0.05; **P<0.01; ***P<0.001. (Alghamdi, et al., 2020) 
 
 
There is a good correlation between TbAQP2-mediated pentamidine transport and 
the proton-motive force (Figure 5.9), but CCCP has a stronger effect than expected 
from previously observations for the uptake of [3H]-hypoxanthine in T. brucei 
bloodstream forms as noted by De Koning and Jarvis (1997b).  
 
 
Figure 5.9: High affinity pentamidine uptake in T. b. brucei is sensitive to ionophores. 
The labels indicate the concentrations in µM. A plot showing the correlation between the rate of 
pentamidine transport and protonmotive force (PMF). The black points show several ionophores that 
strongly inhibited pentamidine uptake, including N-ethylmaleimide (NEM), nigericin and gramicidin. The 
red point shows the CCCP outlier and has not been used in the regression analysis. The data points 
represent the average of four or more independent repeats conducted in quadruplicate. The PMF 
values were taken from De Koning and Jarvis (1997b).  
 
 
Thus, an investigation of any direct effect of CCCP on TbAQP2 was conducted and 
found that the uptake of [3H]-glycerol (neutral) in tbaqp1-2-3 null cells expressing 
TbAQP2-WT was inhibited by CCCP, with an IC50 value of 20.7 ± 2.6 µM (n=3) (Figure 
5.10). The uptake of [3H]-pentamidine was also inhibited in the same cells, with the 
same IC50 value (Figure 5.11). Additionally, the results also show that pentamidine 
(which acts as a control) inhibits the uptake of [3H]-glycerol, with a mean EC50 value 
of 27.5 nM (n=2), same as the EC50 value of pentamidine inhibiting [3H]-pentamidine 






























uptake. This shows that CCCP inhibits TbAQP2 directly, independent of the effects 





Figure 5.10: The 0.25 µM [3H]-glycerol uptake by aqp1/aqp2/aqp3 null cells expressing 
TbAQP2WT.  
Dose response of pentamidine (PMD) and CCCP based on an incubation time of 1 minute. The graph 






Figure 5.11: Uptake of 0.025 µM [3H]-pentamidine by aqp1/aqp2/aqp3 null cells expressing 
TbAQP2WT. 
The graph represents dose response with CCCP and pentamidine (PMD), using an incubation time of 
30 second. The graph shown was performed in triplicate and representative of three independent. 





























































To investigate the independence from endocytosis, the tetracycline-inducible CRK12 
RNAi cell line that was employed to provide an endocytosis defect that is highly 
reproducible and progressive in T. brucei (Monnerat et al., 2013). The aim of this 
study was to distinguish between uptake by transporters and via endocytosis, since 
the current evidence (Morgan et al., 2002; Allen et al., 2003) suggest that all 
endocytosis in T. brucei exclusively occurring in the flagellar pocket is dependent 
on clathrin and independent of AP-2. The implication of this is that the endocytotic 
mechanisms of TbAQP2 and suramin receptor ISG75, which are both directed to the 
lysosome after ubiquitylation (Quintana et al., 2020; Zoltner et al., 2015), are likely 
to be similar enough for a direct comparison. After 12 h of CRK12 RNAi induction, 
pentamidine transport was not significantly reduced although uptake of [3H]-
suramin, which is accumulated by endocytosis through the T. brucei flagellar pocket 
(Zoltner et al., 2016), was reduced by 33% (P=0.0027), an indication that the 
experiment was successfully timed to the early stage of endocytosis slow-down.  
 
Similar to previous studies on protonmotive force-influenced transport processes in T. 
brucei (De Koning and Jarvis, 1997a, b, 1998; De Koning et al., 1998), ionophore 
CCCP strongly inhibited pentamidine uptake. This is most likely due to the internal 
negative membrane potential of -125 mV, which attracts the dicationic pentamidine 
(De Koning and Jarvis, 1997b). This result is in line with the prediction of molecular 
dynamics modelling (Alghamdi et al., 2020) and the role of HA1-3 proton pumps in 
pentamidine transport, as stated in previous studies, but not in the resistance of 
melarsoprol (Alsford et al., 2012; Baker et al., 2013). Even though CCCP inhibits 
pentamidine directly through competitive TbAQP2 inhibition, this only begins to 
have a major impact above ~5 µM (IC50 of 20.7 µM), while its effects after combined 
competitive inhibition and reduced protonmotive force (preincubation) shows 
pentamidine transport inhibition of about 63% at 1 µM and about 90% at 5 µM. This 
shows the important role of CCCP after PMF reduction. This is in agreement with the 
conclusion made on the molecular dynamics analysis (Alghamdi et al., 2020) that 
inward pentamidine flux depends on the inside-negative membrane potential.  
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For HAPT-mediated pentamidine uptake, the experimental Vmax in T. brucei BSF can 
be expressed as 9.5×105 molecules/cell/h, whereas that in procyclics is 8.5×106 
molecules/cell/h (De Koning, 2001). Given that the stoichiometric ratio of AQP2: 
pentamidine is 1:1, the endocytosis model would require as many units of TbAQP2 
as possible to be internalised and recycled, which seems impossible particularly in 
procyclic cells, since the half-life time for TbAQP2 turnover in BSF is almost 4 hours 
(Quintana et al., 2020). In addition, the rate of endocytosis in procyclic cells is 
lower, making it difficult to internalise the aquaporins spread over the surface of 
the cell as mentioned above. Based on the rates of uptake and turnover observed, 
about 4×106 TbAQP2 units would be required per BSF cell in the flagellar pocket. All 
these observations are not consistent with the argument that uptake of pentamidine 
by trypanosomes mainly depends on endocytosis. Even though AQP2-bound 
pentamidine is likely to be internalised as part of the protein’s natural turnover, 
this is unlikely to have a significant contribution to the overall rate of the drug’s 
uptake.  
Altogether, it can be concluded that the remarkably large pore of TbAQP2 is the 
primary entry of drugs melarsoprol and pentamidine into T. brucei spp. for 
treatment of sleeping sickness. This renders the parasite extra-sensitive to the drugs 
in comparison to Leishmania mexicana (Munday et al., 2014).   
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Chapter 6 Insights into the role of Leishmania major 




Treatment of leishmaniasis is complicated because the disease is caused by different 
species of Leishmania parasite, which lead to varied clinical manifestations. 
Although there exist more than 25 compounds exhibiting anti-leishmanial effects, 
only a handful are actually used in treatment of the human disease (Fidalgo & Gille, 
2011). In the past six decades, the organic pentavalent antimonial compounds 
meglumine antimoniate (Glucantime), and stibogluconate (Pentostam) have been 
the most preferred first line treatment options against all forms of leishmaniasis, 
while pentamidine, amphotericin B, and Alkyl-lysophospholipids (ALP) such as 
edelfosine and miltefosine have been employed as options for the second line of 
treatments. However, with the emergence of acquired resistance, the clinical 
efficacy of these drugs in the treatment of leishmaniasis is being challenged 
(Ashutosh et al., 2007). For example, Sundar and Chakravarty (2012) report that 
more than 60% of Indian VL patients have shown no response against antimonial 
treatment. Pentavalent antimonials [Sb (V)] are pro-drugs which get reduced to the 
active form, trivalent antimony [Sb (III)] (Ephros et al., 1999). This process occurs 
in the parasite, but it is still not well understood, including the mechanism through 
which antimonials enter into macrophages and phagolysosomes (Shaked et al., 
2001). Yet, according to Gourbal, et al. (2004), Leishmania major aquaglyceroporin 
1 (LmAQP1) is the first Sb (III) facilitator in Leishmania. In 2014, Mukhopadhyay 
stated that AQP1 plays an essential role of accumulating metalloids, methylglyoxal, 
glyceraldehyde, glycerol, water, alongside other solutes in Leishmania amastigotes 
and promastigotes.  
It is thought that the Leishmania major genome encodes for five aquaporins: 
LmAQP1, LmAQPα, LmAQPβ, LmAQPγ, and LmAQPδ. Out of these five, it is only 
LmAQP1 that exhibits adventitious permeability to antimonite. Mukhopadhyay 
(2014) affirms that the roles of the other four aquaporins are not yet known. A 
growing amount of evidence suggests that changes to, or loss of LmAQP1, plays a 
vital role in L. major antimony resistance. Marquis, et al. (2005) reported that if one 
of the two AQP1 alleles present in Leishmania major is interrupted, a 10-fold 
decrease in sensitivity to Sb (III) is recorded compared to wild-type (WT) cells. 
Conversely, if LmAQP1 is overexpressed, then cells exhibit 100-fold higher sensitivity 
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to Sb (III) compared to WT cells. In addition, overexpression of LmAQP1 can possibly 
reverse the phenotype in isolates exhibiting drug resistance (Figarella et al., 2007). 
In a more recent study, generated LmAQP1-knockout L. major strains have been 
shown to exhibit 30-fold increases in resistance to Sb (III) compared to WT parent 
strains (Plourde et al., 2015). As well as the evidence focused on L. major, it appears 
that the strong association between AQP1 and Sb (III) mode of action is conserved in 
other Leishmania species. An example of this was highlighted in a study by Imamura 
et al. (2016) where L. donovani clinical isolates from areas of sub-continental India 
associated with high antimonial treatment failure were found to have acquired an 
insertion in the Leishmania donovani AQP1 gene, spread by means of genetic 
recombination.  
 
In this chapter, the Leishmania major AQP1 WT gene (LmAQP1 WT) was constructed 
into two expression vectors and then transfected in parasite cells for 
characterisation. The study aimed to carry out a systematic examination on the role 
LmAQP1 plays in drug sensitivity and response. This was achieved by cloning and 
expressing the encoding gene in two different trypanosomatidae systems: (i) L. 
major AQP1 null and the T. brucei AQP1-3 null cell lines in order to evaluate the 
effect of LmAQP1 on sensitivity to antimony and arsenic drugs. 
 
6.2. Results 
6.2.1. Successful cloning and expression of Leishmania major AQP1 in 
Trypanosoma cells  
6.2.1.1. Construction of plasmids and transfection 
Section 2.3.4.2, describes how pHDK269 plasmid was constructed by sub-cloning the 
LmAQP1 gene into the pGEM-T Easy subcloning vector (Appendix 3), which was to 
verify the DNA sequence prior to cloning the gene into the pRPa vector (Alsford and 
Horn, 2008). After verifying that the DNA sequence of LmAQP1 was correct, 
restriction enzymes HindIII and XbaI were used to digest the gene out from pHDK269 
plasmid, followed by ligating into the pRPa vector, which is the final destination, 
given pHDK271 plasmid (plasmid map in figure 2.2, section 2.3.4.3). Sanger 
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sequencing was used to verify the presence of the LmAQP1 gene on the pHDK721 
plasmid generated using HDK1519 and HDK430 primers. Further digestions were 
performed to validate the correct cloning (Figure 6.1). The presence of the LmAQP1 
gene was tested using restriction enzymes HindIII and XbaI, whereas AscI was used 
to verify whether the LmAQP1 gene and the pRPa plasmid are integrated correctly 
together. In Figure 6.1, the bands at ~950 bp indicate the presence of the full 
LmAQP1 gene (959 bp) when the generated plasmid was digested using the 
restriction enzymes HindIII and XbaI. The band at ~5.3 kb indicates the proper 
linearization of the plasmid when digested with AscI enzyme. (See plasmid map 
(figure 2.2) in section 2.3.4.3; for restriction sites). 
 
 
Figure 6.1: The generated pHDK271 plasmid was digested by restriction enzymes, prior to 
transfection to ensure correct cloning of LmAQP1 gene into pHDK271.  
L: 1 kb DNA ladder; 1:  arrow indicates expected band at ~950 bp for full LmAQP1 gene, whereas the 
band at ~7 kb represents the expected remaining backbone of the plasmid, when digested using 
restriction enzymes HindIII and Xbal; 2: arrow indicates expected band at ~5.3 kb for the DNA 
expression cassette (containing the LmAQP1 gene and hygromycin antibiotic marker), whereas the 
band at ~2.6 kb represents the expected remaining part of the plasmid, when digested with AscI 
restriction enzyme. 
 
Prior to transfection, AscI restriction enzyme was used to linearize pHDK271 so that 
the expression cassette is properly integrated into the T. brucei genome (Alsford et 


















were run on 1% agarose gel to verify that the linearization was correct, and was 
expected to be at ~5.3 kilobases (kb) long (Figure 6.2). 
 
 
Figure 6.2: The generated plasmid (pHDK271) is digested by the AscI enzyme before 
transfection for proper integration of the expression cassette into the genome of 
tbaqp1/tbaqp2/tbaqp3 null cells. 
L: 1 kb DNA ladder; 1:  arrow indicates expected band at ~5.3 kb for the DNA expression cassette 
(containing the LmAQP1 gene and hygromycin antibiotic marker), whereas the band at ~2.6 kb 
represents the remaining part of the plasmid, when digested with AscI restriction enzyme; 2: control 
plasmid pHDK271 (undigested). 
 
After the linearization process, extraction of the DNA cassettes from the gel were 
performed, followed by cleaning the extracted DNA using the NucleoSpin Gel 
extraction kit (Macherey-Nagel) as per the manufacturer’s instructions. As described 
in section 2.7.1, the cleaned DNA cassettes were then transfected into the 
tbaqp1/tbaqp2/tbaqp3 null cell line (Jeacock et al., 2017) (kind gift from David 
Horn, University of Dundee, UK) which was derived from the 2T1 strain of T. b. 
brucei (Alsford & Horn, 2008). This was followed by selection and cloning of the 
transfected cells in the presence of 2.5 µg/ml hygromycin. The new cell line was 
then tested using PCR to determine the success of transfection. Here, genomic DNA 
obtained from the clones was screened, using Go Taq DNA polymerase (Promega) 
PCR amplifications, for proper integration of the plasmid into the genome of T. 
brucei and to establish the presence of the LmAQP1 gene. Correct transfection was 












amplify the full LmAQP1 gene based on the HDK1519 and HDK1520 primers. In the 
second PCR reaction, the LmAQP1 gene was amplified with surrounding part of the 
expression cassette using HDK1011 and HDK430 primers. Separation of the PCR 
products was done on a 1.5% agarose gel, and visualization was done using SYBR™ 
Safe DNA gel stain. The PCR products obtained from the first reaction are shown in 
Figure 3.3A, band at ~950 bp indicates the expected size of the full LmAQP1 gene 
(959 bp). The second PCR reaction gave product-sized bands at ~1250 bp, which 
corresponds to the expected size of the full LmAQP1 gene with a partially 
fragmented plasmid (1240 bp) (Figure 6.3B). Successful transfection of the clones 
with LmAQP1 was confirmed by the amplified PCR products (See plasmid map (figure 
2.2) in section 2.3.4.3; for primers sites). 
After confirming the PCR, Phusion High-Fidelity DNA Polymerase (NEB) was used to 
amplify the LmAQP1 gene from genomic DNA of each clone. The NucleoSpin PCR kit 
(Macherey-Nagel) was then used to purify the PCR products, and confirmed using 




Figure 6.3: PCR products electrophoresis using Agarose gel showing the LmAQP1 expression 
cassette integrated in tbaqp1/aqp2/aqp3 null cells.  
PCR product amplification of: (A) the full LmAQP1 gene at ~950 bp, (B) fragment at ~1250 bp 
represents LmAQP1 and parts of the expression cassette surrounding the gene. The size of each band 
was approximated with respect to the standard size of the 1Kb molecular weight Ladder. (A-B) L: 1Kb 
Ladder; 1: pRPaLmAQP1 (positive control); 2: TbAQP1-3 KO (negative control); 3: LmAQP1 (clone 1); 4: 
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6.2.1.2. The impact of LmAQP1 on T.b aqp1-3 null strain growth 
Once it was confirmed that the clones were expressing the desired gene, the effect 
of introducing the LmAQP1 into the tbaqp1/tbaqp2/tbaqp3 null cells were 
examined. Growth of clones 1 and 2 were then determined and compared to the 
tbaqp1/tbaqp2/tbaqp3 null cells and 2T1 strains. The tbaqp1-3 null cell line shown 
in Figure 6.4 indicates a reduced rate of growth compared to 2T1, with a 
substantially reduced maximum cell density. In terms of maximum observed cell 
density, both clones expressing the LmAQP1 gene fall between the 2T1 and 
tbaqp1/tbaqp2/tbaqp3 null cell lines. These two clones remained at max cell 




Figure 6.4: T. brucei cell lines growth curves in HMI-9 medium, incubation with 5% CO2 at 37 °C. 
Clones 1 and 2 of of tbaqp1-3 null cells that expressing the LmAQP1 (+LmAQP1) were compared to 
2T1 and tbaqp1-3 null strains. On the first day, a culture of 1×105 cells/mL were set up for each cell 
line, with selective marker added to both clones (2.5 µg/ml hygromycin). Using a haemocytometer, live 
cells were counted every day for 5 days.  
 






















6.2.1.3. Expression of LmAQP1 in Trypanosoma brucei aqp1-3 null strain 
enables antimonial transport  
After expressing the LmAQP1 in tbaqp1/tbaqp2/tbaqp3 null cells, the sensitivity of 
the cells to arsenical and antimonial drugs were determined. Here, the Alamar blue 
assay was used to calculate EC50 of the clones to confirm whether the generated 
cells show sensitivity to the following compounds; Arsenic Oxide, Potassium 
Antimony Tartrate and Sodium Arsenite. The assay was performed alongside the 
aqp1-2-3 null and 2T1 strains, which both acted as controls. Phenylarsine oxide 
(PAO) and pentamidine were used as drug controls throughout the assessment. From 
Figure 3.5a and Figure 3.5e, it is clear that the value of EC50 of 
tbaqp1/tbaqp2/tbaqp3 null cells is significantly higher (276 ± 15.9 nM) and (71.7 ± 
8.6 nM) than that of 2T1 cells (40 ± 7.7 nM) and (4 ± 1.6 nM) for Potassium Antimony 
Tartrate and Pentamidine, respectively, an indication that the presence of 
aquaporins 1-3 influences the sensitivity of T. b. brucei to these drugs. On the other 
hand, the sensitivity of T. brucei to Arsenic Oxide, Sodium Arsenite and Phenylarsine 
Oxide is not significantly affected by these aquaporins (Figure 6.5B-D). For 
Potassium Antimony Tartrate (PAT), the two clones expressing the LmAQP1 show an 
almost 10-fold lower value of EC50 (P<0.001) compared to the 
tbaqp1/tbaqp2/tbaqp3 strain (Figure 6.5A). The EC50 is closely comparable to that 
of 2T1 cells, showing that that the LmAQP1 restores sensitivity to PAT. None of the 
tested cell lines were sensitised to Arsenic Oxide, Sodium Arsenite and PAO, all 
arsenic compounds, and all had nearly the same average values of EC50, i.e. no 
significant differences were observed (Figure 6.5B-D). Conversely, the clones 
expressing the LmAQP1 fails to restore sensitivity to pentamidine given that the EC50 
values (cl1= 61.2 ± 7.5, cl2= 55 ± 7.8) are significantly higher than the values of 2T1 
cells (EC50= 4.0±1.6), and are very similar to EC50 values of the 
tbaqp1/tbaqp2/tbaqp3 null strain (EC50= 71.7 ± 8.6; P>0.05) (Figure 6.5E). Following 
this outcome, it is suggested that expression of the LmAQP1 gene in T. brucei 





























































































































































Figure 6.5: Drug sensitivity of clones 1 and 2 that expressing LmAQP1 compared to tbaqp1-3 
null and 2T1 strains.  
The cells were incubated at 37 °C for 48 hours, with 5% CO2 and serial dilutions of: (A) Potassium 
Antimony Tartrate, (B) Sodium Arsenite, (C) Arsenic Oxide, (D) Phenylarsine Oxide (PAO) and (E) 
Pentamidine, followed by incubation with Alamar Blue dye for another 24 hours. All experiments are 
the average and SEM of three independent experiments. Significance was determined by two-tailed 
unpaired Student’s tests. ***, P<0.001, ns, non-significant. 
 
 
6.2.2. Successful cloning and expression of Leishmania major AQP1 in 
Leishmania cells  
6.2.2.1. Construction of plasmids and transfection  
The same techniques that were described in section 6.2.1.1 were applied in cloning 
LmAQP1 gene into the expression vector for Leishmania cells. Initially, the LmAQP1 
gene was sub-cloned into the pGEMT Easy subcloning vector to produce pHDK270 
(Appendix 4), before cloning the gene into the pNUS-HcN plasmid, i.e. pNUS vector, 
which is an appropriate vector of expression in Leishmania (Tetaud et al., 2002). 
The produced plasmid pHDK270 was confirmed by Sanger sequencing. Next, both the 
LmAQP1 gene and the plasmid were digested with restriction enzymes and ligated 
into the backbone of the expression vector pNUS-HcN, giving the new plasmid 







































enzymes as a method of validating the proper cloning (Figure 6.6). Testing for the 
presence of the full LmAQP1 gene was accomplished by BgIII and XbaI, whereas BgIII 
and XhoI were used to check for correct integration of the gene into the PNUS-HcN 
plasmid. In Figure 6.6, the bands can be observed at 950 bp and 1500 bp, showing 
that LmAQP1 gene is present and correctly integrated into the pNUS-HcN plasmid 
(See plasmid map in figure 2.3 for restriction sites). The primers HDK1519 and 
HDK340 were used in Sanger sequencing to verify the plasmid pHDK272 prior to 
transfection into L. major AQP1 null strain. Following the confirmation of the 
sequence, pHDK272 was transfected, exactly as described in section 2.5.2, into 
LmAQP1 null cells (Marie et al., 2015) (obtained from Marc Ouellette lab). The 
generated clones were then grown in the presence of geneticin (G418), a neomycin 
analogue, at 50 µg/ml – an antibiotic for the neomycin resistance marker in the 
plasmid. After selecting surviving clones, gDNA was extracted for confirmation of 
the correct transfections by PCR. The presence of the LmAQP1 gene in the mutant 
null cells was confirmed by performing two PCR reactions. The results of PCR 1 are 
shown in Figure 6.7A; the expected bands appear at ~950 bp and they represent the 
full gene (942 bp) based on the forward primer (HDK1519) and reverse primer 
(HDK1520). PCR 2 was applied for gene amplification with the plasmid partially 
fragmented and using HDK851 and HDK340 primers (Figure 6.7B). The bands 
appeared as expected at 1228 bp of the fragment (See plasmid map (figure 2.3) in 
section 2.3.4.4 for primers sites). Based on the results of the two PCR amplifications, 
the transfection of the LmAQP1 gene into the mutant null cells is a success. After 
the PCR confirmations, the LmAQP1 gene was then amplified from the genomic DNA 
of each strain using Phusion High-Fidelity DNA Polymerase (NEB). The PCR products 
were purified using NucleoSpin PCR kit (Macherey-Nagel), and were confirmed by 




Figure 6.6: The generated pHDK272 plasmid was digested by restriction enzymes, prior to 
transfection to ensure correct cloning of LmAQP1 gene into pHDK272.  
L: 1 kb DNA ladder; 1:  arrow indicates expected band at ~950 bp for full LmAQP1 gene, whereas the 
band at ~6.2 kb represents the remaining backbone of the plasmid, when digested using restriction 
enzymes BgllI and XhoI; 2: arrow indicates expected band at ~1.5 kb for the full LmAQP1 gene and 
parts of the expression cassette surrounding the gene, whereas the band at ~5.7 kb represents the 
remaining part of the plasmid, when digested with BgllI and XbaI restriction enzyme. 
 
 
Figure 6.7: PCR products electrophoresis using Agarose gel showing the LmAQP1 expression 
cassette integrated in LmAQP1 null cells.  
PCR product amplification of: (A) the full LmAQP1 gene at ~950 bp, (B) fragment at ~1250 bp 
represents LmAQP1 and parts of the expression cassette surrounding the gene. The size of each band 
was approximated with respect to the standard size of the 1Kb molecular weight Ladder. (A and B) L: 
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6.2.2.2. The impact of LmAQP1 on Leishmania major aqp1 null strain growth 
 
It was observed that the time between passages was longer for LmAQP1 null cells 
than for the L. major WT cells. Hence, cell counting was performed to establish 
whether reintroduction of LmAQP1 into the null mutant cells would reinstate cell 
growth as the WT strain. Cultures of the clones (+ LmAQP1) were established growth 
was compared with that of the L. major AQP1 null and L. major WT strains. These 
cell lines were cultured in HOMEM medium at a starting density of 1×105 cells/ml. 
Hygromycin B antibiotic was added to culture 100 ug/mL for the AQP1 null cells and 
G418 antibiotic (50 µg/ml) for the clones, necessary for cell selection based on 
hygromycin B and neomycin resistance markers present in the respective integrated 
cassettes (Plourde et al., 2015; Tetaud et al., 2002). Cell counts were performed in 
triplicate after every 24 h for 6 days. According to Figure 6.8, the rate of growth of 
the add-back clones is slightly higher than the rate of growth in the null mutant cell 
line, but it is however slower than in the WT cells. 
 
 
Figure 6.8: The growth curve for L. major cell lines in HMI-9 medium, incubation at 25 °C.  
The rate of growth of the clones (+ LmAQP1) was compared to that of L. major AQP1 null and L. major 
WT strains. For every cell line, a culture of 1×105 cells/mL was initially prepared. Each day, cells were 
counted using counting haemocytometer, for 6 days. 
 
 























6.2.2.3. Reintroduction of LmAQP1 gene in Leishmania major aqp1 null strain 
restores antimonial and arsenical sensitivity 
The next step was to test our clones (+ LmAQP1) to find out if they can restore the 
sensitivity of antimonial and arsenical drugs when the LmAQP1 is re-introduced into 
the null mutant cells. In this case, the Alamar blue assay was used to determine the 
EC50 for Arsenic Oxide, Potassium Antimony Tartrate (PAT) and Sodium Arsenite in 
the add-back strain. This assay was carried simultaneously with the LmAQP1 null and 
L. major WT strains, which both acted as controls. Pentamidine was used as a control 
drug. As shown in figure 6.9A-C, the EC50 values of the aqp1-null strain are 
significantly higher (220 ± 2.7, 52.8 ± 0.6, and 75.4 ± 0.6) for PAT, Sodium Arsenite 
and Arsenic Oxide than those of the WT control or the AQP1 add-back clones. This 
suggests that AQP1 is a crucial factor on sensitivity to these heavy metals. 
Interestingly, the average values of EC50 of the two add-back clones was even much 
lower than those of the WT cell line, i.e., 0.18 ± 0.01, 0.6 ± 0.18 and 1.13 ± 0.3 
instead of 8.4 ± 0.2, 3.7 ± 0.20, and 5.2 ± 0.17 for PAT, Sodium Arsenite and Arsenic 
Oxide, respectively. In addition, it was surprising that the add-back strain appears 
to have lower sensitivity to pentamidine, which is significantly different in 











































































































































Figure 6.9: Sensitivity of L. major cell lines, evaluated by use of the Alamar blue assay.  
The cells were incubated at 25°C for 72 hours, with serial dilutions of: (A) Potassium Antimony Tartrate, 
(B) Sodium Arsenite, (C) Arsenic Oxide, and (D) Pentamidine. This was followed by incubation with 
Alamar Blue dye for another 48 hours. The experimental results are the average and SEM of three 
experiments performed independently. The significance was determined by use of two-tailed unpaired 
Student’s tests. ***, P<0.001, ****, P<0.001, ns, non-significant.  
 
6.3. Discussion 
The aim of this study was to create new cell lines for further work by successfully 
cloning the LmAQP1 gene and transfecting this into Leishmania and Trypanosoma 
strains. PCR confirmed that the two expression vectors generated had the desired 
LmAQP1, before transfecting the vectors into Trypanosoma and Leishmania cell 
lines. Again, using PCR, it was confirmed that the transfection process was successful 
when LmAQP1 gene was correctly inserted into the genome of the parasites. The 
next step was to perform growth curve assays to establish if the removal or insertion 
of the LmAQP1 gene in Trypanosoma cell lines hindered or improved the rate of 
growth, given the important role LmAQP1 exhibits in Leishmania cellular physiology 
and drug response (Mandal et al., 2014; Plourde et al., 2015).  
It was observed that the AQP1 knockout (KO) in Leishmania major cells grew at a 
rate slower than the WT strain. Given that the AQP1-coded aquaporin protein helps 








































that the absence of AQP1 in the KO cell line resulted in poor regulation of cell 
homeostasis and a subsequent slower growth rate as observed in a previous study 
(Plourde et al., 2015). Surprisingly, the WT phenotype was not restored in the 
transfected cell lines as expected. Rather than having a growth rate similar to the 
WT, the growth rates in the transfected clones were more or less the same with the 
AQP1 KO cell line with a very slight increase. One explanation for this result may be 
a much faster water recovery rate experienced by transfected cell lines compared 
to the WT or AQP1 null-lines, as described in Plourde et al. (2015). A faster water 
recovery rate may disrupt the osmoregulation abilities of cells previously 
compensating without a non-essential AQP1 transporter, and the sudden change in 
osmoregulation caused by fast water recovery may be subsequently hindering cell 
growth.  
 
The observation of the trypanosome cells revealed a much slower growth rate in the 
tbaqp1/tbaqp2/tbaqp3 null cells in comparison to 2T1 cells, most likely the result 
of reduced drug uptake and defects in transport, accumulation and metabolism of 
glycerol important for many cell activities including self-replication (Jeacock et al., 
2017). Additionally, it was observed that transfected cell lines with LmAQP1 
reintroduced showed a marginally increased cell growth rate, particularly after day 
2. Given that this cell line did not contain three different aquaporin genes, it is 
speculated that the introduction and expression of the LmAQP1 gene overcame a 
glycerol defect in these cells, and this subsequently led to higher growth rates. 
However, it is clear that LmAQP1 does not compensate for three lost T. brucei 
aquaporins, which would be required to create the cumulative restorative effect on 
glycerol uptake and metabolism in trypanosomes. In turn, this may be necessary for 
reaching the growth rate observed with 2T1 cells. 
In the subsequent steps, drug sensitivity Alamar blue assays were performed for the 
cell lines in attempt to establish the role played by AQP1 in the transportation of 
heavy metals antimony and arsenic. Leishmania infections are treated using 
antimonial drugs, which are transported via Leishmania AQP1 (Kell et al., 2014). As 
a matter of fact, AQP1 is the key route of entry of antimony in Leishmania parasites 
(Mandal et al., 2010). Additionally, previous research suggests that arsenic 
contamination in Indian subcontinent water has given rise to high treatment failures 
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with antimonial treatment, supported both with work in mouse models in vitro and 
in vivo, and from patients that contracted VL local to these areas (Perry et al., 2013; 
Perry et al., 2015). Hence, it was expected that the potassium antimony tartrate 
(PAT) drug assay would give interesting results. The experiments on the trypanosome 
parasites yielded some significant results. The tbaqp1/tbaqp2/tbaqp3 null cell line 
showed significant resistance to the PAT drug assay. It was observed that 
transfecting the LmAQP1 gene reversed the resistance, an observation that has been 
made in previous studies (Gourbal et al., 2004). As for arsenic oxide and sodium 
arsenate in the LmAQP1 null strain, it was observed that removal of the LmAQP1 
gene confers resistance to these compounds, which is reverted when the gene is 
reinstated, conferring a higher level of sensitivity in transfected cell lines compared 
to WT cells. These observations support previous conclusions that AQP1 plays an 
important role in the transportation of arsenic compounds, as well as antimonial 
compounds, in Leishmania (Gourbal et al., 2004; Plourde et al., 2015). These 
observations would also support reasoning that prolonged exposure to arsenic 
compounds through contaminated water, may have led to the long-term selection 
of antimonial resistant parasites as established by Perry et al. (2013, 2015). 
Therefore, changes to, or loss of, Leishmania AQP1 transporter functionality, from 
such selection have plausibly led to widespread antimonial drug resistance and high 
treatment failure rates observed in subcontinental India.  
Though AQPs, including AQP1, are known transport mediators of arsenite (As (III)) 
and Sb (III) (Uzcátegui et al., 2013), observations made on the effect of AQP1 of 
sensitivity to arsenic and antimonial compounds for Leishmania were not replicated 
in T. brucei. Instead, it was found that neither removal of AQP1-3 in T. brucei 2T1 
cells, nor transfection of LmAQP1 to tbaqp1/tbaqp2/tbaqp3 null cell line during T. 
brucei arsenic oxide and sodium arsenate assays made a significant difference to T. 
brucei sensitivity. Indeed, it is likely that T. brucei uptake of arsenic and antimonial 
compounds is dependent on other transport channels than just the AQPs, as has 
already been demonstrated with the uptake of the trivalent organoarsenical 
melarsoprol (Matovu et al., 2003). Therefore, the addition of LmAQP1 makes little 
change to levels of cell sensitivity as T. brucei cells remain sensitive despite the loss 
of AQPs.     
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Testing of Phenylarsine oxide (PAO) was only done with the Trypanosoma parasites. 
From the results obtained, AQP1 failed to show any impact on transportation of PAO. 
This was expected because PO diffuses freely across membranes (Fairlamb et al., 
1992) and was therefore an excellent control. Lastly, pentamidine (PMD), a drug 
that has been used in the treatment of Trypanosoma and Leishmania infections, was 
tested. The exact mechanism of PMD uptake in Leishmania is not well understood, 
but its actions include the disruption of the mitochondrial inner membrane potential 
of the parasite (Basselin et al., 1996; Coelho et al, 2007). In this observation, the 
loss and reinstatement of AQP1 in T. brucei did not substantially alter its sensitivity 
to PMD. Removal of AQP1-3 from T. brucei 2T1 cells resulted in a significant loss in 
PMD sensitivity compared to 2T1 cells, whilst transfection of LmAQP1 to 
tbaqp1/tbaqp2/tbaqp3 null cells made little impact in reversing the sensitivity 
profile of these cells. This was expected, as previous research has established AQP2, 
rather than AQP1, as the major determinant for PMD uptake in African trypanosomes 
(Baker et al., 2012). On the other hand, it was observed that Leishmania aqp1-null 
lines exhibited a significant loss in PMD sensitivity compared to WT cells. It appeared 
that re-introduction of LmAQP1 by transfection to aqp1-null cell lines made no 
impact towards restoring cells to the WT sensitivity phenotype. This observation may 
also be attributed to the significant increase in cell volume recovery rate observed 
when LmAQP1 is reintroduced to aqp-1 null cell lines (Plourde et al., 2015). This 
could have a possible disruptive effect on T. brucei cell osmoregulation activities, 
and in turn, disrupt pentamidine uptake in transfected cell lines leading to the 
resistance profiles observed. 
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Chapter 7 General discussion 
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Kinetoplastid parasites, particularly Leishmania and Trypanosoma species cause a 
range of diseases in humans, most of which are neglected in the world. Although the 
WHO and other non-governmental organisations have put significant efforts in 
fighting these insect-transmitted diseases, they remain a major challenge in public 
health, especially for the populations directly affected. The development of 
vaccines, which has proven to be a successful approach to management of many 
infectious diseases, has not been successful in the case of trypanosomatid diseases. 
This is because the parasites that cause these diseases possess immune-suppression 
and evasion mechanisms that are very efficient, such as intracellular locations for 
T. cruzi and for Leishmania spp. in the human host (Cardoso et al., 2016; McConville 
& Naderer, 2011), and antigenic variation by African trypanosomes (Gehrig & 
Efferth, 2008; Horn, 2014). Given the lack of vaccines, and the practical 
impossibility of vector control over enormous rural areas, the only viable alternative 
to control these diseases is chemotherapy. However, the drugs used in treating the 
diseases are far from ideal because they are ineffective at certain stages of the 
disease or to some parasite strains, or the routes of administering the drug are not 
convenient, have unacceptable toxicity, have induced resistance, and/or are not 
cost-effective (Kalel et al., 2017; Ranjbarian et al, 2017; Barrett & Croft, 2012; Field 
et al, 2017). With the rapid development of resistance, treatment efforts have 
diminished efficacy, and there is little or no financial incentive for the development 
of newer drugs to replace those against which resistance has developed (Fairlamb 
et al., 2016; Giordani et al., 2016). The major mechanisms of resistance involve: 
reducing the level of free drug at the target site, reducing the drug-binding affinity, 
reducing drug uptake, target overexpression, or failure to activate a prodrug (De 
Koning, 2017; Fairlamb et al., 2016). 
The key to the survival of kinetoplastid parasites such as Trypanosoma brucei and 
Leishmania major is the ability to overcome different environmental challenges in 
insect and mammalian hosts. Thus, the interface between the environment and the 
kinetoplastid cell, the plasma membrane, plays an important role in managing the 
survival in these different niches. Together with uptake of essential nutrients and 
outflow of metabolites, plasma membrane transporters sometimes also facilitate 
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the entry of drug compounds of high clinical importance (Tetaud et al., 1997; 
Landfear, 2008; Munday et .al, 2015a). 
Aquaporins (AQPs) are integral membrane proteins, known to play an important role 
in allowing the movement of water into- and out of the cell in a rapid and regulated 
manner (Borgnia et al., 1999). Aquaglyceroporins are type of aquaporins, also known 
to conduct and some very small uncharged solutes such as glycerol, CO2, ammonia, 
and urea across the membrane (Gourbal et al., 2004, Verkman, 2014). Unlike most 
known aquaglyceroporins, TbAQP2 is responsible for the increased sensitivity of T. 
brucei to melarsoprol (398 Da) and pentamidine (340 Da) (Baker et al., 2012). 
Although TbAQP2 is described as the first aquaporin with the potential to transport 
drug-like molecules, the mechanism that underpins these phenomena remained 
unclear. However, a structural analysis described in Munday et al (2015) 
hypothesised that the key difference that allowed TbAQP2 to take up large drug-like 
molecules was the size of several of the selectivity filter residues, and the absence 
of the cation-repulsing arginine that sticks out into the pore. To investigate this 
hypothesis a mutational analysis, swapping TbAQP2 and TbAQP3 selectivity filter 
residues, and altering the pore width at the cytoplasmic end was performed.  
With the evolution of TbAQP2 by positive selection due to the high ratio of dN/dS, 
eliminating all points of constriction including the NPA/NPA motif, the cationic 
arginine of the ar/R selectivity filter, and the aromatic amino acids, the pore size 
has been enlarged to an unprecedent degree (Baker et al., 2012; Munday et al., 
2015). It is worth noting that this enlargement apparently stemmed from a copy of 
the existing AQP in the ancestor (now called TbAQP3), which itself was left 
unchanged and with a completely conventional selectivity and cation filter, while in 
the copy all those residues were systematically replaced towards a larger pore while 
keeping an otherwise strong homology. This could be interpreted as the species 
deriving a benefit from both genes - conventional AQP3 and enlarged-pore AQP2. 
This is consistent with the observation that the AQP2-AQP3 allele seems to be very 
stable. Hypothesising that it first evolved in Trypanosoma brucei (as far as evidence 
allows) the arrangement remained unchanged in the subsequent sub-speciation 
events to T. b. gambiense, T. b. rhodesiense, T. evansi and T. equiperdum. What 
remains completely unclear is what advantage the trypanosome derives from this 
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situation. Apart from the conventional AQP substrates such as small trioses and 
glycerol (Uzcategui et al., 2004; 2013) no metabolite substrate could be identified 
for TbAQP2 (Alghamdi et al., 2020), having tested everything from amino acids to 
polyamines, nucleosides and vitamins. It may well be that the gained function 
TbAQP2 is not related to uptake at all, but to the efflux of an unwanted metabolite. 
Untargeted metabolomics sampling the cells and medium of WT and tbaqp2-3 null 
cells did not identify any candidate substrates, however (Munday and De Koning, 
unpublished), but it is possible that the TbAQP2 function is not operational in vitro 
in rich culture medium, only in vivo; moreover, it may give an advantage in the 
tsetse fly stage or short-stumpy stage rather than the short-slender bloodstream 
form that is the only one present in culture with these strains. Nonetheless, chances 
are that the advantage is in the mammalian host rather than in the insect as TbAQP2 
is retained unchanged in T. evansi and T. equiperdum, which do not require passage 
and development in the tsetse fly. To address these issues, strains of WT and tbaqp2-
null T. b. brucei have been transfected with different fluorescent markers 
(collaboration with Mark Carrington, University of Cambridge) and will be co-
infected in mice, to see whether either gains an advantage in vivo. Should that not 
be the case, the experiment will be repeated with tsetse fly infections. 
It is thus reasonable to speculate that the widened pore of TbAQP2 allows for the 
passage of substances other than those transported by TbAQP1 and TbAQP3. The 
work on the W(G)YR filter residues shows that these residues indeed appear to be 
important determinants for the transport of pentamidine by AQPs, and introducing 
all three TbAQP2 residues into TbAQP3 was required to create an AQP3 that can at 
least facilitate mild sensitisation to pentamidine, and a detectable level of 
pentamidine uptake. On the other hand, any mutations in the unusual selectivity 
filter of the three amino acids residues I(V)LL of TbAQP2 was sufficient to all but 
eradicate the transport of pentamidine. Likewise, the conserved NPA/NPA motif in 
TbAQP3, which contains two serine residues NSA/NPS in TbAQP2, is also linked to 
the blockage of cations passage (Wree et al., 2011). The TbAQP2 motif has unique 
serine residues halfway down the pore, which could be able to make hydrogen bonds 
with pentamidine. Reinstating the NPA/NPA motif resulted in a TbAQP2 variant with 
a significant reduction in [3H]-pentamidine transport rate. 
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Yet, it could be argued that the selectivity filter of TbAQP2 allows access to a 
pentamidine binding site halfway in the pore and is still not clear evidence of the 
drug traversing the pore into the cytoplasm. In order to further investigate this, I 
engineered constrictions at the cytoplasmic end of the pore, well below the 
selectivity filter, by making a site-specific mutation to each of the cytoplasmic-end 
amino acids L84, L118 and L218 that reside in the transport channel below the 
unique T. brucei selectivity filter (Baker et al., 2012). The introduction of bulky 
tryptophan on the cytoplasmic end of the TbAQP2 pore showed a disabling of 
pentamidine transport. In contrast, the result of a swap back to a medium size amino 
acid (methionine) into the same three positions showed a significant increase in 
uptake rates of pentamidine. Altogether, with the presented results of glycerol 
efflux and uptake being maintained in the mutant strains, verifying that these 
mutant AQPs weather they still functional aquaglyceroporins, it is likely that this 
effect depended on the amino acid size at the cytoplasmic end of the TbAQP2 pore. 
Interestingly, the position of L118 showed an almost similar phenotype (significant 
pentamidine resistance) for substitution with either tryptophan or methionine, 
showing that the original leucine may be in a quite critical position for pentamidine 
passage. This should be further investigated with further mutagenesis and 
modelling. Altogether, it can be concluded that the remarkably large pore of 
TbAQP2 is the primary entry of drugs melarsoprol and pentamidine into T. brucei 
spp. for treatment of sleeping sickness.  
The project also aimed to distinguish between pentamidine uptake by transporters 
and via endocytosis. Indeed, it is not sufficient to prove that pentamidine can 
traverse the TbAQP2 pore, as it is not unthinkable that the total cellular entry of 
pentamidine via TbAQP2 is the sum of the two processes, in which case the division 
into the separate contributions becomes of interest. Current evidence (Morgan et 
al., 2002; Allen et al., 2003) suggest that all endocytosis in T. brucei exclusively 
occurs in the flagellar pocket, is clathrin-dependent and AP-2 independent. This 
means that the endocytotic mechanisms of TbAQP2 and suramin receptor ISG75, 
which are both directed to the lysosome after ubiquitylation (Quintana et al., 2020; 
Zoltner et al., 2015), are likely to be similar enough for a direct comparison. The 
tetracycline-inducible CRK12 RNAi cell line was employed to provide an endocytosis 
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defect. Although this approach is necessarily limited to partially inhibited 
endocytosis in BSF T. brucei, because full inhibition of endocytosis is lethal in 
bloodstream trypanosomes (Monnerat et al., 2013). The data obtained from this 
work showed that, inhibition on endocytosis has little or no impact on the uptake of 
pentamidine, but does reduce suramin uptake, consistent with current models that 
propose suramin uptake via edocytosis mechanism (Zoltner et al., 2016; Alsford, 
2013).  
The proton ionophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP) has an 
obvious effect for the uptake of [3H]-hypoxanthine in T. brucei bloodstream forms 
(De Koning and Jarvis 1997b). Through a combination of competitive inhibition and 
reducing the protonmotive force, an investigation of whether the CCCP has a direct 
effect on TbAQP2-mediated pentamidine transport was conducted. The results 
showed an important role of CCCP after protonmotive force (PMF) reduction. This is 
in agreement with the conclusion made on the molecular dynamics analysis 
(Alghamdi et al., 2020) that inward pentamidine flux depends on the inside-negative 
membrane potential. It is also reported that the rate of endocytosis of TbAQP2 
would not be able to account for the amount of pentamidine internalised (Quintana 
et al., 2020). With the conducted investigation of the structure-activity relationship 
(SAR) of the interactions between pentamidine and TbAQP2 and the molecular 
dynamics (Alghamdi et al., 2020), which shows minimal energy to be associated with 
a near-elongated pentamidine centrally in the TbAQP2 pore, the current study offers 
detailed, multifarious evidence of the uptake of organic drugs with molecular 
weights of 340 and 398 by an aquaporin. 
Moreover, reconciling the literature on transport/resistance of pentamidine with 
uptake through endocytosis poses a challenge. For example, bloodstream 
trypanosomes exhibit a higher rate of endocytosis than the procyclic lifecycle forms 
(Langreth & Balber, 1975; Zoltner et al., 2016), but the rate of uptake of HAPT-
mediated [3H]-pentamidine in procyclics is nearly 10 times higher than that in 
bloodstream forms (De Koning, 2001a; Teka et al., 2011). This is despite the fact 
that the level of TbAQP2 expression is similar in both cases (Siegel et al., 2010; 
Jensen et al., 2014). In addition, TbAQP2 is spread out over the surface of procyclic 
cells (Baker et al., 2012), whereas endocytosis occurs exclusively in the flagellar 
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pocket (Field & Carrington, 2009), which is about three times smaller in procyclics 
compared to the bloodstream forms (Demmel et al., 2014), since the pellicular 
microtubule networks under the plasma membrane precludes endocytosis (Zoltner 
et al., 2016). This implies that the uptake of pentamidine mediated by TbAQP2 
should not be possible in procyclic T. brucei, if it all depends on endocytosis. 
Likewise, the TbAQP2 expression in Leishmania mexicana promastigotes showed a 
[3H]-pentamidine uptake rate of more than ten times higher than the rate observed 
in T. brucei BSF (Munday et al., 2014), despite the fact that these cells have a much 
lower rate of endocytosis (Langreth & Balber, 1975). There was no difference 
between the Km and the inhibitor profile of the pentamidine transport mediated by 
TbAQP2 in these promastigotes (Munday et al, 2014) and that of HAPT in bloodstream 
or procyclic form T. brucei (De Koning, 2001a). The endocytosis model would require 
the same number of units of TbAQP2 to be internalised and recycled, which seems 
impossible particularly in procyclic cells, since the half-life time for TbAQP2 
turnover in BSF is almost 4 hours (Quintana et al, 2020). In addition, the rate of 
endocytosis in procyclic cells is lower, making it difficult to internalise the 
aquaporins spread over the surface of the cell. All these observations are not 
consistent with the argument that uptake of pentamidine by trypanosomes mainly 
depends on endocytosis. Even though AQP2-bound pentamidine is likely to be 
internalised as part of the protein’s natural turnover, this is unlikely to have a 
significant contribution to the overall rate of the drug’s uptake. It should be noted 
that the paper by Song et al (2016) that proposed the endocytosis model did not 
actually measure any endocytosis or uptake of pentamidine, lacking a pentamidine 
radiolabel, but hypothesised it on the basis that other, smaller cations could not 
apparently pass through the channel. In a very recent paper the authors of that study 
stated that the method they use for measuring AQP permeation would not have been 
sensitive enough to detect pentamidine at the observed transport rate, which is of 
course much slower than that of water or glycerol (Petersen & Beitz, 2020). Thus, 
there is a strong suggestion, incorporating all these strands of data, that 
pentamidine is not taken up by endocytosis, nor does induce endocytosis of TbAQP2.  
The last part of my project was to get insight in the role of Leishmania major AQP1 
in drug transport. It has been reported that the Sb(III) traverses the pore of AQP1 
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and that loss of functionality of this aquaporin contributes to antimonial resistance. 
While pentavalent antimonials are still the first-line drugs against Leishmania spp., 
their effectiveness is hindered by high levels of toxicity and drug resistance 
(Ashutosh et al., 2007). Leishmania AQP1 was found to be one of markers that is 
commonly linked to antimonial resistance (Marquis et al., 2005; Decuypere et al., 
2005; Mandal et al., 2010; Maharjan et al., 2008; Kazemi-Rad et al., 2013). 
Therefore, a further exploration of LmAQP1 functions, including their regulatory 
mechanisms, will eventually reveal their real potential for novel chemotherapeutic 
approaches and/or transmission intervention(s). Herein, a systematic examination 
of the LmAQP1 in sensitivity and response to antimony and arsenic drugs was 
conducted. The results of expressing LmAQP1 into tbaqp1/tbaqp2/tbaqp3 null cells 
suggested that it is likely that T. brucei uptake of arsenic and antimonial compounds 
is dependent on other transport channels than just the AQPs. This conclusion has 
been demonstrated with the uptake of the trivalent organoarsenical melarsoprol 
(Matovu et al., 2003). On the other hand, the outcomes of the reintroduction of 
LmAQP1 into LmAQP1 null cells support previous conclusions that AQP1 plays an 
important role in the transportation of arsenic compounds, as well as antimonial 
compounds, in Leishmania (Gourbal et al., 2004; Plourde et al., 2015). Therefore, 
changes to, or loss of, Leishmania AQP1 transporter functionality, could lead to 
widespread antimonial drug resistance and high treatment failure rates. 
Due to time constraints, however, I was unable to make microscopy observations for 
the transfected cells (LmAQP1 null + LmAQP1). Thus, I recommend staining the cells 
with fluorescent probes such as Lyso Tracker and Mito Tracker, since the shape of 
the cells appear much rounder, which could be due to an enhanced water influx rate 
experienced by those cells, as previously described in Plourde et al. (2015). 
Fluorescence experiments would determine the organelle localizations and sizes in 
those cells. Importantly, with the knowledge about the characteristics that enable 
the transport of large, supple, molecules via TbAQP2, similar investigations should 
be also done on the LmAQP1 to gain insight into the structural determinants that 
enable it to transport Sb(III) and arsenic. 
In conclusion, the results of the TbAQP2 work provide strong evidence of 
pentamidine being able to permeate TbAQP2 directly, through the central pore. This 
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should now allow the evaluation of aquaporins in other species for similar 
adaptations. In addition, the cloning of the LmajAQP1 gene provides an essential 
molecular tool for studying the role of transporters in drug uptake and their 
potential involvement in the development of drug resistance. This might allow the 
identification and cloning of additional aquaporin members from additional species 
and give important new insights into the role of these important proteins in many 
organisms. Taken together, the outcomes of this thesis anticipate that better 
knowledge of the role of these AQPs will aid optimisation of future drugs and/or 











Appendix 1: General buffers and solutions  
 
Luria Bertani (LB) broth (pH 7) 
LB powder (Sigma-Aldrich) 12.5 g 
Distilled water 500 ml 
 
LB Agar 
Luria Agar (Sigma-Aldrich) 17.5 g 
Distilled water 500 ml 
 
 
Appendix 2: Protocol for gradient PCR 
 
PCR Mix:  52 µl GoTaq green buffer 
      13 µl 10 mM dNTPs 
      13 µl Forward primer (taken from a 10 µM stock solution) 
      13 µl Reverse primer (taken from a 10 µM stock solution) 
      2.6 µl gDNA (10 ng/µl conc) 
      2.6 µl GoTaq G2 polymerase 
      163.8 µl dH2O 
 
Put 20 µl of this mix into 12 tubes, and run the following PCR program: 
Put hot lid on 
Temperature step:  95°C - 3 min 
Start cycle x35 
 Temperature step:   95°C - 30s  
 Gradient step:   50°C to 70°C – 1.30s 
 Temperature step:  72°C - 3 min 
End cycle 













The pHDK269 plasmid map showing the full LmAQP1gene sub-cloned into the pGEMT Easy 








The pHDK270 plasmid map showing the full LmAQP1 gene sub-cloned into the pGEMT Easy 
sub-cloning vector, prior to cloning the gene into the pNUS-NcH vector (final destination) 





Appendix 5: Amino acid sequence alignments of TbAQP2 WT and the TbAQP2 

























The figures show correct mutation(s) at the right position in the mutant cell lines. (A) Double 
mutations (S131P/S263A). (B) Single mutation (L258Y). (C) Single mutation (I110W). (D) 
Single mutation (L264R). (E) Double mutations (I110W/L264Y). Alignments were created 























The plasmid map shows the TbAQP3WT and the vector confers hygromycin resistance to the 
transfected cells. The rRNA targeting fragment and Hygromycin B phosphotransferase 
ensures that the constructs are located to the tagged locus of 2T1 cells. This plasmid was 
used as a template to generate mutation in the AQP3 throughout the project. The positions 
of the primers that were used for the amplification of the AQP3 gene (HDK0529, HDK0329), 
and for the gene with the partial plasmid fragment (HDK1011, HDK430) are highlighted. The 


















Appendix 7: Amino acid sequence alignments of TbAQP3WT and the TbAQP3 








The figures show correct mutation at the right position in transfected tbaqp2/tbaqp3 null 
cells. (A) Sequence of the double mutation W102I/R256L. (B) Triplicate mutation 
W102I/R256L/Y250L. Alignments were created using the CLC Genomic workbench software 















Appendix 8: Amino acid sequence alignments of TbAQP2WT and the TbAQP2 















The figures show correct mutation at the right positions. (A) Single mutation I190T. (B) 
Single mutation W192G. (C) Double mutation I190T/W192G. The generated cell lines were 
checked by Sanger Sequencing (Source BioScience, Nottingham, UK) for the presence of 
TbAQP2 and the correct mutation(s). Alignments were created using the CLC Genomic 
workbench software (version 7.0, developed by CLC bio). 
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The figures show correct introduction of tryptophan into the positions of the three selected 
leucine. (A) single mutation (L84W). (B) single mutation (L118W). (C) single mutation 
(L218W). (D) double mutation (L84W/L118W). Alignments were created using the CLC 
Genomic workbench software (version 7.0, developed by CLC bio). 
 
Appendix 10: Amino acid sequence alignments of T.b AQP2 W.T and the T.b AQP2 















The figures show correct substitution of leucine to methionine at the three selected 
positions. (A) single mutation (L84M). (B) single mutation (L118M). (C) single mutation 
(L218M). Alignments were created using the CLC Genomic workbench software (version 7.0, 
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